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Introduction and outline of the thesis
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1.38 million women are diagnosed with
breast cancer each year
Breast-conserving surgery
2 in 5in up to 1 in 3
1 in 8
women will develop breast 
cancer in their lifetime
3 in 4
women with breast cancer are 
eligible for breast-conserving surgery
women tumour-involved margins are 
observed
women have a poor cosmetic outcome 
after breast-conserving surgery
>95%
of women with early stage breast cancer are 
still alive 5 years after diagnosis
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B RE A S T  CA N C ER
A br ief  histor y  of  breast  c ancer
Breast cancer was first described in ancient Egypt around 1600 B.C., appearing as bulging 
tumours of the breast. Later stages of breast cancer were depicted as visible tumours with 
ulceration of the breast.
For over 20 centuries, the theory of cancer put forward by the Greek physician Galen of Pergamum 
(129-200 BC) prevailed. Adhering to the humeral theory of Hippocrates, Galen viewed breast 
cancer as an expression of excess black bile in the blood, and based on his observation that breast 
cancer was more prevalent in women who ceased to menstruate, Galen recommended bleeding 
in these women to remove excess black bile.
The 18th century saw the first modern surgical procedures for breast cancer, described by Jean 
Louis Petit (1674–1750) in Paris. The procedure included the removal of the entire breast 
without use of general anaesthesia (which was unknown at the time). The surgeon used ropes for 
traction or breast clamps, followed by a swift amputation at the base of the breast. If available, a 
cauterizing iron provided haemostasis. Clearly, these techniques were not only painful but also 
disfiguring (Figure 1).
It was not until the 19th century that the treatment of breast cancer took a major step forward. 
The implementation of general anaesthesia and antiseptic technique resulted in a broader 
acceptance of surgery and permitted surgeons to concentrate on precision rather than rapid 
completion of a procedure (to limit patient discomfort). Furthermore, knowledge of human 
tissues became increasingly accurate as German pathologists examined cells and tissues using 
improved microscopes. At this time Germany was the centre of new pathophysiological 
developments, under the leadership of Johannes Müller at the University of Berlin. In 1838 
Müller showed that cancer was composed of cells and not lymph. Müller thought that rather 
than originating from normal cells, cancer cells originated from blastema (pluripotent cells 
capable of differentiating into a specific tissue).1 One of Müller’s students, Rudolph Virchow 
(1821-1902, Figure 2), introduced the idea that “all cells come from other cells” (omnis cellula 
e cellula), including cancer cells. During his research, Virchow performed autopsies on breast 
cancer cases and discovered that the cancer spread along fascial planes and through lymphatic 
channels. This led Virchow to emphasize removal of the entire tumour and dissection of the 
axillary lymph node. Virchow’s most important publication, “Die Cellularpathologie in ihrer 
Begründung auf physiologische und pathologische Gewebelehre”, is now seen as the foundation 
of modern pathology.2
Across Europe, other surgeons also made noteworthy observations. An important review of 
extant knowledge of breast cancer was published in 1854, “Traité des maladies du sein”, by 
Alfred Velpeau, a French surgeon in Paris (1795-1867). Further pioneers included Charles 
Moore (1821 – 1870), based at the Middlesex Hospital in London, who advocated “en bloc” 
removal of the breast, because partial removal of breast aided spread of tumour cells in the 
wound.3 Surgeon William M. Banks from Liverpool was the first to introduce routine removal 
of the axillary lymph nodes, reporting a reduction in axillary tumour recurrence.4 Axillary lymph 
node dissection was soon adopted for all women undergoing breast cancer surgery.
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Figure 1. Instruments and techniques used in the 18th century, illustrated by Louis-Jacques Goussier.
 1. Breast elevated by ropes
 2. Fork for the removal of large tumours
 3. Cutting instrument in breast surgery
 4. Instrument for the removal of small tumours
 5 & 6. Clamp and cutting instrument for the removal of the breast
 7. Belt used to elevate the breast
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Without doubt the most celebrated name in the history of breast cancer is that of American 
surgeon, William Halsted (Figure 3). After completing his medical education at Columbia 
University College of Physicians and Surgeons, Halsted attended the University of Vienna, the 
University of Leipzig and the University of Würzburg. In these European institutions Halsted 
learned various surgical techniques and was introduced to Virchow’s ideas on pathology. At 
this time, a long-running dispute as to whether pectoral muscles should be removed during 
mastectomy was already underway.
Virchow’s findings had a profound influence on Halsted. In 1880, Halsted returned to the 
United States, incorporating Virchow’s ideas and the breast cancer surgery he had learned in 
Europe into his own practice. The results were published in a manuscript in the Annals of 
Surgery entitled “The Results of Operations for the Cure of Cancer of the Breast Performed at 
the Johns Hopkins Hospital”. The manuscript described radical mastectomy and was of major 
importance in modern breast cancer surgery.5 This extensive procedure included removal of the 
breast and chest muscles in a single en bloc procedure including the axillary lymph nodes and 
lymphatic channels. Radical mastectomy remained the gold standard for almost a century, thanks 
to proven improvements in survival, especially when performed in earlier stages. However, due 
to the disfigurement resulting from such an extensive procedure, many women chose not to 
undergo surgery.6,7 Halsted eventually became Professor of Surgery at Johns Hopkins Hospital 
in Baltimore and is now seen as ‘the father of American Surgery’. 
Figure 2. Rudolph Virchow, the German 
pathologist who laid the foundation of modern 
pathophysiology
Figure 3. William Stewart Halsted, the American 
surgeon who developed the modified radical 
mastectomy.
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After the Second World War new treatment modalities were introduced, both in surgery and 
with the introduction of radiotherapy. In contrast to the Halsted era, women presented at an 
earlier stage and less often with ulcerating tumours of the breast.
A modified Halsted radical mastectomy procedure was described in 1948, by Patey and Dyson 
of the Middlesex Hospital in London.8 The modified radical mastectomy preserved the pectoral 
muscles, making the procedure less disfiguring, and showed outcomes equivalent to the standard 
radical procedure. The modified radical mastectomy is still widely used in the treatment of 
locally-advanced breast cancer.
The foundations for the current treatment of breast cancer were laid by the 1948 paper of 
McWhirter “The value of simple mastectomy and radiotherapy in the treatment of cancer of the 
breast”, in the British Journal of Radiology.9 The addition of radiotherapy resulted in less extensive 
types of surgery, based on the theory that the extent of the operation should be correlated to 
the size of the tumour.10,11 As women with breast cancer presented at an earlier stage, thus with 
smaller tumours, less extensive types of surgery were desirable. These new approaches to surgery 
were referred to as breast-conserving surgery (BCS) and implied a complete excision of the 
tumour while preserving the breast. BCS in combination with radiotherapy is also known as 
‘breast-conserving therapy’ (BCT). Two randomized controlled trials published by Veronesi et 
al. and Fisher et al., with a 20-year follow-up, have demonstrated that BCT for early stage breast 
cancer achieves similar local recurrence and overall survival rates as compared to more extensive 
surgical techniques. Shorter and more convenient radiotherapy schedules after BCS (22-day 
schedule, hypofractionated) have shown similar results in terms of local control and morbidity 
compared to a 35-day schedule (in the EORTC trial of Whelan et al).12 BCT is now accepted 
as the standard of care for early stage breast cancer and the current 5-year disease-free survival 
rate for node-negative breast cancer patients is excellent (>95%).13-16
Unlike the transition from mastectomy to BCS, the surgical management of the axilla remained 
more or less unaltered through much of the 20th century. It was only in the 1990’s that the 
sentinel node procedure for nodal staging was introduced. This procedure made it possible to 
avoid axillary lymph node dissection (ALND) in cases with tumour-free lymph nodes. ALND 
often results in lymphedema, nerve injury, and shoulder dysfunction, thereby compromising 
functionality, quality of life and cosmetic outcome.17-19 In the Netherlands, the sentinel lymph 
node procedure has since been accepted as a simple standard procedure and minimally invasive 
technique for the identification of patients without axillary node involvement, thereby obviating 
the need for unnecessary axillary lymph node dissection in the majority of early stage breast 
cancer patients.20 Recently, and as an alternative for axillary lymph node dissection in sentinel 
node positive patients, radiotherapy of the axilla is performed to avoid surgery and morbidity 
related to axillary dissection, while maintaining a good local control.21
At present, breast cancer is the most frequently diagnosed form of cancer and the leading cause 
of cancer death worldwide. With 15,000 new cases yearly in the Netherlands alone and an 
estimated incidence of 1.38 million cases each year, breast cancer affects women of all ages and 
approximately 1 in 8 women (13%) will develop the disease over the course of their lifetime.22 
Over the past decades, advances in early diagnosis have been achieved through greater patient 
awareness and self-examination, widespread screening mammography and improved imaging 
techniques. This has resulted in an increase in the rate of BCS, and these procedures can now be 
safely offered to the majority of breast cancer patients.13,15,23
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B RE A S T- CO N S ERV I N G  T H ERA P Y
Breast-conserving therapy (BCT) refers to breast-conserving surgery (BCS) followed by whole 
breast irradiation to eradicate any microscopic residual disease. While modern mastectomy 
techniques are less extensive than radical mastectomy (which included the removal of the breast 
muscle), mastectomies still entail loss of the whole breast. The goals of BCT are to provide low 
local recurrence rates and equivalent survival rates to mastectomy, while achieving an acceptable 
cosmetic outcome. Although the criteria for BCT are relative, patients with unifocal tumours, 
patients with multifocal tumours limited to a single quadrant of the breast and patients with 
larger tumours downstaged by neoadjuvant therapy are all eligible. Although it seems logical that 
the size of the tumour in relation to breast size is of major importance to the feasibility of BCT 
and the final cosmetic outcome, there is actually no literature to corroborate these assumptions.
Pr imar y  oncologic al  goals : “ Margin status  def init ion 
remains  an impor tant  topic  of  debate ”
Obtaining tumour-free resection margins is one of the primary goals of BCS. As patients with 
tumour-involved margins face an increased risk of local recurrence, they should undergo a re-
excision or even a mastectomy in order to achieve clear margins, although radiotherapy boost 
may suffice in some patients with focally-involved margins.14,24-26 Even today, incidences for 
tumour-involved margins in BCS are observed in up to 40% of patients and thus remain a 
considerable challenge in modern breast-conserving surgery.14,27,28 29 
Unfortunately, direct comparison of studies is difficult due to the use of varying definitions 
for positive margins, an example of which is the use of the term “close margin” for either a 
positive or negative margin. Internationally, close margins are defined as tumour cells ≤1mm 
from the resection margin. In the United Kingdom, earlier guidelines recommended a margin 
>2mm, whereas current guidelines do not include a clear definition of margin status and simply 
recommend that breast units develop their own guidelines regarding acceptable margin width.30 
Danish National Guidelines, however, still recommend tumour-free margins ≥2mm.31 Germany, 
Scotland and France have national and regional BCS guidelines on margin status which indicate 
that margins should be >1mm, and recommend that patients with margins ≤1mm undergo 
additional surgery.32-34 Other countries, including the Netherlands and the United States, have 
national guidelines for BCS which state that all specimens lacking tumour cells at the inked 
margins have tumour-free margins, and that these tumours do not necessitate additional local 
treatment (surgery or radiotherapy).35,36 However, two recent surveys in the United States 
reported that 85% of breast surgeons find a margin ≤1mm to be unacceptable.37,38 This attitude 
results in re-excisions to attain wider clear margins, despite the fact that this ignores national 
breast cancer guidelines.39
Notwithstanding the international controversy regarding the definition of tumour margins, it is 
important to note that a tumour-free resection margin of >1mm is unrelated to local recurrence 
or overall survival, and local recurrence rates range from 2% to 5%.13,14,16,24,40,41 Putting this into 
perspective, Morrow et al. stated, “any margin without tumour cells is enough”. Surgeons should 
therefore aim to excise as little healthy breast tissue as possible, as large excision volumes often 
result in poor cosmetic outcomes.42
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S econdar y  goals
Due to the high and continually improving survival rates achieved with BCT, the focus is now 
shifting towards achieving a satisfactory cosmetic outcome, a factor crucial to patient satisfaction 
and quality of life.43,44 Psychological distress is common in breast cancer sufferers, affecting 
approximately 30% of patients.45 Many studies have shown that cosmetic outcome is a major 
determinant of psychological distress, with a large impact on levels of anxiety, depression, body 
image, sexuality and self-esteem. Because up to 40% of patients still experience poor cosmetic 
outcomes, it is reasonable to assume that focusing on the best achievable cosmetic result will 
help reduce psychological distress.46
Cosmet ic  O utcome
Once BCS was established as a safe oncological procedure over the long term, the secondary 
goal of BCS, a ‘satisfactory cosmetic outcome’, became increasingly important. Since the 1980’s, 
studies have examined the factors influencing cosmetic outcome. These studies quickly ran up 
against problems in the assessment of cosmetic outcome, chiefly due to difficulties in finding 
reliable scoring methods.47 
Various techniques were examined, including subjective evaluation methods by panel evaluation 
and more objective techniques such as breast asymmetry calculations using the nipple position 
or breast contour. It should be stressed that many reports on cosmetic outcomes after BCS lack 
clear descriptions of their cosmetic evaluation methods. At present, subjective methods (such 
as panel and patient self-evaluation) and objective methods (breast asymmetry calculations and 
computerized software) are both available. A drawback of these methods is that they were not 
correlated to patient satisfaction and quality of life, factors that are indispensable to a patient’s 
psychological adaptation to the cosmetic result.
While breast cancer surgery increasingly aims to improve cosmetic outcome, oncological safety 
remains the primary and most important outcome. Many localised tumours can be successfully 
treated by standard lumpectomy, but some large lesions are difficult to excise without the risk of 
cosmetic deformity and/or margin involvement. In these cases, special approaches to resection 
accompanied by reconstruction have been developed and received much attention over the past 
decades. These surgical approaches, referred to as oncoplastic breast surgery (OPBS), combine 
a wide oncological resection (to increase the chances of obtaining tumour-free margins) with 
plastic surgery techniques in a single procedure for both reconstructive and cosmetic reasons.
OPBS is a broad concept that can be used for several different combinations of oncological 
surgery and plastic surgery. The term may refer to simple volume-displacement techniques or to 
more complex techniques of volume replacement by using local or regional flaps. The advocates 
of OPBS emphasize the opportunity for performing a wider excision of the tumour, potentially 
reducing margin involvement and thus local recurrence. Although scientific evidence on the 
oncological and cosmetic outcomes of OPBS is currently sparse, a considerable number of 
surgeons are now using these techniques.
a. Factor s  inf luenc ing  co smet i c  outcome
Factors that negatively influence cosmetic outcomes following BCT are largely understood: 
younger patient age, central inner quadrant localisation, axillary dissection, larger excision 
volumes, re-excision, complications, and radiotherapy boost.18,47-53 It should be stressed that the 
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achievement of “no ink on the tumour” in BCS is of great importance, as tumour-involved 
resection margins result in additional treatment such as higher radiotherapy boost volumes and 
doses, re-excisions and even mastectomy, thereby ensuring oncological safety but negatively 
influencing cosmetic outcome. Overall, the two key determinants of cosmetic outcome are the 
total volume of breast tissue resected and radiotherapy (administration of boost and whole breast 
irradiation dose).49,53
The volume of breast tissue excised is one of the most significant factors, especially relative to 
breast size; a large excision in a small breast is likely to have a poor cosmetic outcome due to 
the relative deformity conferred. Larger excision volumes also significantly influence breast and 
nipple retractions, lifting of the breast, breast volume and breast contour. A number of studies 
have shown that the rate of cosmetic failure is significantly higher if the size of the lumpectomy 
exceeds 50cm³, regardless of breast size.47,50,54-57
Radiation therapy, and specifically the radiation boost, have a large impact on cosmesis as they 
may induce skin teleangiectasias, oedema and fibrosis, while also contributing to nipple retraction 
and asymmetry.49,50,54-56 Although radiotherapy has a decisive impact on cosmetic outcome, a 
poor cosmetic outcome following surgery remains central to the final cosmetic outcome. In 
2012, Barnett et al. stressed that poor surgical cosmesis, defined as a poor cosmetic outcome after 
surgery and before radiotherapy, more frequently resulted in a poor cosmetic outcome at 2-year 
follow-up and more late toxicity effects resulting from radiotherapy, such as breast shrinkage 
and fibrosis.53
The accuracy of a lumpectomy is directly associated with the type and dose of administered 
radiotherapy. Unfortunately, and despite large excision volumes, margins are often tumour-
involved due to the eccentric location of the tumour in the specimen. This suggests that, 
with greater accuracy, it should be possible to excise smaller volumes of breast tissue without 
decreasing the minimal tumour-free margin and thereby avoid an additional radiotherapy 
boost.58 Although radiotherapy treatment has a negative influence on cosmetic outcome, the 
key factor in a poor cosmetic result following BCS remains the volume of breast tissue resected. 
This suggests that, in an ideal situation, BCS should consist of a complete excision of the breast 
tumour, while sacrificing as little healthy breast tissue as possible.53,54,56,59
b. Cal cu lated  Rese c t ion  R atio  (CRR) 
As the volume of breast tissue resected is crucial to the cosmetic outcome, one should try to limit 
resection of healthy breast tissue. A tool was introduced to define the amount of tumour and 
healthy breast tissue in a surgical specimen, the calculated resection ratio (CRR), that indicates 
excess resection of healthy tissue (Figure. 4). The CRR is defined by the volume of the fresh 
specimen measured in the operating theatre by fluid displacement, divided by the ‘optimal 
specimen volume’ defined as the spherical tumour volume plus an arbitrarily chosen ‘optimal’ 
tumour-free resection margin of 1 cm.29,35,60 This means that, in an ideal situation, the specimen 
volume is equal to the optimal resection volume and therefore the CRR equals 1. A CRR >1 
indicates that the resection margin was larger than 1 cm and that excess healthy breast tissue 
was resected.
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Figure 4a. Calculation of the optimal resection volume (ORV)
The tumour was defined as a sphere and the tumour volume was calculated by the formula 4/3πr³, 
whereby r represents the radius, which is equal to one half of the diameter measured by the pathologist. 
An ORV was calculated for each tumour. ORV was defined as the spherical tumour volume with an 
added 1.0 cm margin of healthy breast tissue, calculated by the formula 4/3π(r+1.0cm)³.
Figure 4b. Calculation of the total resection volume (TRV)
TRV represents the volume of the surgical specimen. TRV was assumed to be ellipsoid in shape and was 
calculated using the three dimensions of the surgical specimen (in cm) measured by the pathologist. The 
formula applied to calculate TRV was 4/3π(a·b·c), with a, b, and c representing one half of each of the 
three dimensions of the surgical specimen.
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Cosmet ic  e valuat ion
As the goal of achieving a satisfactory cosmetic outcome following BCT has grown in importance, 
new breast-conserving surgical and radiotherapeutical techniques that may improve cosmetic 
outcomes without compromising oncological principles are increasingly being evaluated.61-64
To evaluate the efficacy of these various techniques, and for meaningful comparisons, a reliable 
and reproducible assessment of cosmetic outcome is essential.
a. De f ining  evaluat ion i tems
In an ideal situation, cosmetic outcome should be evaluated by comparing pre-treatment 
photographs with photographs after a considerable period of follow-up. However, the 
comparison of both breasts may suffice, assuming that a better cosmetic outcome corresponds to 
more symmetrical breasts. Because achieving identical breasts is the ultimate cosmetic objective 
in BCT, asymmetry measurements and assessments would appear to be the key parameter 
during analysis of cosmetic results. When comparing the treated and untreated breasts, the most 
important factors are breast shape, breast volume, deformity, nipple position, scar visibility and 
skin changes. These items seem to encompass the range of cosmetic issues that arise from BCT, 
and allow a global appreciation of the cosmetic outcome.47 
b. Timing and methods
Timing is of great importance when assessing cosmetic outcome, as radiotherapy has long-lasting 
effects on breast appearance. Amongst others, Olivotto et al. (1989) observed that cosmetic 
results after BCS and radiotherapy were similar at 3, 5 and 7-years follow-up. A substantial 
body of literature suggests that the most appropriate time to assess cosmetic outcome is at least 3 
years postoperatively, a conclusion supported by studies on the effects of irradiation boost which 
confirmed that major changes in breast appearance occur within 3 years of initial treatment.47,65 
Nevertheless, cosmetic outcome at 1-year follow-up can be considered to give a good indication 
of the final cosmetic outcome.48,49,54,58,59,66
Many of the methods used to evaluate cosmetic outcome after breast surgery are based on digital 
photography; these photographs are taken at several time-points before or after surgery. The 
frontal view of the breasts is the most important, as it allows reproducible assessment of cosmetic 
outcome. Furthermore, with the advent of techniques for objective and computerised evaluation 
of cosmetic outcome, photographs are now indispensable.
In terms of scoring, the most widely used scale for cosmetic outcome assessment is the so-called 
4-point Likert scale or Harvard scale, which classifies overall cosmetic outcome as excellent, 
good, fair or poor.67
c . Type  o f  evaluat ions
Various evaluation techniques have been examined over the years, including subjective evaluation 
methods (panel evaluation, patient self-evaluation) and more objective techniques (Breast 
Retraction Assessment, Lower Breast Contour, BAT software and BCCT.core software). 
Cosmetic evaluation methods for BCT are frequently based on digital photography, with 
photographs taken at several time-points before or after surgery. In an ideal situation, cosmetic 
outcome should be evaluated by comparing pre-treatment photographs with photographs after 
a considerable period of follow-up. However, most authors prefer to use comparison between 
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the breasts, assuming that greater symmetry corresponds to a better cosmetic outcome. In line 
with this, techniques that allow objective cosmetic outcome measurements have been developed. 
i . Panel  evaluat ion
As single-observer cosmetic outcome assessment after BCS and radiotherapy has proven to be 
fairly reproducible.68 A more reliable alternative is panel evaluation, which consists of evaluation 
of 4-point view pictures of the breasts by a panel of six professionals and non-professionals.59,69 
Vrieling et al. recommended that a panel should consist of at least 5 persons from different 
backgrounds, as wide variation between observers is likely. Furthermore, they stressed that 
objective evaluation methods are rather poor in the detection of scars or changes to skin.47,65
i i . Obje c t ive  breas t  a symmet r y  ca l cu lat ions
Over several decades, various attempts have been undertaken to develop objective techniques 
for the evaluation of cosmetic outcome. The Breast Retraction Assessment (BRA), the Lower 
Breast Contour (LBC) and the Upward Nipple Retraction (UNR) were the first described 
methods for objective cosmetic evaluation and showed correlations with tumour size and 
radiotherapy. A correlation was also found between objective measurements and subjective panel 
scores. However, these objective methods mostly focus on breast asymmetry calculations and are 
thus probably insufficient. BRA, for instance, uses nipple displacement as its main determinant: 
this produces unreliable outcomes for tumours located in the lower breast and ignores possible 
changes in skin colour or texture. As a response to these shortcomings, various computerised 
methods were developed that fully assess all aspects of cosmetic outcome after BCT.46,51,70
i i i . Computer i s ed  evaluat ion methods : BAT and BCCT.core
In order to assess items related to breast appearance more objectively, new software tools such as 
the Breast Analyzing Tool (BAT) and Breast Cancer Conservative Treatment.cosmetic results 
(BCCT.core) have been developed. These software tools have shown value in the analysis of 
cosmetic outcome, with both tools carrying out an independent evaluation once the observer has 
digitally marked the nipples, axillas and sternum jugular notch. 68 In the case of BCCT.core, the 
software automatically identifies the breast contour for further automated calculations. BCCT.
core provides an extensive set of automated measurements, including well-known asymmetry 
calculations such as BRA, LBC and UNR. Colour difference features, scar visibility and, finally, 
a score on a 4-point scale can be generated. The claimed advantages of BCCT.core are the 
fast and accurate reporting of calculations and results, data that were very time-consuming to 
produce before the advent of this program. Furthermore, an automated and reliable system for 
the assessment of cosmetic outcome enables comparison between different breast units around 
the world.66
 
d. Patient  s e l f-evaluat ion
Patient self-evaluation is the assessment that most closely reflects the psychological adaptation 
of a patient to the cosmetic result. This assessment is particularly valuable because subjective 
patient experience is central to assessment of quality of life. However, various studies have shown 
that reproducibility of patient self-evaluation is low, probably because several factors are poorly 
amenable to quantification, such as age and socioeconomic status. Patients also tend to report 
higher scores than professionals.59,69
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Most studies that included patient self-evaluation relied on a single question related to the 
appearance of the breast, comparing the treated with the untreated breast. A more comprehensive 
approach to patient self-evaluation involves use of a questionnaire assessing cosmetic outcome 
and patient satisfaction with the appearance of the treated breast compared to the untreated 
breast. This type of questionnaire should include factors such as scar visibility, volume, breast 
contour, firmness, nipple position, skin colour, overall result and satisfaction with the cosmetic 
result, scored on a 4-point Likert scale.
U LT RA S O N O G RA P H Y  F O R 
B RE A S T  LE S I O N S
High-frequency ultrasonography (US) was introduced in the 1970’s. This imaging technology 
subsequently evolved, producing better image quality, increased depth and more portable devices. 
Alongside the mammography, radiologists use ultrasonography as a diagnostic tool to examine 
suspicious breast lesions, axillary lymph nodes and to guide biopsies. It now appears to be the 
diagnostic tool of choice for breast lesions that are visible with ultrasonography.
The advantages of ultrasonography are not exclusively reserved for radiologists, as the imaging 
modality has since become a valuable therapeutic tool in operating theatres. In relation to BCS, 
ultrasound-guided surgery (USS) has proven itself to be a useful and precise method of excising 
non-palpable breast cancer. An extensive body of literature has confirmed the numerous benefits 
of USS over needle localization for non-palpable breast cancer excision. 
In 1999, the research groups of Harlow et al. and Rahusen et al. were the first to describe the use 
of ultrasonography to guide surgical excision of non-palpable breast cancer, showing that USS 
was feasible and that good oncological results could be achieved.71,72 The use of ultrasonography 
in non-palpable breast cancer was confirmed to be superior to wire-guided excision (WGE) in 
2002, when a randomized clinical trial reported adequate excisions in 89% vs. 55% of patients, 
respectively.73 Other trials using intra-operative ultrasound in BCS performed in 2007 and 2008 
have shown exceptional results in terms of reduction in margin involvement.74-76 
Ultrasonography for non-palpable breast cancer has also proven to be superior to other techniques 
used in the North-Holland region of the Netherlands (including Amsterdam). A multicentre 
retrospective study was performed to compare WGE, radio-guided occult lesion localisation 
(ROLL) and ultrasound-guided surgery (USS) for the excision of non-palpable breast cancer. 
This study concluded that USS was the most accurate excision technique and decreased the need 
for additional surgery.77
In light of the advantages when applied to non-palpable tumours, USS for palpable breast cancer 
could potentially improve surgical outcomes by preventing margin involvement. Surprisingly, a 
review of literature on breast-conserving ultrasound-guided excision of palpable breast cancer 
showed that the first study to report use of USS for palpable breast cancer only appeared in 2001 
(Moore et al.). This study compared a standard lumpectomy or palpation-guided surgery (PGS) 
with USS in a randomized setting (27 patients vs. 24, respectively). Although only 51 patients 
were included, this study showed clear improvements in surgical accuracy and margin status with 
ultrasound-guided surgery compared to palpation-guided surgery.78 These encouraging results 
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should have stimulated further studies of USS, with detailed comparisons of cosmetic outcomes, 
quality of life and cost analysis. Regrettably, this potential breakthrough for BCS was overlooked 
and today far too many surgeons still use palpation-guided techniques for palpable breast cancer.
Other BCS studies were identified in the review in which ultrasonography was used either 
before incision to precisely localise the tumour, or for ex-vivo specimen checking in order to 
determine possible margin involvement.28,79-81 Surgical accuracy was improved by the use of 
ultrasonography in all studies, but unfortunately this did not stimulate wider adoption of the 
USS technique despite demonstrable improvements in oncological outcomes. These positive 
experiences with USS for non-palpable lesions, as well as the data of Moore et al., were not 
entirely ignored and prompted us to initiate the COBALT trial in 2011.63 The first results of 
the COBALT trial showed improved margins status and less resection of healthy breast tissue 
with USS compared to PGS, potentially resulting in improved cosmetic outcomes and patient 
satisfaction. Other studies have also appeared that report decreased margin involvement rates 
determined by ex vivo ultrasound scanning of a lumpectomy. However, these studies did not use 
intra-operative ultrasound guidance to excise the tumour.
In terms of the training in USS required for palpable breast cancer excision, studies have shown 
that surgeons trained in USS achieve tumour-free margins at their very first procedure and 
that it takes only 8 procedures to obtain a CRR of 1.82 In some countries specialists other than 
radiologists are trained in performing ultrasonography, but for therapeutic rather than diagnostic 
reasons. A recent American survey reported that 39% of breast surgeons believe themselves to be 
adequately trained in breast ultrasound to perform biopsies.83 
The excellent results achieved by surgeons using USS for non-palpable breast cancer should 
remove any doubts regarding the ability of surgeons to perform ultrasound-guided breast-
conserving surgery.71,77,84-86 However, non-palpable breast cancer excisions should always include 
a radiologist in the procedure.
U ltrasound guided surger y  technique
The following video demonstrates the technical aspects of ultrasound-guided surgery for 
palpable breast cancer. 
Please scan the QR-code:
Or visit https://youtu.be/08N4t6SXyjI
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O U T LI N E  O F  T H E  T H E S I S
Since the radical mastectomy proclaimed by Halsted, breast cancer surgery has undergone a 
profound evolution driven by the fact that a majority of patients now present at an early stage. 
The current 5-year survival rates after breast-conserving therapy for early stage breast cancer 
(with or without chemotherapy or hormonal therapy) are excellent. The focus of BCS therefore 
appears to be shifting towards improving cosmetic outcomes.
The COBALT trial was initiated in 2010 with the primary goal of comparing USS and PGS in 
terms of margin involvement, lumpectomy volume and amount of healthy breast tissue resected. 
The current thesis focuses on the secondary goals of the COBALT trial, including cosmetic 
outcomes, patient satisfaction and healthcare costs.
Chapter 2. This chapter describes the primary outcomes of the COBALT trial, palpation-guided 
surgery (PGS) vs. ultrasound-guided surgery (USS) in a randomized controlled setting, in terms 
of margin involvement, healthy breast tissue resection and additional therapy.
Chapter 3. A recurring theme during discussions on the implementation of USS in daily 
practice is the purchase cost of an ultrasound system, an ostensibly large investment. We therefore 
examine whether the benefits of USS (margin involvement and less additional therapy) could 
actually result in cost-savings compared to PGS, despite the purchase of the USS system.
Chapter 4. Studies often report cosmetic outcome after breast-conserving surgery using 
different subjective and objective evaluation techniques. The varying techniques used in different 
studies and the lack of a gold standard in the evaluation of cosmetic outcome complicate the 
comparison of studies. In this chapter we study single and combinations of existing cosmetic 
outcome evaluation techniques to determine relative reliability.
Chapter 5. Given the reduction in additional therapy, lumpectomy volume and the amount 
of healthy breast tissue resected with USS, we examine if USS leads to an improved cosmetic 
outcome after 1-year follow-up compared to PGS. The evaluation methods used rely on the 
outcomes of chapter 4. Furthermore, we evaluate patient satisfaction in both groups.
Chapter 6. Although it was already clear that the tumour-involved margin rate in the North-
Holland region is high, we wished to examine current margin involvement rates (including 
close margins) and the extent of healthy breast tissue resection after BCS in the Netherlands 
during 2012 and 2013. We therefore analysed over 10,000 pathology reports on BCS included 
in the PALGA database (a national network and registry of histology and cytopathology in the 
Netherlands).
Chapter 7. New surgical trends, referred to as oncoplastic breast surgery (OPBS), combine 
oncological resection of breast cancer with plastic surgery techniques in a single procedure. In 
this chapter, the oncological safety, indications, advantages and limitations of OPBS are studied 
in a systematic review of literature.
Chapter 8. The results and conclusions of this thesis are discussed and a perspective is provided 
on the future of breast cancer surgery.
Chapter 9. A summary in English, Dutch and French, is provided.
28
References
1. Muller J. Elements of physiology: London Taylor & Walton; 1838.
2. Virchow RLK. Cellular pathology, 1859 special edition. London: John Churchill; 1859.
3. Moore CH. On the Influence of Inadequate Operations on the Theory of Cancer. Medico-
chirurgical transactions 1867; 50: 245-80.
4. Banks WM. On Free Removal of Mammary Cancer, with Extirpation of the Axillary Glands as 
a Necessary Accompaniment. British medical journal 1882; 2(1145): 1138-41.
5. Halsted WS. I. The Results of Operations for the Cure of Cancer of the Breast Performed at the 
Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 1894; 20(5): 497-555.
6. Halsted WS. I. A Clinical and Histological Study of certain Adenocarcinomata of the Breast: 
and a Brief Consideration of the Supraclavicular Operation and of the Results of Operations for 
Cancer of the Breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 1898; 28(5): 
557-76.
7. Halsted WS. I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann 
Surg 1907; 46(1): 1-19.
8. Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of 
operation performed. British journal of cancer 1948; 2(1): 7-13.
9. Mc WR. The value of simple mastectomy and radiotherapy in the treatment of cancer of the 
breast. The British journal of radiology 1948; 21(252): 599-610.
10. Crile G, Jr. The smaller the cancer, the bigger the operation? Rationale of small operations for 
small tumors and large operations for large tumors. JAMA 1967; 199(10): 736-8.
11. Crile G, Jr. Biological considerations in the treatment of cancer. Cleve Clin Q 1972; 39(4): 145-
52.
12. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after 
lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002; 
94(15): 1143-50.
13. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing 
total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive 
breast cancer. N Engl J Med 2002; 347(16): 1233-41.
14. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and 
radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on 
local recurrence. J Clin Oncol 2000; 18(8): 1668-75.
15. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small 
breast cancer: long-term results of a randomized trial. Eur J Cancer 1990; 26(6): 668-70.
16. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study 
comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J 
Med 2002; 347(16): 1227-32.
17. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node 
biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe 
detection. J Am Coll Surg 1998; 186(3): 275-83.
18. Fabry HFJ, Zonderhuis BM, Meijer S, Berkhof J, Van Leeuwen PAM, Van der Sijp JRM. 
Cosmetic outcome of breast conserving therapy after sentinel node biopsy versus axillary lymph 
node dissection. Breast Cancer Res Treat 2005; 92(2): 157-62.
19. Rahusen FD, Pijpers R, van Diest PJ, Bleichrodt RP, Torrenga H, Meijer S. The implementation 
of the sentinel node biopsy as a routine procedure for patients with breast cancer. Surgery 2000; 
128(1): 6-12.
29
20. Meijer S, Pijpers R, Borgstein PJ, Bleichrodt RP, van Diest PJ. [The sentinel node procedure: 
standard intervention for surgical treatment of breast cancer]. Ned Tijdschr Geneeskd 1998; 
142(41): 2235-7.
21. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after 
a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, 
multicentre, open-label, phase 3 non-inferiority trial. The Lancet Oncology 2014; 15(12): 1303-
10.
22. Nederlands Kankerregistratie (NKR); cijfers, overleving; borst. 6e editie; 2003-2007.
23. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database 
Syst Rev 2009; (4): CD001877.
24. Kaufmann M, Morrow M, von Minckwitz G, Harris JR. Locoregional treatment of primary 
breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010; 
116(5): 1184-91.
25. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast 
conservation therapy. Am J Surg 2002; 184(5): 383-93.
26. Poortmans PM, Collette L, Horiot JC, et al. Impact of the boost dose of 10 Gy versus 26 Gy in 
patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year 
results of the randomised EORTC boost trial. Radiother Oncol 2009; 90(1): 80-5.
27. Jacobs L. Positive margins: the challenge continues for breast surgeons. Ann Surg Oncol 2008; 
15(5): 1271-2.
28. Davis KM, Hsu CH, Bouton ME, Wilhelmson KL, Komenaka IK. Intraoperative ultrasound 
can decrease the re-excision lumpectomy rate in patients with palpable breast cancers. Am Surg 
2011; 77(6): 720-5.
29. Krekel N, Zonderhuis B, Muller S, et al. Excessive resections in breast-conserving surgery: a 
retrospective multicentre study. Breast J 2011; 17(6): 602-9.
30. Association of Breast Surgery at B. Surgical guidelines for the management of breast cancer. Eur 
J Surg Oncol 2009; 35 Suppl 1: 1-22.
31. Danish Breast Cancer Group. Vedr. Resektionsrande ved lumpektomi. 10-23-2015 2009. http://
www.dbcg.dk/PDF Filer/Retningslinier resektionsrande 061009.pdf.
32. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des 
Mammakarzinoms. 10-23-2015 2012. http://www.awmf.org/uploads/tx_szleitlinien/032-
045OL_k_S3__Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf 
(accessed february 7 2015).
33. Réseau Espace Santé-Cancer Rhône-Alpes. Les Référentiels Cancer du Sein. [5-12-2013]. 2013. 
http://www.rrc-ra.fr/Ressources/referentiels/PRA-SEI-1312SEIN.pdf (accessed february 7 
2015).
34. Référentiel locorégional et métastatique des Cancers Cancers du sein ‐ Juin 2010 Languedoc-
Roussillon. http://www.oncolr.org/upload/Espace_patients/Referentiels_regionaux/ONCO_
LR_-_Referentiel_locoregional_et_metastatique_des_Cancers_du_seinn_-_Juin_2010.pdf 
(accessed february 7 2015).
35. Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn mammacarcinoom. 2008. 
http://www.oncoline.nl/uploaded/FILES/mammacarcinoom/Richtlijn Behandeling van het 
Mammacarcinoom oktober 2005.pdf (accessed february 7 2015).
36. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for 
Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-
breast irradiation in stages I and II invasive breast cancer. International journal of radiation 
oncology, biology, physics 2014; 88(3): 553-64.
30
37. Blair SL, Thompson K, Rococco J, Malcarne V, Beitsch PD, Ollila DW. Attaining negative 
margins in breast-conservation operations: is there a consensus among breast surgeons? J Am 
Coll Surg 2009; 209(5): 608-13.
38. Azu M, Abrahamse P, Katz S, Jagsi R, Morrow M. What is an adequate margin for breast-
conserving surgery? Surgeon attitudes and correlates. (1534-4681 (Electronic)).
39. Morrow M. Trends in the surgical treatment of breast cancer. Breast J 2010; 16 Suppl 1: S17-S9.
40. Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM. Obtaining adequate 
surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current 
modalities and future directions. Ann Surg Oncol 2009; 16(10): 2717-30.
41. Waljee JF, Hu ES, Newman LA, Alderman AK. Predictors of re-excision among women 
undergoing breast-conserving surgery for cancer. Ann Surg Oncol 2008; 15(5): 1297-303.
42. Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer--bigger is 
not better. N Engl J Med 2012; 367(1): 79-82.
43. Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early-stage breast cancer 
patients treated with radical mastectomy or breast-conserving procedures: results of EORTC 
Trial 10801. Eur J Cancer 1998; 34(3): 307-14.
44. Waljee JF, Hu ES, Ubel PA, Smith DM, Newman LA, Alderman AK. Effect of esthetic outcome 
after breast-conserving surgery on psychosocial functioning and quality of life. J Clin Oncol 
2008; 26(20): 3331-7.
45. Al-Ghazal SK, Fallowfield L, Blamey RW. Does cosmetic outcome from treatment of primary 
breast cancer influence psychosocial morbidity? Eur J Surg Oncol 1999; 25(6): 571-3.
46. Sneeuw KC, Aaronson NK, Yarnold JR, et al. Cosmetic and functional outcomes of breast 
conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning. 
Radiother Oncol 1992; 25(3): 160-6.
47. Van Limbergen E, Rijnders A, Van der Schueren E, Lerut T, Christiaens R. Cosmetic evaluation 
of breast conserving treatment for mammary cancer. Radiother Oncol 1989; 16(4): 253-67.
48. Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast 
conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 
‘boost versus no boost’. Eur J Cancer 2008; 44(17): 2587-99.
49. Immink JM, Putter H, Bartelink H, et al. Long-term cosmetic changes after breast-conserving 
treatment of patients with stage I-II breast cancer and included in the EORTC ‘boost versus no 
boost’ trial. Ann Oncol 2012; 23(10): 2591-8.
50. Olivotto IA, Rose MA, Osteen RT, et al. Late cosmetic outcome after conservative surgery and 
radiotherapy: analysis of causes of cosmetic failure. Int J Radiat Oncol Biol Phys 1989; 17(4): 
747-53.
51. Sneeuw KC, Aaronson NK, Yarnold JR, et al. Cosmetic and functional outcomes of breast 
conserving treatment for early stage breast cancer. 1. Comparison of patients’ ratings, observers’ 
ratings, and objective assessments. Radiother Oncol 1992; 25(3): 153-9.
52. Zonderhuis BM, Jacobs GJA, Meijer S, van den Tol MP. Better cosmetic results in patients with 
limited axillary surgery after breast conserving therapy. Eur J Surg Oncol; submitted.
53. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned 
intensity modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat 
Oncol Biol Phys 2012; 82(2): 715-23.
54. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors 
on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. 
Radiother Oncol 2000; 55(3): 219-32.
31
55. Cochrane RA, Valasiadou P, Wilson ARM, Al-Ghazal SK, Macmillan RD. Cosmesis and 
satisfaction after breast-conserving surgery correlates with the percentage of breast volume 
excised. Br J Surg 2003; 90(12): 1505-9.
56. Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation 
therapy for breast cancer. IntJ Radiat Oncol Biol Phys 1995; 31(4): 753-64.
57. Matory WEJ, Wertheimer M, Fitzgerald TJ, Walton RL, Love S, Matory WE. Aesthetic results 
following partial mastectomy and radiation therapy. Plast Reconstr Surg 1990; 85(5): 739-46.
58. Cardoso MJ, Cardoso JS, Vrieling C, et al. Recommendations for the aesthetic evaluation of 
breast cancer conservative treatment. Breast Cancer Res Treat 2012; 135(3): 629-37.
59. Vrieling C, Collette L, Bartelink E, et al. Validation of the methods of cosmetic assessment after 
breast-conserving therapy in the EORTC “boost versus no boost” trial. EORTC Radiotherapy 
and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of 
Cancer. Int J Radiat Oncol Biol Phys 1999; 45(3): 667-76.
60. Krekel NM, van Slooten HJ, Barbe E, de Lange de Klerk ES, Meijer S, van den Tol MP. Is breast 
specimen shrinkage really a problem in breast-conserving surgery? J Clin Pathol 2012; 65(3): 
224-7.
61. Fitoussi AD, Berry MG, Fama F, et al. Oncoplastic breast surgery for cancer: analysis of 540 
consecutive cases [outcomes article]. Plast Reconstr Surg 2010; 125(2): 454-62.
62. Gray RJ, Pockaj BA, Karstaedt PJ, Roarke MC. Radioactive seed localization of nonpalpable 
breast lesions is better than wire localization. Am J Surg 2004; 188(4): 377-80.
63. Krekel NM, Zonderhuis BM, Schreurs HW, et al. Ultrasound-guided breast-sparing surgery to 
improve cosmetic outcomes and quality of life A prospective multicentre randomised controlled 
clinical trial comparing ultrasound-guided surgery to traditional palpation-guided surgery 
(COBALT trial). BMC Surg 2011; 11(1): 8.
64. Rampaul RS, Bagnall M, Burrell H, Pinder SE, Evans AJ, Macmillan RD. Randomized clinical 
trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of 
occult breast lesions. Br J Surg 2004; 91(12): 1575-7.
65. Pezner RD, Patterson MP, Hill LR, et al. Breast retraction assessment: an objective evaluation of 
cosmetic results of patients treated conservatively for breast cancer. Int J Radiat Oncol Biol Phys 
1985; 11(3): 575-8.
66. Cardoso MJ, Cardoso J, Amaral N, et al. Turning subjective into objective: the BCCT.core 
software for evaluation of cosmetic results in breast cancer conservative treatment. Breast 2007; 
16(5): 456-61.
67. Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary 
radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 1979; 
5(2): 257-61.
68. Cardoso MJ, Cardoso JS, Wild T, Krois W, Fitzal F. Comparing two objective methods for the 
aesthetic evaluation of breast cancer conservative treatment. Breast Cancer Res Treat 2009; 
116(1): 149-52.
69. Sacchini V, Luini A, Tana S, et al. Quantitative and qualitative cosmetic evaluation after 
conservative treatment for breast cancer. Eur J Cancer 1991; 27(11): 1395-400.
70. Pezner RD, Lipsett JA, Vora NL, Desai KR. Limited usefulness of observer-based cosmesis 
scales employed to evaluate patients treated conservatively for breast cancer. Int J Radiat Oncol 
Biol Phys 1985; 11(6): 1117-9.
71. Harlow SP, Krag DN, Ames SE, Weaver DL. Intraoperative ultrasound localization to guide 
surgical excision of nonpalpable breast carcinoma. J Am Coll Surg 1999; 189(3): 241-6.
32
72. Rahusen FD, Taets van Amerongen AH, van Diest PJ, Borgstein PJ, Bleichrodt RP, Meijer S. 
Ultrasound-guided lumpectomy of nonpalpable breast cancers: A feasibility study looking at the 
accuracy of obtained margins. J Surg Oncol 1999; 72(2): 72-6.
73. Rahusen FD, Bremers AJA, Fabry HFJ, van Amerongen AHMT, Boom RPA, Meijer S. 
Ultrasound-guided lumpectomy of nonpalpable breast cancer versus wire-guided resection: a 
randomized clinical trial. Ann Surg Oncol 2002; 9(10): 994-8.
74. Haid A, Knauer M, Dunzinger S, et al. Intra-operative sonography: a valuable aid during breast-
conserving surgery for occult breast cancer. Ann Surg Oncol 2007; 14(11): 3090-101.
75. Ngo C, Pollet AG, Laperrelle J, et al. Intraoperative ultrasound localization of nonpalpable breast 
cancers. AnnSurgOncol 2007; 14(9): 2485-9.
76. Fortunato L, Penteriani R, Farina M, Vitelli CE, Piro FR. Intraoperative ultrasound is an 
effective and preferable technique to localize non-palpable breast tumors. Eur J Surg Oncol 2008; 
34(12): 1289-92.
77. Krekel NMA, Zonderhuis BM, Stockmann HBAC, et al. A comparison of three methods for 
nonpalpable breast cancer excision. Eur J Surg Oncol 2011; 37(2): 109-15.
78. Moore MM, Whitney LA, Cerilli L, et al. Intraoperative ultrasound is associated with clear 
lumpectomy margins for palpable infiltrating ductal breast cancer. Ann Surg 2001; 233(6): 761-8.
79. Eichler C, Hubbel A, Zarghooni V, et al. Intraoperative ultrasound: improved resection rates in 
breast-conserving surgery. Anticancer Res 2012; 32(3): 1051-6.
80. Fisher CS, Mushawah FA, Cyr AE, Gao F, Margenthaler JA. Ultrasound-guided lumpectomy 
for palpable breast cancers. Ann Surg Oncol 2011; 18(11): 3198-203.
81. Olsha O, Shemesh D, Carmon M, et al. Resection margins in ultrasound-guided breast-
conserving surgery. Ann Surg Oncol 2011; 18(2): 447-52.
82. Krekel NM, Lopes Cardozo AM, Muller S, Bergers E, Meijer S, van den Tol MP. Optimising 
surgical accuracy in palpable breast cancer with intra-operative breast ultrasound--feasibility and 
surgeons’ learning curve. Eur J Surg Oncol 2011; 37(12): 1044-50.
83. Sclafani LM, Bleznak A, Kelly T, El-Tamer MB. Training a new generation of breast surgeons: 
are we succeeding? Ann Surg Oncol 2012; 19(6): 1856-61.
84. Fine RE, Staren ED. Updates in breast ultrasound. SurgClinNorth Am 2004; 84(4): 1001-10vi.
85. Holmes DR, Silverstein MJ. A minimally invasive breast biopsy clinic: an innovative way to teach 
breast fellows how to perform breast ultrasound and ultrasound-guided breast procedures. Am J 
Surg 2006; 192(4): 439-43.
86. Staren ED, Knudson MM, Rozycki GS, Harness JK, Wherry DC, Shackford SR. An evaluation 
of the American College of Surgeons’ ultrasound education program. Am J Surg 2006; 191(4): 
489-96.
33
34
Intraoperative ultrasound guidance for palpable breast cancer 
excision: results of a multicentre, parallel group randomised 
controlled trial. (COBALT)
NMA Krekel 
MH Haloua 
AMF Lopes Cardozo 
RH de Wit 
A Bosch 
LM de Widt-Levert 
S Muller 
H van der Veen 
E Bergers 
ESM de Lange de Klerk 
S Meijer 
MP van den Tol
The Lancet Oncology. January 2013; 14 (1), 48-54
2
36
A B S T RAC T
Bac kground
Breast-conserving surgery for palpable breast cancer is associated with both tumour-involved 
margins in up to 41% of cases and with excessively large excision volumes. Ultrasound-guided 
surgery has the potential to resolve both problems, thereby improving surgical accuracy for 
palpable breast cancer. We aimed to compare ultrasound-guided surgery with the standard for 
palpable breast cancer, palpation-guided surgery in terms of margin status and extent of healthy 
breast tissue resection.
Methods
In this comparative, parallel group randomised clinical trial, patients with palpable T1-T2 
invasive breast cancer were recruited between October 2010 and closing of the trial in March 
2012 in 6 medical centres in the Netherlands. Participants were randomly assigned (1:1) by 
computer-generated random sequence via a web system, and stratified by study centre, to either 
ultrasound-guided surgery or palpation-guided surgery. Patients and investigators were not 
masked to treatment assignment. The primary outcomes were surgical margin involvement 
(classified as tumour-free, focally positive, or positive), and excess healthy tissue resection 
which was defined by a calculated resection ratio (CRR) (derived from excision volumes and 
tumour diameters). Data was analysed on an intention to treat basis. This trial is registered at 
TrialRegister.nl, NTR2579.
 
F indings
A total of 134 patients were randomly assigned to ultrasound-guided surgery (n = 65) or 
palpation-guided surgery (n=69). A dramatic difference in margin involvement was seen with 2 
(3%) of the 65 patients had tumour-involved margins in the ultrasound-guided surgery group 
compared to 12 (17%) of the 69 patients in the palpation-guided surgery group (difference 14%, 
95% CI 4 – 25, p=0.0093). Ultrasound-guided surgery also resulted in reduced excision volumes, 
38 vs. 58 cc (difference 20 cc, 95% CI 7 - 31) and reduced CRR , 1.0 vs. 1.7 (difference 0.7, 95% 
CI 0.4 – 1.0), compared with palpation-guided surgery (both, p<0.002).
Inter pretat ion
By allowing continuous intraoperative tumour visualisation, ultrasound-guided surgery can 
significantly lower the high rate of tumour-involved resection margins following palpable breast 
cancer excision, thus reducing the need for additional interventions, including re-excision, 
mastectomy and radiotherapy boost. In addition, through the achievement of optimal resection 
volumes, ultrasound-guided surgery significantly reduces unnecessary healthy breast tissue 
resection and may therefore contribute to improved cosmetic results and quality of life of breast 
cancer patients.
Funding
The randomised controlled trial was supported by the Dutch Pink Ribbon Foundation, Osinga-
Kluis Foundation and Toshiba Medical Systems.
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I N T RO D U C T I O N
Breast-conserving surgery (BCS) has gained wide acceptance as the treatment of choice for 
early-stage breast cancer. Over the past decades, advances in early diagnosis have been achieved 
through greater patient awareness, widespread screening mammography and improved imaging 
techniques. This has resulted in an increase in the rate of BCS and these procedures can now be 
safely offered to the majority of breast cancer patients.1-3 
One of the primary goals of BCS is to obtain tumour-free resection margins. Margins positive 
or focally positive for tumour cells are associated with an increased risk of local recurrence, and 
in case of tumour-positive margins, re-excision or even mastectomy are often required to achieve 
definite, clear margins. In cases of focally positive margins, either a second surgery or additional 
boost radiotherapy should be considered.4-7 These additional treatments increase patient stress 
and have a major impact on the final appearance of the breast. An important secondary goal of 
BCS is the achievement of a satisfactory cosmetic outcome. The cosmetic outcome of BCS has 
received increasing attention in recent years due to the close relationship with patient well-being 
and quality of life.8,9 The key factor in a poor cosmetic result following BCS is the volume of 
breast tissue resected, which means that a surgeons should aim for a complete excision of the 
carcinoma, while sacrificing as little healthy breast tissue as possible.10,11
In practice, the excision of a palpable breast carcinoma is guided by pre-operative diagnostic 
images and the intraoperative tactile skills of the surgeon. The somewhat ‘blind’ approach 
of using palpation-guided surgery is known to be highly inaccurate, with studies worldwide 
reporting positive resection margins in up to 41% of patients.7,12-14 Moreover, a surgeon tends 
to overexcise normal breast tissue in an effort to attain negative margins, resulting in needlessly 
large excision volumes.11,13 
High-frequency real-time ultrasonography was introduced in the 1970’s and the technology 
has steadily improved, resulting in increased sensitivity, greater portability and the availability 
of ultrasonography in the operating theatre. In recent years, ultrasonography has emerged as an 
effective guidance tool during surgery and ultrasound-guided surgery has been introduced into 
breast cancer surgery as a method of excising nonpalpable breast cancer. An extensive body of 
literature has accumulated showing the manifold benefits of ultrasound-guided surgery over 
needle localisation for nonpalpable breast cancer excision, including improved margin clearance, 
fewer re-excision procedures, smaller excision volumes, and better lumpectomy specificity.15-19 
In light of the advantages when applied to nonpalpable masses, ultrasound-guided surgery 
for palpable breast cancer should similarly decrease margin positivity and excision volumes. 
Nevertheless, reports on the application of ultrasonography in palpable breast cancer excision 
are limited, with only a single report describing the prospective comparison of the outcomes of 
ultrasound-guided surgery with palpation-guided surgery in palpable invasive ductal carcinomas 
and showing a significant improvement of margin status in patients who underwent ultrasound-
guided surgery.20
The present study was designed as a randomised, controlled trial and aimed to compare the 
effectiveness of ultrasound-guided surgery in palpable invasive breast cancer with standard 
palpation-guided surgery, including the main outcomes of incidence of tumour-involved 
margins and extent of healthy breast tissue resection.21
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M E T H O D S
 
S tudy Design, R andomisat ion and Masking
The COBALT study was a prospective, multicentre, comparative, two-arm, parallel randomised 
clinical trial undertaken in 6 hospitals in the Netherlands from October 2010 to March 2012. A 
computer-generated randomisation was used by the principal investigators at the coordinating 
centre to assign patients equally to the study arms. Randomisation was stratified for each study 
centre. All patients and investigators were aware of study group assignments. The participating 
breast surgeons had all participated in an ultrasonography training program outside of the trial, 
as previously described.22 The same breast surgeons performed both ultrasound-guided surgery 
and palpation-guided surgery, without the presence of a dedicated radiologist in the operating 
theatre.
This study was conducted in accordance with the principles of the declaration of Helsinki, the 
guidelines for Good Clinical Practice and the CONSORT statement.23 The study protocol was 
approved by the central and local independent medical ethics review boards of the participating 
hospitals, and the trial was registered under NTR2579 (COBALT study). Protocol details have 
been published previously.21 All patients provided written informed consent.
Par t ic ipants
Patients were eligible to participate if diagnosed with a palpable early-stage (T1-2N0-1) 
invasive breast cancer and scheduled to undergo BCS. Breast cancer was diagnosed by physical 
examination, mammography, ultrasonography of the breast and axilla followed by cytological 
puncture or image-guided core needle biopsy. Magnetic Resonance Imaging (MRI) was rarely 
used in this study. Patients with preoperatively diagnosed ductal carcinoma in situ (DCIS), 
multifocal disease, a history of neo-adjuvant therapy, previous surgical treatment or radiation 
therapy of the affected breast were excluded from the study. It should be stressed that patients 
with invasive carcinoma with limited or extensive DCIS as postoperatively diagnosed by the 
pathologist (i.e. unexpectedadditional DCIS) were not excluded. 
Inter vent ions
Patients were assigned to undergo either ultrasound-guided surgery or palpation-guided surgery. 
The aim in both ultrasound-guided surgery and palpation-guided surgery was to achieve 
complete tumour removal with grossly healthy tissue margins of up to 1 cm. Ultrasound-
guided surgery was performed using a THI 14-MHz ultrasonography probe (Toshiba Viamo 
portable ultrasound system, Japan), allowing continuous tumour visualisation during the surgical 
procedure. The method of ultrasound-guided surgery has been described previously.22 Briefly, 
the surgeon localised the tumour in the breast by palpation and ultrasonography imaging, 
and compared images with the digital pre-operative ultrasonography images. The surgeon 
measured the tumour diameter, the lesion-to-skin distance and the lesion-to-fascia distance, in 
millimeters, and marked the tumour margins on the skin. These markings were used to determine 
the incision line and the extent of dissection. Dissection was further assisted by placing the 
ultrasonography repeatedly in or around the wound at different angles, continuously visualising 
the tumour margins, thereby checking the attainment of adequate resection margins. During the 
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Figure. CONSORT diagram for the trial. 
64 received ultrasound-guided surgery
1 received palpation-guided surgery
65 allocated to ultrasound-guided surgery 69 allocated to palpation-guided surgery
69 received palpation-guided surgery
0 lost to follow-up
69 analysed by intention to treat
0 lost to follow-up
65 analysed by intention to treat
142 Assessed for eligibility
 8 excluded
     6 did not meet inclusion criteria
     2 other reasons
134 underwent random allocation
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ultrasound-guided surgery surgeons did not guide their surgery by palpation; they merely focused 
on ultrasound images. Following excision, the specimen was scanned with ultrasonography ex 
vivo so that additional tissue could be excised if the tumour excision appeared incomplete.
palpation-guided surgery was guided by palpation in the standard manner and the fingers were 
used to palpate the tumour, retract it and guide the dissection. The adequacy of the resection 
using this approach relied on the experience and tactile abilities of the surgeon, and did not make 
use of objective imaging during the surgery.
The orientation of the specimen was preserved with marking sutures, such that positive resection 
margins could be identified and re-excised if necessary. In neither of the treatment modalities 
were frozen section analysis, cavity shavings or specimen radiography performed. Axillary surgery 
was performed in the same surgical session, according to international guidelines.24,25 All cases 
were pre-and postoperatively reviewed by a multidisciplinary team, and adjuvant radiotherapy or 
systemic therapy was administered according to institutional and national guidelines. 
S tudy O utcomes
The first coprimary outcome was a composite of margin status and the requirements for 
additional treatment interventions. The method of pathological examination was standardised, 
according to Dutch national guidelines. Margins were categorised as negative, focally positive, 
or positive (respectively, no ink on any tumour cells, an area with a diameter of ≤ 4 mm with 
tumour, grossly discernible tumour at the inked edge of the specimen) in accordance with Dutch 
national guidelines.26 The second coprimary outcome was excess volume resection. A calculated 
resection ratio (CRR) was introduced, whereby the volume of the fresh specimen was measured 
in the operating theatre by fluid displacement and divided by the ‘optimal specimen volume’, 
defined prior to this study as the spherical tumour volume plus an arbitrarily chosen ‘optimal’ 
tumour-free resection margin of 1 cm.13,26,27 Secondary outcomes were excision time, defined 
as the time from the first mammary incision to wound closure (in minutes), and post-operative 
complications requiring intervention. Cosmetic outcomes, quality of life and local recurrence 
rates were evaluated following surgery, and will be evaluated at least at 3, 6 12, 24, and 36 months.
S tat ist ic a l  Anal y s is
A sample size of 120 patients gives a power of 80% to detect a 17.5% reduction in tumour-
involved margins, thereby reducing the rate of tumour-involved margin from 22.5% to 5%. 
Secondly, worldwide literature and our previous retrospective multicentre study showed that 
excision volumes exceeding 85cc result in poor cosmetic outcome in 33% of patients. We assumed 
a 23% reduction in cases with excess tissue resection (from 33% to 10%). A statistical power of 
80% to detect this 23% improvement would require 57 patients in each group. Anticipating a 
10% exclusion rate, at least 132 patients would need to be initially recruited, and trial end was 
anticipated when at least 132 patients were recruited.13,21
All analyses were performed with Statistical Package for the Social Sciences (SPSS statistical 
software, Version 15.0; SPSS, Inc., Chicago, IL, USA) and Confidence Interval Analysis for 
Windows, which goes with the book Statistics with Confidence 2nd (Eds: Altman, Machin, 
Bryant and Gardner). Values were expressed as mean and range, and percentages were given 
where appropriate. The two intervention groups were generally compared using an independent 
samples T-test, a Chi-square or an exact test for nominal data. Stratified analysis was performed 
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post-hoc for margin status using Cochran’s test for conditional independence. Post-hoc stepwise 
linear regression analysis was applied for analysis of resection of excess healthy tissue resection 
controlled for centre and surgeons. The results are presented with the corresponding P values 
and differences were considered significant at P<0.05. 
This trial is registered at TrialRegister.nl, NTR2579.
Detai ls  of  Funding
The Dutch Pink Ribbon Foundation provided funding for this trial, and for future related 
studies. The Osinga-Kluis Foundation provided funding for a Toshiba Viamo portable 
ultrasound system. Toshiba Medical Systems Corporation provided two extra Viamo portable 
ultrasound systems for use during the study period. The study sponsors were not involved in the 
study design, collection, analysis or interpretation of data, in the writing of the report, or in the 
decision to submit the paper for publication. All researchers were independent of the funders. 
N.M.A. Krekel, M.H. Haloua, S. Meijer and M.P. van den Tol had complete access to the data 
and were responsible for the decision to submit the manuscript.
RE S U LT S
Patient  and tumour  character ist ics
A total of 142 patients were enrolled from 6 hospitals in the Netherlands from October 4th 2010 
to March 22nd  2012. Of these, 6 were excluded due to either multifocal disease (n=3), neo-
adjuvant chemotherapy (n=2), or the absence of invasive carcinoma (n=1). Two patients refused 
to participate despite having previously given informed consent (Figure 1). The remaining 
134 patients were randomly assigned to undergo either ultrasound-guided surgery (n = 65) or 
palpation-guided surgery (n = 69). There was no bias due to unequal weighting of the numbers 
of each procedure conducted by each surgeon. The patient and tumour characteristics in both 
study groups were comparable (Table 1), with a mean age of 56 years, 80 (61%) of the 132 
tumours located in the upper outer quadrant, and a mean tumour size of 2.0 cm. All palpable 
invasive carcinomas were visible with the ultrasound-system. The majority of patients presented 
with invasive ductal carcinoma. Tumour-associated unexpected ductal carcinoma in situ (DCIS) 
diagnosed at pathological examination of the specimen was present in 84 (64%) of 132 cases. 
Minor lesions of additional DCIS inside or within several millimetres of the invasive tumour were 
found by the pathologist in 73 (55%) of the 132 specimens. In 12 (9%) of the 132 specimens a more 
extensive additional DCIS component was identified in the surgical specimen by the pathologist. 
Margin status
Analysis of resection margins showed a  reduced rate of invasive tumour-involvement when 
using intraoperative ultrasonography, with tumour-free margins in 63 (97%) of the 65 patients 
who underwnt ultrasound-guided surgery, compared with 57 (83%) of the 69 patients in the 
palpation-guided surgery group (difference 14%, 95% CI 4 – 25, p=0.0093) (Table 2). The mean 
size of the smallest tumour-free margin was 0.3 cm with ultrasound-guided surgery, against
0.4 cm with palpation-guided surgery (range 0.1–1.0 cm, p=0.31). Margins were neither involved 
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with invasive carcinoma nor unexpected additional DCIS in 58 (89%) of the 65 patients who 
underwent ultrasound-guided surgery, compared with 50 (72%) of the patients of the palpation-
guided surgery group (difference 17%, 95% CI 3 – 30 p=0.031). Stratified analysis on margin 
involvement showed significant improvement with ultrasound-guided surgery independent 
of surgeons’ performance, or study centre.  In all cases, the initial ultrasound-guided surgery 
excision appeared complete by using ultrasonography ex vivo, thus did not result in additional 
tissue resection. 
The improvement of margin status with ultrasound-guided surgery also resulted in less additional 
treatment in the ultrasound-guided surgery group (difference 17%, 95% CI 3 – 30, p=0.015,
Table 2). Additional boost radiotherapy was considered sufficient for 6 ultrasound-guided surgery 
patients and a re-excision was required in only 1 patient due to the presence of extensive DCIS 
at the surgical margin. In the palpation-guided surgery group, 11 patients received additional 
boost radiotherapy, 3 patients underwent a re-excision and 5 patients underwent a mastectomy 
(in 3 cases because of massively tumour-involved margins following first excision and in 2 cases 
due to margin-positivity following re-excision).
Table 1. Patient and Tumour characteristics
ultrasound-guided surgery
(n = 65)
palpation-guided surgery
(n = 69)
Age  (years) 54 (38-78) 57 (40-78)
Body-mass index (kg/m2) 26 (19-41) 27 (20-48)
Bra cup size C (A-G) C (A-E)
Location carcinoma
Upper outer quadrant
Upper inner quadrant
Lower outer quadrant
Lower inner quadrant
Tumour size (cm)
32 (49%)
12 (18%)
16 (25%)
5 (8%)
2.0 (0.6 – 4.1)
48 (70%)
7 (10%)
9 (13%)
5 (7%)
2.0 (0.5-4.5)
Tumour stage
T1
T2
36 (55%)
29 (44%)
35 (50%)
34 (49%)
Type carcinoma
Invasive ductal carcinoma
Invasive lobular carcinoma
Other
61 (94%)
1 (1%)
3 (5%)
62 (90%)
4 (6%)
3 (4%)
Aditional DCIS
Limited 
Extensive 
38 (59%)
5 (8%)
35 (50%)
7 (10%)
Axillary surgery 
Sentinel lymph node only
Axillary dissection
50 (77%)
15 (23%)
58 (84%)
11 (16%)
Data are number of patients (%) or mean (SD, range)
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Table 2. Margin status
ultrasound-guided surgery
(n = 65)
palpation-guided surgery
(n = 69)
Invasive carcinoma
Negative
Positive
Focally positive
63 (97%)
0 (0%)
2 (3%)
57 (83%)
5 (7%)
7 (10%)
Invasive carcinoma and/or
unexpected additional DCIS
Negative
Positive
Focally positive
58 (89%)
2 (3%)
5 (8%)
50 (72%)
9 (13%)
10 (15%)
Additional treatment
Radiotherapy boost
Re-excision
Mastectomy
7 (11%)
6 (9%)
1 (2%)
0 (0%)
19 (27%)
11 (16%)
3 (4%)
5 (7%)
 
Data are number of patients (%)
Table 3. Postoperative surgical measurements 
ultrasound-guided 
surgery
(n = 65)
palpation-guided 
surgery
(n = 69)
Difference
(95% CI)
p
Specimen weight (g)
Specimen volume (cc)
Calculated resection ratio
38 (6-138)
38 (7-135)
1.0 (0.4-2.6)
52 (2-156)
57 (10-200)
1.7 (0.3-5.4)
14 (4 – 24)
19 (7 – 31)
0.7 (0.4 – 1.0)
0.008
0.002
0.001
 
Data are mean (SD, range). Five patients had missing values for specimen volume and calculated resection ratio, one in the 
ultrasound-guided surgery group and four in the palpation-guided surgery group.
E xcess  healthy  t issue  resect ion
Both specimen weight and volume were significantly lower with ultrasound-guided surgery than 
with palpation-guided surgery (Table 3). The ultrasound-guided surgery group showed a mean 
CRR of 1.0, whereas the mean CRR with palpation-guided surgery was 1.7 (difference 0.7, 
95% CI 0.4 – 1.0, p=0.0001), indicating that while ultrasound-guided surgery facilitates optimal 
volume resection, palpation-guided surgery leads to unnecessarily large resections. A CRR>2.0 
was seen in only 5% (n=3) of the ultrasound-guided surgery group, compared with 30% (n=20) 
of the palpation-guided surgery group (P<0.00014). Patients undergoing ultrasound-guided 
surgery showed 45% (n=29) of CRR>1.0, compared with 67% (n=46) with palpation-guided 
surgery (P=0.015). For all patients with positive or focally-positive margins, the mean resection 
volume was 53cc, and the mean CRR was 1.3. Linear regression analysis of excess tissue resection 
for different surgeons and centres still showed significant improvement of specimen volumes 
with ultrasound-guided surgery. (5 missing values for excision volume and CRR: 1 ultrasound-
guided surgery, 4 palpation-guided surgery).
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Operat ive  t ime and complic at ions  ( Table  4)
Although excision time was equal between the two groups, an additional 5 minutes operative 
time were needed in the ultrasound-guided surgery group for ultrasound-handling prior to and 
following the operative procedure (1 minute for sterile covering of the ultrasonography probe, 
2-3 minutes for tumour-localisation and skin markings, and 1 minute for a specimen check) 
(difference 3 minutes, 95% CI 1 – 6, p=0.0066). Complications requiring intervention were 
infrequent and were distributed equally between the two groups. Cosmetic results, quality of 
life and local recurrence rates are the subjects of an ongoing evaluation, and the first results are 
expected in 2013.
Table 4. Operative time and complications
ultrasound-guided 
surgery (n = 65)
palpation-guided 
surgery (n = 69)
D i f f e r e n c e 
(95% CI)
p
Duration excision (min) 14 (6-30) 15 (2-40) -1 (-2 – 4) 0.38
Operative time (min) 19 (11-35) 15 (2-40) 4 (1 - 6) 0.0066
Complications
Wound infection (%)
Hematoma (%)
4 (6%)
1 (2%)
1 (2%)
3 (4%)
3 (4%)
0 (0%)
1 (-6 – 1.5)
-2 (-5 – 11)
1 (-4 – 8)
0.35*
-
-
Data are number of patients (%) or mean (SD, range) 
*Calculated with Fisher’s exact test for wound infection and haematoma cross-tabulation
D I S C U S S I O N
Pr imar y  outcomes
The results of this multicentre, randomised controlled trial unequivocally demonstrate that the 
intra-operative use of ultrasonography significantly improves the surgical accuracy of palpable 
breast cancer excision. The rate of adequate, clear resection margins was exceptionally high when 
using ultrasound-guided surgery with tumour-free resection margins in over 95% of cases, almost 
15% higher than with palpation-guided surgery. In our study, the improved margin clearance 
achievable through ultrasound guidance lowered the rate for both additional boost radiotherapy 
and re-operation, thus potentially avoiding adverse effects on cosmesis, psychological distress 
and health costs. Moreover, ultrasound-guided surgery resulted in significantly lower excision 
volumes and less resection of healthy breast tissue, and in contrast to the excessive specimen 
volumes seen in the group that underwent palpation-guided surgery, ultrasound-guided surgery 
achieved near optimal resection volumes. It is reasonable to assume that this reduction in 
excision volumes will translate to improved cosmetic outcomes, and thereby improved patient 
satisfaction and quality of life. These data are expected in the near future. 
The dramatic improvements in surgical accuracy obtained with ultrasound-guided surgery are 
made tangible by the fact that despite the small excision volumes in the ultrasound-guided 
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PA N EL : RE S E A RC H  I N  CO N T EXT
S y stematic  Re vie w
PubMed and EMBASE databases were searched up to August 14th, 2012 for randomised 
clinical trials using the search terms “palpable breast cancer”, “ultrasound-guided surgery” and 
“breast-conserving surgery”. Additional keywords and further logical combinations of these and 
related terms were used to maximise sensitivity. Randomised clinical trial comparing ultrasound-
guided surgery with palpation-guided surgery were not found. One prospective comparative 
study was found using continuous intraoperative ultrasonography-guidance, and this study 
showed improvement of surgical accuracy and margin status with ultrasound-guided surgery 
for palpable breast cancer excision compared to palpation-guided surgery.20 Four studies were 
found using ultrasonography in BCS, either for use of ultrasonography prior to incision or for 
ex vivo specimen check, or both.14,32,33,40 All studies showed improvements of surgical accuracy 
when using ultrasonography. However, these procedures are substantially different from ours as 
we used the ultrasonography during the entire procedure, thereby allowing continuous tumour 
visualisation. 
Inter pretat ion
Although many studies have demonstrated improved surgical accuracy with ultrasound-guided 
surgery for non-palpable invasive breast cancer, this study is the first multicentre randomised 
clinical trial to compare ultrasound-guided surgery with palpation-guided surgery for palpable 
T1-T2 invasive breast cancer.15-19 This trial clearly demonstrates that ultrasound-guided surgery 
significantly improves surgical accuracy in terms of margin status and extent of healthy breast 
tissue resection, thereby reducing the need for additional treatment and possibly improving 
cosmetic outcomes. Surgeons should be encouraged to learn the skills needed to perform 
intraoperative ultrasound-guided surgery. These skills will allow surgeons to achieve a higher 
surgical accuracy of BCS for invasive breast cancer.
46
surgery group, the rate of tumour-free margins was high, even in cases with additional in situ 
carcinoma. DCIS is mostly located in or around the invasive tumour, and although the surgeons 
were unaware of the presence of a tumour-associated intraductal component - being nonpalpable 
and mostly invisible with ultrasonography- the accuracy of ultrasound-guided surgery in the 
localisation of the central point of the tumour allowed additional complete resection of DCIS. 
Additional post-hoc analyses of different surgeons and centres on margin status, excess healthy 
tissue resection and operative time showed no statistical differences, implying there was no 
difference in performance among surgeons and centres.
The benefits of an ultrasonography-based procedure over palpation-based approaches are 
clear. The only assistance during palpation-guided surgery derives from the surgeons’ tactile 
skills and pre-operative imaging. Physical examination during these ‘blind’ palpation-guided 
procedures may not accurately delineate the extent of the breast cancer, particularly in patients 
with dense breasts, a palpable hematoma (from percutaneous biopsy) or an adjacent, palpable 
cyst. Furthermore, the interpretation of the pre-operative images in terms of the full extent 
and precise location of the carcinoma is often problematic, and patient positioning in both 
mammography and MRI (although MRI was rarely used in this study) differ considerably 
from that in the operating theatre. ultrasonography is free of all these problems. Ultrasound-
guided surgery enables the surgeon to localise and measure the tumour precisely, to optimally 
position the incision on the breast, and to operate under direct vision. This allows the surgeon 
to reorientate intraoperatively, while continuously monitoring the attainment of tumour-free 
resection margins and avoiding unnecessary sacrifice of healthy breast tissue. Following the 
procedure, the completeness of tumour excision can be checked once again with ultrasonography 
and additional tissue can be excised if necessary.
The benefits of intraoperative ultrasonography for nonpalpable breast cancer excision have 
been consistently demonstrated; ultrasound-guided surgery is practical, simple, time-efficient, 
comfortable for the patient due to the lack of additional interventions, and it carries a minimal 
risk of procedure-related complications. In addition and most importantly, ultrasound-
guided surgery is highly accurate in nonpalpable breast cancer and even in DCIS by using 
an appropriate marker, showing impressive overall success rates of between 81%-97% negative 
margins.16,17,19,28,29  It is therefore remarkable that ultrasound-guided surgery has not been 
widely integrated into daily surgical practice and that wire-localisation remains the method of 
choice for intraoperative guidance for nonpalpable carcinomas. Possible explanations may be the 
surgeons’ lack of experience with ultrasonography and the fact that dedicated radiologists are not 
readily available at all times.
In contrast to nonpalpable carcinomas, few studies have reported the use of ultrasound-guided 
surgery in palpable breast cancer. In 2001, Moore et al. were spurred to prospectively evaluate 
ultrasound-guided surgery due to the poor results obtained with palpation-guided surgery. 
Comparing 27 patients undergoing ultrasound-guided surgery for palpable invasive ductal 
breast cancer with 24 undergoing palpation-guided surgery, the results were striking; only 3% 
tumour-margin positivity was found in the ultrasound-guided surgery group, compared to 29% 
for the palpation-guided surgery group (p<0.05).20 More recently, two smaller retrospective 
studies supported the high rates of tumour-free resections margins as obtained with ultrasound-
guided surgery, however, these authors described the use of ultrasonography mainly prior to 
incision as a method to mark the tumour extent onto the skin.30,31
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In contrast to intraoperative ultrasound-guidance, some authors describe techniques and devices 
for ex vivo specimen margin assessment following tumour excision to perform immediate re-
excision if necessary. These techniques do not guide the surgeon through surgery. As described 
by Olsha et al. and Eichler et al., this approach resulted in tumour-free margins in 95% and 96% 
of patients, respectively.32,33 Using radiofrequency spectroscopy technique, the MarginProbe has 
recently been recommended as a device to ex vivo detect the presence of invasive carcinomas 
and even DCIS at the surgical specimen margins.34 The results of a clinical study showed the 
necessity of an intraoperative re-excision in 41% of cases, resulting in less secondary surgical 
interventions.35 The performance of the MarginProbe seems promising, in particular for the 
detection of DCIS which is generally ultrasonography-invisible.35,36
Our study clearly shows that intraoperative ultrasonography can significantly improve surgeon 
performance and we now strongly recommend that surgeons gain personal competence in the 
use of ultrasonography, thus avoiding the need for a radiologist and, most importantly, improving 
hand-eye coordination by single-individual performance of ultrasound-guided surgery. In our 
opinion and experience surgeons can learn the skills needed to perform ultrasound-guided 
surgery in a relative short training period of up to 8 procedures. Furthermore, an ultrasound 
device should be available in the operating room, and in most clinics is already present for 
other procedures. Despite the greater use of resources, analysis showed that ultrasound-guided 
surgery is cost-saving due to an improved surgical accuracy with lower costs for additional 
treatment..16,22,37
This study also has a number of limitations. As study centres did not collect a screening log, 
both the total number of patients screened and deemed eligible and the reasons for exclusion 
were not fully recorded. Further, it should be noted that the definition of a negative resection 
margin remains a subject of debate, and there is still no worldwide consensus of what constitutes 
a positive or negative margin. In this trial, the Dutch national guidelines were applied, which 
state that margins are involved only when tumour is present at the inked margin.26 Morrow et 
al. suggested to end the discussion on margin width, as margin width is not related to higher 
local recurrence rates and negative margins should therefore be considered as margins without 
residual tumour (NSABP definition).38
It is well known that the excision of invasive lobular cancer can be complicated by indistinct 
tumour margins or inconspicuous spiculations, generally resulting in high rates of tumour-
involved margins.13,39 As lobular carcinomas are often poorly visible with ultrasonography, 
the advantage of using ultrasound-guided surgery in lobular carcinomas seems limited. Only 
five patients with invasive lobular carcinoma have been included in this study, and drawing 
any conclusions on this subject is impossible. Further research should specifically evaluate the 
efficacy of ultrasound-guided surgery for lobular invasive cancer.
CO N C LU S I O N
In conclusion, this multicentre, randomised study showed that ultrasound-guided surgery for 
palpable, invasive (ductal) carcinomas facilitates a higher rate of margin clearance with fewer 
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additional treatment interventions following first excision. Ultrasound-guided surgery also 
leads to lower levels of excess tissue resection. Study follow-up will focus on comparisons of 
ultrasound-guided surgery- and palpation-guided surgery-related cosmetic outcomes, quality of 
life and local recurrence rates, with improvements with ultrasound-guided surgery in all areas 
anticipated. 
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A B S T RAC T
Ultrasound-guided surgery (USS) has recently been proven to result in a significant reduction 
of tumour-involved surgical margins, for patients with palpable invasive breast cancer. The 
objective of this economic evaluation alongside a randomised trial was to evaluate the costs and 
benefits of USS compared to palpation-guided surgery (PGS). The hospital perspective was 
used. On the cost side of the analysis, resource use related to baseline treatment was taken into 
account and on the benefit side, resource use related to additional treatments was included. On 
the cost side, the difference in costs per patient was €193 (95% CI €153-€233) with higher costs 
in the USS group. On the benefit side, the difference in costs per patient was -€349 (95% CI 
-€591 to -€103) with higher costs in the PGS group. This resulted in a cost decrease of -€154 
(95% CI -€388 to €81) in the USS group compared to the PGS group. Intra-operative use of a 
US-system during BCS reduces the rate of tumour-involved margins and thereby the costs of 
additional treatments.
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I N T RO D U C T I O N
Breast cancer remains the most common cancer among women in the Western world and 
approximately 1 in 8 women will be diagnosed with breast cancer during the course of their 
lifetime, resulting in 13.000 new breast cancer cases in the Netherlands each year. Approaches to 
the surgery of breast cancer have changed dramatically over the past decades and the emergence 
of breast-conserving surgery (BCS) now allows the preservation of the breast without 
compromising oncological outcomes. The introduction of widespread mammographic screening, 
better imaging techniques, improved patient awareness and breast self-examination have all 
contributed to an increase in early diagnoses and accordingly, in the number of BCS procedures. 
Around 75% of all breast cancer patients are eligible for BCS and BCS is now accepted as the 
treatment of choice for early-stage breast cancer.1,2
Palpable breast carcinoma is present in approximately 3 out of 4 patients and excision is 
normally guided by palpation. The success of palpation-guided surgery (PGS), i.e. achieving 
adequate tumour-free resection margins while sparing healthy breast tissue, depends on 
pre-operative imaging techniques and the experience and tactile abilities of the surgeon. 
3-9 The somewhat ‘blind’ approach of PGS is known to be highly inaccurate, with studies 
worldwide reporting up to 25% positive resection margins and excessively large excision 
volumes.10-13 Ultrasound-guided surgery (USS) allows for continuous localisation of the 
breast carcinoma during the surgical procedure and results in significantly improved surgical 
accuracy of palpable breast cancer excision, with high rates of tumour-free resection margins 
(>96%) while also achieving optimal resection volumes.14 Consequently, USS requires 
less additional treatment (either boost radiotherapy, re-excision or mastectomy) to obtain 
definite, clear margins, while the reduction in excision volumes and additional treatments will 
presumably result in an improved cosmetic outcome, patient satisfaction and quality of life. 
From a clinical viewpoint, all surgeons should be encouraged to perform USS. However, a major 
obstacle to the use of USS is the additional expenditure required, particularly the costs associated 
with purchasing a high-end US machine, and the costs of the extra operative time needed for 
USS. On the other hand, the improved margin clearances as obtained with USS eliminate the 
expenses associated with subsequent treatment for tumour-involved margins. The aim of this 
cost-benefit analysis, alongside our randomised controlled clinical trial (RCT), was therefore 
to weigh the additional costs of USS compared to PGS against the benefits of USS in terms of 
reduced re-treatment costs.
M AT ERI A L S  A N D  M E T H O D S 
The study protocol was approved by the central and local independent medical ethics review 
boards of the participating hospitals, and the trial was registered under NTR2579. Protocol 
details and an evaluation of the clinical outcomes of this trial have been published previously.14,15
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Par t ic ipants
Patients were eligible to participate if diagnosed with a palpable early-stage (T1-2N0-1) invasive 
breast cancer and scheduled to undergo BCS. Patients with pre-operatively diagnosed primary 
ductal carcinoma in situ (DCIS), multifocal disease, a history of neo-adjuvant therapy, previous 
surgical treatment or radiation therapy of the affected breast were excluded from the study.
Treatment
Patients were randomised to undergo either USS or PGS. The aim in both groups was to achieve 
complete tumour removal, with healthy tissue margins of up to 1cm. USS was performed using 
a THI 14-MHz US probe (Toshiba Viamo portable ultrasound system, Japan). The probe was 
covered with a sterile glove and a plastic sheath filled with sterile acoustic gel. The method of USS 
has been described previously.16 Briefly, the surgeon carefully localised the tumour in the breast 
by palpation and US imaging. The tumour was then excised under continuous US imaging and 
control. Following excision, the specimen was scanned with US ex vivo to determine complete 
tumour excision.
PGS was guided by palpation by the surgeon in the standard manner. The fingers were used to 
palpate the mass, retract it and guide the dissection, without the use of imaging modalities.
In neither treatment modality were frozen section analysis, cavity shavings or specimen 
radiography performed. Axillary surgery was performed in the same surgical session, following 
international guidelines.17,18
Health  outcomes
The main outcomes were margin status and the requirements for additional treatment 
interventions. Margins were categorised as negative, focally positive, or positive in accordance 
with the World Health Organization (WHO) classification. For tumour-positive or focally-
positive margins, radiotherapy boost rates, re-excision lumpectomy rates and mastectomy rates 
were recorded.
Other outcomes included excess volume resection. A calculated resection ratio (CRR) was 
introduced, whereby the specimen volume - measured by fluid displacement - was divided by the 
‘optimal specimen volume’, defined as the spherical tumour volume plus an arbitrarily chosen 
‘optimal’ tumour-free resection margin of 1 cm.16,19,20 Operative time (minutes) was recorded for 
both surgical methods.
Cost-benef i t  anal y s is
The hospital perspective was used in this cost-benefit analysis and as such, only hospital costs 
related to breast cancer were included. Since we were interested in differences in costs and 
benefits between the two groups rather than absolute costs and benefits, only those resource 
use items were included for which a difference between the groups was expected or considered 
possible.
Dutch standard costs were used to value most resource items.21 Additional resource prices were 
provided by the information and cost management department of the VU University Medical 
centre Amsterdam, Netherlands (VUMc).
57
Rele vant  costs  ( Table  1)
T he cost  s ide: basel ine  t reatment
Costs concerned resource use related to the index operation. Resource items included for the 
cost side of the analysis were use of the US system and operative time. Costs of complications 
were not included, because no differences were expected between the groups.
The costs for operative time were calculated by multiplying individual operative times (in hours) 
by a cost price per hour. Operative time was measured on an individual level and defined as the 
time from incision to wound closure. The extra time for the pre- and post-surgical use of the US 
system (5 minutes) was added to the US group. The cost price per hour included operating room 
time and salary for operating room personnel (two nurses, one breast surgeon, one intern and 
an anaesthesiologist), with the prices for separate items provided by the VUmc. The total cost of 
one hour operative time was € 1020 or € 17 per minute. 
The average cost per patient of using the US system was estimated to be €127. This price was 
derived as follows; although various US systems are available, ranging in price from € 28,950 
to € 58,500, excluding VAT, a high-end € 58,500 US system was used in this study and these 
costs were applied in the analysis. With an estimated 7-year durability of the US system, the 
US costs were € 8,357 per year. A mean of 68 patients with palpable breast cancer are expected 
to be operated on with a US system per year in each hospital in the Netherlands, leading to an 
estimated € 8,357/68, or € 123,- per patient. In addition, a sterile small T-shaped latex-free 
probe cover with gel was used during each procedure, at a cost of € 4.
Table 1.  Relevant costs
Price of an ultrasound system € 58.500
Probe cover per unit € 4
Price of an ultrasound pp.* € 127
OR-price per minute € 17
Boost price per fraction € 180
Total costs of radiotherapy boost** € 900
Outpatient clinic visit € 87
Hospital stay per day € 365
Pathological evaluation € 465
Re-excision € 1.217
Total costs re-excision*** € 3.034
Mastectomy € 1.823
Total costs mastectomy**** € 3.105
* Based on an assumed number of 68 patients per hospital per year and a 7-year use of the ultrasound system. (€ 58,500/(7*68)), 
including an additional € 4 for the ultrasound probe cover 
** Includes 5 additional fractions of radiotherapy 
*** Includes a 1-day hospital stay, one additional outpatient clinic visit, radiotherapy boost, and pathology 
**** Includes 2-day hospital stay, one additional outpatient clinic visit, and pathology
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T he b enef i t  s ide: addit ional  radiother apy  boost  and 
surger y
Benefits included resource use related to the number of re-operations (either re-excision or 
mastectomy), pathology investigations of re-excisions and mastectomies, hospital days, number 
of visits to the outpatient clinic and number of additional radiotherapy boosts were included.
According to the 2012 Dutch national guidelines for radiotherapy, all patients younger than 50 
years and patients older than 50 years with involved margins, DCIS and angioinvasion receive 
boost radiotherapy (21 fractions of 2.2 Gy with an integrated boost on the tumour bed of 2.67 
or 2.85 Gy). Women older than 50 years and without margin involvement receive 16 fractions of 
2.67 Gy. In cases with margin involvement and a patient age above 50 years (excluding patients 
undergoing mastectomy), 5 additional fractions of radiotherapy are required at a total cost of
€ 900.
The cost of a re-operation was calculated using prices for surgery based on hospital costs, the 
costs of the pathology evaluation, a one-day hospital stay and an additional outpatient visit 
one week following surgery. With additional radiotherapy, the total cost of a re-excision was 
estimated at € 3034.
For mastectomy, a two-day hospital stay and one additional outpatient visit is required in addition 
to the surgery and the pathological evaluation. No additional radiotherapy boost is administered 
following mastectomy. The total costs for a mastectomy amounted to € 3105. Pathology costs 
included histopathology and quantitative analysis of the surgical specimen.
S tat ist ic a l  anal y s is
The statistical analysis of the clinical outcomes of USS and PGS was reported previously. 
(Krekel 2012) As cost data is typically skewed, confidence intervals for cost differences cannot 
be estimated with conventional methods that assume normality. We therefore applied bias-
corrected accelerated bootstrapping techniques, i.e. 2000 samples of the same size as the original 
dataset were sampled with replacement from the data.22-24 These resamples were used to estimate 
95% confidence intervals for the differences in costs and benefits between the two groups. The 
results were represented in a cost-benefit plane. For the cost-benefit analysis, the difference in 
baseline costs was compared to the difference in retreatment costs between the two groups. 
Total cost-savings or cost-expenditures were calculated by summing the differences in costs 
and benefits. The return on investment was calculated by dividing the difference in benefits by 
the difference in costs. Finally, the results were extrapolated to other hospitals with differing 
numbers of annually-treated patients from the number included in this trial. Independent of 
the number of patients per year, each hospital requires one US system in order to perform USS 
and as such, the average cost of USS per patient depends on the total number of patients treated 
per year. We explored the relation between the return on investment and the total cost-savings 
or cost-expenditure on the one hand, and the number of patients treated per year on the other 
hand, by varying the cost price of use of the US system per patient.
Statistical Analysis was performed with Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA) and Stata SE 12.
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RE S U LT S
Patients
From October 2010 through March 2011, a total of 142 patients were enrolled from 6 hospitals 
in the Netherlands. Of these, 8 were excluded for various reasons. The remaining 134 patients 
were randomly assigned to undergo either USS (n=65) or PGS (n=69). The patient and tumour 
characteristics in both study groups were comparable. Mean age was 56 years, 60% of tumours 
were located in the upper outer quadrant, and mean tumour size was 2.0 cm. All palpable 
invasive carcinomas were visible with the ultrasound-system. The majority of patients (64%) 
presented with tumour-associated unexpected ductal carcinoma in situ (DCIS) diagnosed at 
pathological examination of the specimen. Additional DCIS lesions were defined as minor 
(inside or within several millimetres of the invasive tumour) or more extensive lesions and were 
distributed equally between the two groups.14
Health eff ects
Margin invol vement  and addit ional  t reatment  ( Table  2)
Analysis of resection margins showed a reduction in invasive tumour-involvement when using 
intraoperative US, with tumour-free margins in 97% of all USS, compared with 83% in PGS 
(P<0.01). Margins were tumour-free for invasive carcinoma and unexpected additional DCIS in 
89% of USS, compared with 73% of PGS cases (P<0.04). 
The improvement of margin status with USS resulted in less additional treatments in the USS 
group (P<0.04). Only 1 USS needed a re-excision and no mastectomies were required in the 
USS group. Additional boost radiotherapy was considered sufficient for an additional 6 patients. 
In the PGS group, 3 patients underwent a re-excision, 5 patients underwent a mastectomy and 
11 patients received additional boost radiotherapy.
Table 2. Margin status and additional treatment
ultrasound-guided 
surgery
(n = 65)
palpation-guided 
surgery
(n = 69)
p
Invasive carcinoma 
Negative
Positive
63 (97%)
2 (3%)
57 (83%)
12 (17%)
<0.0093
Invasive carcinoma and unexpected 
additional DCIS 
Negative
Positive
58 (89%)
7 (11%)
50 (73%)
19 (27%)
<0.031
Additional treatment
Mastectomy
Re-excision
Radiotherapy boost
7 (11%)
0 (0%)
1 (2%)
6 (9%)
19 (27%)
5 (7%)
3 (4%)
11 (16%)
<0.015
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Operat ive  t ime
Although the mean excision time was equal for both USS and PGS (respectively 13 minutes 
[range, 6-30] and 14 minutes [range, 2-40]) (P>0.05), an additional 5 minutes were needed for 
US handling prior to and following the operative procedure (1 minute for sterile covering of the 
US probe, 2-3 minutes for tumour-localisation and skin markings, and 1 minute for a specimen 
check). For this reason, 5 minutes were added to the operative time of patients in the USS group 
(€ 85 additional operative time costs for USS).
Cost-benef i t  anal y s is
The 2000 bootstrap estimates of the difference in costs and benefits between the USS and PGS 
groups are shown in a cost-benefit plane in Figure 1. Cost differences are depicted on the y-axis 
and benefits on the x-axis. Note that the x-axis is inverted to show negative differences, i.e. cost 
savings, on the right. On the cost side, the difference in costs per patient was €193 (95% CI €153 
to €233) with higher costs in the USS group. On the benefit side, the difference in costs per 
patient was € -349 (95% CI € -591 to € -103) with higher costs in the PGS group due to a larger 
number of re-treatments. In total, the sum of the differences in costs and benefits amounted to 
cost-savings of € -154 (95% CI € -388 to €81) in the USS group compared to the PGS group.
The return on investment was 1.80 (95% CI 0.64 to 3.01), which means that on average 1.8 
times more benefits than costs are obtained in the USS group compared to the PGS group. Note 
that the confidence interval is very broad, which is caused by the large variability in costs in the 
two groups.
Benefits in €
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Figure 1. Cost benefit plane.
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E xtr ap olat ion of  the  results  to  other  hospita ls
In this trial, the average cost price for the US system per patient was €127. In Table 3, the 
average cost price is shown for a total of 50, 100, 150 or 200 patients treated per year using one 
USS system. For each of these cost prices, the average return on investment is shown and the 
95% confidence interval. Above 150 patients per year, the return on investment is higher than 
2.79 and statistically significant.  
Figure 2 shows the cost-savings (minus (costs + benefits)) of USS relative to PGS for the total 
patient volume that is treated using one US system. With patient volumes below 30 the cost-
savings are negative, indicating that use of the US system amounts to cost expenditure. Above 30 
patients, use of the USS system leads to cost savings. These savings increase linearly with patient 
volume, reaching € 47,000 when 200 patients per year are treated using USS-BCS. Note that 
the 95% confidence intervals are broad, due to the large individual variability in costs. The lower 
limit of the cost-savings is positive (i.e. cost-saving) for patient volumes above 200.
Figure 3 essentially shows the same results, but here the average cost per patient is depicted on 
the y-axis. It is interesting to see that whereas total cost savings increase as the patient volume 
increases, the average cost-saving per patient reaches an asymptote of around € 240 for patient 
volumes above 150.
Table 3. Return on investment
Number of patients 
receiving USS
US system costs per 
patient (€)
Average return on 
investment
95% Confidence 
Interval
50 171 1.46 0.51 – 2.46
68 127 1.80 0.64 – 3.01
100 88 2.27 0.81 – 3.82
150 60 2.79 0.99 – 4.74
200 46 3.15 1.13 – 5.46
Number of patients receiving BCS for palpable breast cancer
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Figure 2. Total cost-savings (minus [costs+benefits]) per volume of patients treated, using one US system 
relative to PGS (including 95% confidence intervals estimated by bootstrapping).
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E xt r apolat ion to  the  D utc h pat i ent  p op u l at i on
Patient  volumes  in  the  Nether lands 
Approximately 13,000 patients are diagnosed in the Netherlands with breast cancer each year, of 
whom 9,000 undergo BCS. Of the breast tumours approximately 75% are palpable, thus 6,750 
breast cancer patients are suitable for ultrasound-guided excision. Approximately 100 hospitals 
perform breast cancer surgery, thus 68 patients per hospital per year could benefit from USS. 
This means that total healthcare costs for BCT in the Netherlands could be decreased by € 
1,001,655 per year through the use of USS. Greater cost-savings might be achieved through the 
concentration of healthcare, when fewer hospitals operate on higher volumes of patients with 
palpable breast cancer.
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Figure 3. Mean cost-savings (minus [costs+benefits]) per patient treated, using one US system relative 
to PGS (including 95% confidence intervals estimated by bootstrapping).
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D I S C U S S I O N
Breast-conserving therapy (BCT) has gained wide acceptance as the treatment of choice for 
early-stage breast cancer. The surgical accuracy of palpable breast cancer excision is significantly 
improved by the use of USS, as shown by both exceptionally high rates of tumour-free resection 
margins and optimal resection volumes. Although cost benefits may vary amongst clinics and 
countries due to differences in procedure and resource costs, the increased surgical accuracy 
with less need for additional treatment (re-excisions, mastectomies and additional radiotherapy 
boosts) irrefutably leads to less secondary costs after initial treatment for early stage breast 
cancer. Consequently, the benefits expressed in monetary units were significantly larger in the 
USS group than in the PGS group, with the re-treatment related healthcare costs € 349 lower 
for USS than for PGS. On the other hand, costs related to the use of the US system during 
initial treatment were significantly higher in the USS group, but as this difference was only € 
193 the average return on investment was 1.8. Varying the number of patients per US system, 
and as such the US price per person, showed that for any number of patients above 30, use of 
a US system in BCS is cost-saving. As expected, with an increase in patient volume, total cost 
savings also increase but the average cost-savings per patient reaches an asymptote above a 
volume of 150 patients. An average clinic operating 68 patients per year would save around € 
10,000 annually.
It should be noted that although the benefits of intraoperative US over needle localization have 
been consistently demonstrated, USS for non-palpable breast cancer was not evaluated in this 
trial. USS may lead to even greater cost-savings when applied to non-palpable breast cancer.
US-guided excision is a widely available and feasible tool. The technique is easy, straightforward, 
non-invasive, not time consuming, and it can be learned in a relatively short time.16 Furthermore, 
as USS does not require additional interventions, such as the placement of a wire or injection 
of material, it allows the surgeon flexibility in scheduling patients. Additionally, the US system 
could be used for surgical purposes other than breast surgery alone.
In general, new treatment options for breast cancer can be justified only if they result in increased 
survival rates or improved quality of life, at acceptable costs. Margins positive for tumour are 
associated with an increased risk of local recurrence with its influence on survival, thereby 
affecting the amount and type of additional treatments.11,25,26 These additional treatments 
also increase patient stress and have a major impact on the final appearance of the breast. The 
volume of breast tissue resected is the key factor in a poor cosmetic result following BCS and is 
strongly related to patient well-being and quality of life.27-29 Although USS has a major impact 
on treatment costs, it should be noted that improved surgical accuracy as achieved with USS 
avoids the need for additional treatment in many cases, thereby probably resulting in decreased 
treatment-related stress.
In addition to the reduction in excision volumes, USS has the potential to achieve improved 
cosmetic outcomes, patient satisfaction and quality of life by reducing additional treatment.4,8,30 
Furthermore, as USS may lead to fewer patients demanding reconstructive surgery due to poor 
cosmetic outcome, additional cost-savings could be achieved in the long term. 
When presenting economic evaluations alongside randomised trials, it is customary to include 
results on health-related quality of life (HR-QOL).29,31 However, economic evaluations including 
HR-QOL evidence based on validated instruments are not yet available for BCT and although 
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we have not included HR-QOL in this cost-benefit evaluation, the randomised trial on which 
this evaluation is based has repeatedly measured both HR-QOL and cosmetic outcomes. These 
results are expected in 2014.
Relatively few cost- or cost-effectiveness analyses of BCS are currently available. A study of 
the costs of treating breast cancer in the United States indicated that BCS and mastectomy 
were equally expensive.32 Other available studies reported the cumulative medical costs over 5 
years for patients receiving mastectomy or BCS combined with radiotherapy and showed higher 
costs in the mastectomy group due to higher complication rates, higher inpatient-care costs and 
late surgical breast reconstruction.33-35 Our study is the first to present a cost-benefit analysis 
comparing two different methods of BCS.
This study has a number of limitations. As it is difficult to include the latest patterns of practice 
in terms of adjuvant therapies, especially systemic therapies following BCS, only USS and PGS 
costs due to margin involvement in patients with T1-T2 palpable breast cancer were included.32 
Furthermore, only USS costs for palpable breast cancer excisions were included, while additional 
cost-savings may be achieved when USS is also applied to nonpalpable breast cancer excision. 
Study follow-up will focus on comparisons of USS- and PGS-related cosmetic outcomes and 
quality of life.
CO N C LU S I O N S
USS increases the surgical accuracy of palpable breast cancer excision as shown by a higher rate 
of margin clearance resulting in a lower need for additional treatment interventions following 
excision and lower levels of excess tissue resection. Furthermore, this study shows that USS 
is cost-saving when applied to a minimum of 30 patients per hospital per year, due to less re-
treatment interventions for tumour-positive resection margins. USS is hereby recommended 
as the preferred method of treatment for patients with palpable T1-T2 invasive breast cancer 
undergoing BCS.
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A B S T RAC T
Bac kground
Despite an increasing interest in the evaluation of cosmetic outcomes following breast-conserving 
therapy (BCT) over recent decades, no consensus has yet been reached on the optimal approach 
to cosmetic evaluation. The present study compared the strengths and weaknesses of the BCCT.
core software with a 10-member panel from various backgrounds.
Methods
Digital photographs of 109 consecutive patients, all with a follow-up of at least 1-year after 
initial BCT for primary T1-T2 invasive breast cancer were evaluated for 7 items by a panel 
consisting of 2 breast surgeons, 2 residents, 2 laypersons and 4 plastic surgeons. All photographs 
were objectively evaluated using the BCCT.core software (version 20), and an overall cosmetic 
outcome score was reached using a 4-point Likert scale.
Results
Based on the mean BCCT.core software score, 41% of all patients had fair or poor overall 
cosmetic results (10% poor), compared with 51% (14% poor) obtained with panel evaluation. 
Mean overall BCCT.core score and mean overall panel score substantially agreed (weighted 
kappa: 0.68). By contrast, analysis of the evaluation of scar tissue revealed large discrepancies 
between the BCCT.core software and the panel.
The analysis of subgroups formed from different combinations of the panel members still 
showed substantial agreement with the BCCT.core software (range 0.64-0.69), independent of 
personal background.
Conc lusion
Although the analysis of scar tissue by the software shows room for improvement, the BCCT.
core represents a valid and efficient alternative to panel evaluation. 
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I N T RO D U C T I O N
Breast  Conser ving T herapy
Breast cancer treatment has changed dramatically over the past few decades. In many countries 
breast-conserving therapy (BCT), i.e. breast-conserving surgery combined with postoperative 
radiotherapy, has become the standard of care for early-stage breast cancer.1-5 BCT was primarily 
developed to decrease morbidity and improve cosmetic outcome without compromising 
oncological outcomes, factors that may be crucial to patient satisfaction and quality of life. 6-8
However, fair to poor cosmetic outcomes following BCT are still observed in up to 33% of 
patients undergoing BCT.6,8-10 As a consequence, new surgical techniques (oncoplastic and/or 
ultrasound-guided surgery) and radiotherapeutic strategies (i.e. boost dose) have been developed 
to improve cosmetic outcomes and lower patient morbidity.11-13 These new treatment modalities 
should now be evaluated using reliable, time efficient and reproducible cosmetic evaluation tools.
Despite the fact that factors influencing cosmetic outcome have been under evaluation since 
the 1980’s and that various subjective and objective evaluation techniques have been studied, 
consensus has not yet been reached on optimal approaches to cosmetic evaluation and the 
development of comparable scoring methods.14-16
S ubject ive  e valuat ion methods: pat ient  se l f-e valuat ion 
and panel  e valuat ion
Of the many subjective evaluation methods are available, patient self-evaluation is valuable due 
to the central role of the patient’s subjective experience in the assessment of quality of life. 
Drawbacks associated with patient self-evaluation include dependence on several factors that 
are not amenable to quantification, such as age and socioeconomic status, and the consistent 
reporting of better scores by patients than by professionals.17
Panel evaluation remains the most common and accepted approach to the subjective evaluation 
of cosmetic results, and the approach also takes breast asymmetry, scars and skin changes 
into account.14,16 Using photographs of the breasts, panel evaluation rates a range of aspects 
and generally uses the so-called 4-point Likert or Harvard scale, with classification of overall 
cosmetic outcome as excellent, good, fair or poor.17-19 Because strong variation between observers 
is common, a panel should consist of at least 5 members, including both professionals and 
non-professionals from diverse backgrounds.17 Despite the widespread use of panels, the inter-
observer reliability of different panel constitutions (e.g. panels including observers from different 
backgrounds and specialisations) and the validity of such panel evaluations remains unclear.
O bject ive  e valuat ion methods: BCCT.core
When assessing objective evaluation methods, the key parameter in analysing cosmetic results 
appears to be the assessment and measurement of asymmetry, in which the ultimate cosmetic 
objective of BCT is the attainment of two identical breasts.16 Objective computerised methods 
have been developed with this goal in mind. These include the recently developed Breast Cancer 
Conservative Treatment.cosmetic results (BCCT.core) software, which provides an extensive set 
of automated measurements that covering a broad range of items that reflect overall cosmetic 
outcome.15 Using digital marks on the nipples, axillae and sternum jugular notch, this software 
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automatically identifies the breast contour and carries out automated measurements including 
breast shape, breast volume, deformity, nipple position, scar visibility and skin changes. Using 
this range of items and a 4-point scale, the results reflect cosmetic issues that may arise following 
BCT, and allow overall assessment of cosmetic outcome.20
The claimed advantages of the BCCT.core software compared to panel evaluation include the 
fast and accurate reporting of results that were previously very time-consuming. In addition, 
a reliable and automated approach to the assessment of cosmetic outcomes would enable 
comparison of results from different breast surgery units worldwide.21
Aims of  the  study
In this study, the level of agreement between BCCT.core software and panel evaluation was 
evaluated by comparing both the overall scores and the specific items in each evaluation method 
(e.g. volume, scar and skin). The inter-observer reliability of various panel constitutions (in order 
to assess the influence of background and specialisation), and intra-observer reliability of the 
individual panel members were also investigated.
M E T H O D S
Patients
A total of 109 consecutive patients who had undergone BCT from January to November 2006 
were included in this study. All patients underwent BCT for T1-T2 breast cancer and were 
photographed after at least a 1 year follow-up period measured from the beginning of the 
treatment. Patients who underwent previous surgery of the breasts and those who previously 
had radiation of the chest region were excluded from the study. Patient, tumour and treatment 
characteristics (such as radiotherapy, type of axillary surgery, weight and volume of the specimen) 
were collected from hospital records and written informed consent was obtained.
Breast surgery consisted of palpation-guided lumpectomy for palpable tumours and wire- or 
ultrasound-guided lumpectomy for non-palpable tumours. Axillary surgery consisted of either 
a sentinel node procedure (SN) or an axillary lymph node dissection (ALND). All patients 
received radiation therapy of the whole breast and a radiotherapy boost to the tumour bed, where 
indicated. Adjuvant chemotherapy or hormonal therapy was administered depending on the 
tumour characteristics of the patient and according to national guidelines.
P hotogr aphs
Digital frontal photographs of the breasts, including the suprasternal notch, were taken at a 
mean follow-up time of 20 months (range 12-40 months). All patients were photographed in a 
standardised manner, with their arms at their sides, allowing meaningful comparison between 
patients. All photos were taken by a single photographer using a RICOH Caplio R3 5.0 mega 
pixel digital camera. Photographs were then compiled into a PowerPoint presentation for panel 
evaluation.
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Panel  scor ing
All photographs were scored by a 10-member panel consisting of two experienced breast 
surgeons (male and female; at least 10 years of experience with breast cancer surgery), two surgical 
residents (both female), two laypersons (male and female) and four experienced plastic surgeons 
(all male; at least 10 years of experience with breast reconstruction surgery). The evaluation took 
place in june 2013. Cosmetic scoring was performed using a digital video projector. All members 
of the panel were blinded to each other. Twenty randomly selected photographs (not included 
in the actual study) were shown to the panel before scoring began in order to avoid skewness 
between observations. The panel scored various topics on a four-point Likert scale as described 
in table 1. Intra-observer reliability was tested by once again evaluating a set of 50 randomly 
selected photographs at 4 weeks after the first evaluation, and blinded for the original scores.
A questionnaire was used to evaluate the cosmetic outcome of the treated breast compared to the 
untreated breast for seven items using the 4-point Likert scale, and based on the questionnaire 
described by Aaronson et al: I. Breast shape; II. Breast volume; III. Breast deformity; IV. Nipple 
position; V. Appearance of the surgical scar; VI. Skin alterations VII. Overall cosmetic result.
BCCT.core
The BCCT.core software (version 20) incorporates a broad set of automatic asymmetry 
calculations, including scar and skin changes, but also provides an overall cosmetic outcome 
on the same 4-point Likert scale used in the panel evaluation. The frontal photographs of 
the 109 patients were analysed in September 2013 according to the BCCT.core manual. The 
investigator digitally marked the following points: the nipples, axillas and sternum jugular notch. 
The BCCT.core software then automatically identified the breast contour for further automated 
calculations. These dimensionless asymmetry calculations include the following: pBRA (the 
relative breast retraction assessment), quantifying the relative difference in nipple position 
between both breasts; pUNR (the relative upward nipple retraction), quantifying the relative 
difference between nipple levels; pBCE (the relative breast compliance evaluation), quantifying 
the relative difference between the left and right nipple to inframammary fold distance; and 
pBAD (the relative breast area difference) quantifying the relative difference between areas of 
left and right breasts.22
Colour difference and scar visibility were also evaluated with the BCCT.core software, each with 
8 different variables as described by Cardoso et al.23 Finally, the software generated an overall 
score on the same 4-point Likert scale as used by the panel (Table 1).
Table 1. Harvard scale (4-point Likert scale).
Excellent Treated breast nearly identical to untreated breast
Good Treated breast slightly different to untreated breast
Fair Treated breast clearly different from untreated but not seriously distorted
Poor Treated breast seriously distorted
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S tat ist ic a l  anal y s is
All analyses were performed with IBM Statistical Package for the Social Sciences (Version 20.0; 
IBM, Armonk, NY, USA). Patient, tumour and treatment characteristics were compared using 
Student’s T-test and Chi-square statistical tests.
In order to assess the agreement of the BCCT.core overall score with the mean 10-member 
panel score, the weighted Kappa was used. Calculation of the weighted Kappa was performed in 
SPSS using the intraclass correlation coefficient (ICC, two-way random effects model), which 
has the same value as the quadratic weighted Kappa.23,24 Inter- and intra-observer variability 
among the panel members were also calculated using the weighted Kappa method. Landis and 
Koch characterised values of 0 – 0.20 as slight agreement, 0.21 – 0.40 as fair, 0.41 – 0.60 as 
moderate, 0.61 – 0.80 as substantial and 0.81 – 1 as almost perfect.25
Weighted Kappa was subsequently calculated for different subgroups of raters, initially 
excluding laypersons, then excluding laypersons and residents, and finally solely with plastic 
surgeons, thereby allowing differences in reliability within subgroups of the panel by speciality 
and experience to be assessed. Percentage of absolute agreement was also calculated. In order 
to compare the BCCT.core with the panel on a 4 point Likert scale, the mean overall cosmetic 
score of the 10 panel members was calculated and rounded to the nearest integer.
Spearman’s correlation and Pearson correlation were used to assess the correlation of the mean 
score of different panel items to automated calculations of the BCCT.core software. This was 
only applicable for certain panel items that matched a calculated score of the software (e.g. 
panel item nipple position and the dimensionless feature pBRA). The absolute values of the 
correlations can be interpreted as very weak (0 – 0.20), weak (0.21 – 0.40), moderate (0.41 – 
0.60), strong (0.61 – 0.80), and as very strong (0.81 – 1).
RE S U LT S
Patient  and tumour  character ist ics  ( Table  2)
The average age of the 109 patients included in this study was 57.8 years (range 36-83), at the 
time of the operation.  Of the tumours, 72 (66%) were palpable and 37 (34%) were non-palpable, 
which resulted in 64 (59%) palpation-guided excisions, 17 (15%) wire-guided excisions and 
28 (26%) ultrasound-guided excisions. In 58 cases (53%) tumours were located in the upper 
outer quadrant, invasive ductal carcinoma was present in 93 cases (85%), all patients received 
radiotherapy, and radiotherapy boost was administered in 92 cases (84%). Nineteen patients 
(17%) had to undergo a re-excision for tumour-involved margins.
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Table 2. Patient and tumour characteristics
Patient Population Mean (Range)
Patient age at operation (years) 57.8 (36-83)
Tumour size (cm) 1.8 (0.3-5.5)
 Palpable
 Non-palpable
72 (66%)
37 (34%)
A xillary surgery
 Sentinel node
 Axillary lymph node dissection
73 (67%)
36 (33%)
Side
 Left
 Right
57 (52%)
52 (48%)
Type of carcinoma
 Ductal
 Lobular
 Other
93 (85)
5 (5%)
11 (10%)
Quadrant
 Lateral upper quadrant
 Lateral under quadrant
 Medial upper quadrant
 Medial under quadrant
 Central
 Missing
58 (53%)
17 (15%)
5 (5%)
24 (22%)
4 (4%)
1 (1%)
Boost
 Yes
 No
92 (84%)
17 (16%)
Type of surgery
 Palpation-guided surgery
 Wire-guided localisation
 Ultrasound-guided surgery
64 (59%)
17 (15%)
28 (26%)
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Cosmetic  outcome and inter-  and intra-obser ver 
agreement  ( Table  3)
Panel  e valuat ion
The average of the overall cosmetic outcome as evaluated by the whole panel was excellent in 8 
patients (7%), good in 46 (42%), fair in 40 (37%) and poor in 15 patients (14%). Inter-observer 
agreement for the whole panel, calculated using weighted Kappa, was 0.66 (95% confidence 
interval 0.59 – 0.73). The mean percentage inter-observer absolute agreement of the panel, 
defined as the percentage of scores that were exactly the same between two raters for the overall 
score, was 48% (range 36 – 65).
Intra-observer agreement of individual raters, calculated with the use of the weighted Kappa, 
varied between 0.54 – 0.80, suggesting moderate to substantial agreement.
BCCT.cor e
The overall cosmetic outcome with BCCT.core was excellent in 10 patients (9%), good in 54 
(50%), fair in 34 (31%) and poor in 11 patients (10%).
Panel  e valuat ion  vs . BCCT
The mean absolute agreement of the BCCT.core software and individual panel members was 
47% (range 39 – 53). The weighted Kappa of the overall BCCT.core software score and the 
average overall panel score per patient was 0.68 (95% confidence interval 0.57 – 0.77), suggesting 
substantial agreement.
Table 3. Percentage inter-observer agreement (above the black line), and inter-observer Weighted Kappa 
(below the black line); (n=109).
Percentage inter-observer agreement
Observers 1 2 3 4 5 6 7 8 9 10 BCCT.core
1 50 54 62 43 56 45 61 52 52 52
2 0.67 50 55 53 59 52 55 50 64 46
3 0.67 0.66 51 53 55 41 52 51 49 40
4 0.76 0.75 0.71 38 53 50 59 60 50 52
5 0.59 0.68 0.67 0.65 65 37 36 48 58 39
6 0.70 0.72 0.73 0.73 0.75 36 48 52 51 53
7 0.60 0.77 0.54 0.55 0.51 0.50 61 47 44 45
8 0.72 0.70 0.69 0.70 0.64 0.63 0.68 61 51 53
9 0.68 0.63 0.66 0.71 0.64 0.69 0.56 0.71 44 51
10 0.67 0.78 0.64 0.71 0.75 0.68 0.56 0.71 0.60 39
BCCT.core 0.50 0.54 0.52 0.65 0.55 0.61 0.52 0.61 0.59 0.50
Inter-observer Weighted Kappa
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S ubgroup panel  anal y s is
Panel  without  laype rsons
This subgroup panel consisted of 2 surgical residents, 2 breast surgeons and 4 plastic surgeons. 
The weighted kappa of the inter-observer reliability of the panel was 0.69 (95% confidence 
interval 0.62 – 0.75). The weighted kappa of the average score compared with the BCCT 
software was 0.69 (95% confidence interval 0.57 – 0.77).
Highly  spec ia l i sed  panel
This panel consisted of 2 breast surgeons and 4 plastic surgeons, and the weighted kappa of the 
inter-observer reliability was 0.67 (95% confidence interval 0.60 – 0.74). The weighted kappa 
of the average score of the specialised panel compared with the BCCT software was 0.67 (95% 
confidence interval 0.55 – 0.76).
P last i c  surgeon panel
This panel consisted of 4 plastic surgeons; the weighted kappa of the inter-observer reliability was 
0.70 (95% confidence interval 0.63 – 0.77). The weighted kappa of the average plastic surgeons’ 
score compared with the BCCT software was 0.64 (95% confidence interval 0.52 – 0.74).
Compar ison of  panel  i tems with  speci f ic  BCCT.core  i tems
Volume
Inter-observer agreement of the panel on the item volume was substantial (weighted Kappa 
of 0.61). The average score of the volume scored by the panel showed a substantial correlation 
between with the pBAD (dimensionless Breast Area Difference) of the BCCT.core software, 
with a Pearson correlation of 0.60.
Nipple  pos i t ion
Inter-observer agreement of the panel on the item nipple position was also substantial (weighted 
Kappa of 0.63). The average score of the nipple position by the panel showed a substantial 
correlation with the pBRA, pUNR and pBCE of the BCCT.core software (Spearman’s 
correlation ranging between 0.38 and 0.44).
Skin
Inter-observer panel agreement on the appearance of skin was moderate (weighted Kappa 0.47). 
The average score for skin appearance by the panel showed a substantial correlation with all 
colour specific items of the BCCT.core software (cX2L, cX2a, cX2b, cX2Lab, cEMDL, cEMDa, 
cEMDb and cEMDLab) (Spearman correlation ranging between 0.24 and 0.36).
Sc ar
Scoring of scar features by the panel also showed moderate inter-observer agreement (weighted 
Kappa 0.45). Low correlations were obtained for the average scar score of the panel with the scar 
specific items of the BCCT.core (sX2L, sX2a, sX2b, sX2Lab, sEMDL, sEMDa, sEMDb and 
sEMDLab) (Spearman correlation ranging between 0.09 and 0.13).
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D I S C U S S I O N
In the absence of a gold standard for cosmetic outcome analysis, panel evaluation has long 
been considered the most appropriate method of assessing cosmetic outcome.8,26,27 The present 
study clearly showed that panel evaluation with 10 observers results in a substantial agreement 
between observers (Kappa 0.66). In addition, we showed that the constitution of the panel did 
not impact on the level of agreement, which indicates that agreement between panel members 
did not increase with greater experience with breast surgery (e.g. a panel lacking laypersons and 
surgical residents did not lead to higher levels of agreement). 
Due the substantial workload associated with evaluation by 10 observers, we explored the 
feasibility of smaller panels using 20 random combinations of 3 observers from the initial 
database. These panels showed substantial agreement between observers, with a mean weighted 
Kappa of 0.66 (range 0.58 – 0.73), indicating that a reliable overall cosmetic outcome score can 
be achieved using a panel with any constitution of 3 observers. This finding contrasts with that 
of Vrieling et al., who suggested that a panel of at least 5 observers is required.17
To date, only a limited number of research groups have evaluated BCCT.core software. This 
software was originally validated against a panel of 12 expert observers (surgeons operating 
more than 200 patients per year), in a study with a consensus design, meaning that the software 
was compared with the observer’s score with the highest agreement with the consensus score on 
30 cases, and not by calculating the mean overall score of 12 expert observers.19,28 The BCCT.
core software has also been compared with panel evaluation in a study by Heil et al. of overall 
cosmetic outcome following BCT. These authors reported fair agreement between observers 
(mean weighted kappa of 0.31) and fair to moderate agreement between the panel and the 
software (mean weighted kappa of 0.24 – 0.45).29
Because use of BCCT.core software is now being described in an increasing number of studies, it 
is important to assess the reliability of the software.30-34 The approach taken in the present study, 
by investigating specific software items (e.g. skin, scar, volume) in comparison to the same items 
when scored by a panel, is the first of its kind and will facilitate understanding of the software.
Our results showed that the overall BCCT.core software score was substantially in agreement 
with the mean overall panel score for cosmetic outcome (Kappa 0.68). Analysis of specific 
items such as volume, nipple position and skin showed correlations ranging from very weak to 
strong between the panel and the software with especially very weak correlations on scar items 
(between 0.09 and 0.13). Further analyses of the scar specific items showed that patients with 
marked scarring of the breast received a better overall classification with the BCCT.core than 
from the panel. This indicates that BCCT.core software does not yet adequately detect marked 
scarring, and that there is room for improvement on scar specific items.
A limitation of the present study was the absence of a comparison between the software and 
patient self-evaluation. Patient self-evaluation might have provided valuable information not 
only on items related to breast cosmetic outcomes (subtle retraction or firmness), but also on 
functional aspects.26 We suggest that patient self-evaluation should be performed alongside 
panel or BCCT.core evaluations, as self-evaluation reflects the psychological adaptation of the 
patient to the appearance of the breast.
With the increasingly widespread use of oncoplastic breast surgery techniques, and the 
accompanying lack of robust studies with good methodology, the evaluation of the reliability 
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and validity of the various techniques for the assessment of cosmetic outcome should now be 
a priority. Well-designed prospective studies on oncoplastic breast surgery should incorporate 
the evaluation of cosmetic outcome as standard, with the use of reliable and valid techniques 
providing the best possible assessment of cosmetic outcome.11 Although BCCT.core software 
can provide valid cosmetic outcome scores when compared to a panel evaluation and thus 
facilitate comparison of different breast surgery units worldwide, the analysis of some items 
shows a need for improvement when compared to panel evaluation.
The claimed advantages of BCCT.core are the fast and accurate reporting of results and 
calculations that were previously time-consuming prior to the development of this software.21 
The rapid assessment of results (approximately 3 minutes per photograph)., is clearly facilitated 
by the BCCT.core. Following improvements in the analysis of scar features, the BCCT.core 
software could represent a valid tool in the assessment of cosmetic outcome.
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A B S T RAC T
Intro duct ion
Ultrasound-guided breast-conserving surgery (USS) results in a significant reduction in both 
margin involvement and excision volumes (COBALT-trial). The aim of the present study was to 
determine whether USS also leads to improvements in cosmetic outcome and patient satisfaction 
when compared to standard palpation-guided surgery (PGS).
Methods
A total of 134 patients with T1-T2 invasive breast cancer were included in the COBALT 
trial (NTR2579) and randomised to either USS (65 patients) or PGS (69 patients). Cosmetic 
outcomes were assessed by a three-member panel, by computerised software (BCCT.core) and 
by patient self-evaluation, including patient satisfaction. Time points for follow-up were 3, 6 
and 12 months after surgery. Overall cosmetic outcome and patient satisfaction were scored on 
a 4-point Likert scale (excellent, good, fair or poor). Outcomes were analyzed using a multilevel 
mixed effect proportional odds model for ordinal responses.
Results
USS achieved better cosmetic outcomes, with 20% excellent overall and only 6% rated as poor, 
whereas 14% of PGS outcomes were rated excellent and 13% as poor. USS also had consistently 
lower odds for worse cosmetic outcomes (OR=0.55, p=0.067) than PGS. The chance of having 
a worse outcome was significantly increased by a larger lumpectomy volume (ptrend=0.002); a 
volume >40cc showed odds 2.78 times higher for a worse outcome than a volume ≤40cc. USS 
resulted in a higher patient satisfaction compared with PGS.
Conc lusion
USS achieved better overall cosmetic outcomes and patient satisfaction than PGS. Lumpectomy 
volumes above 40cc resulted in significantly worse cosmetic outcomes.
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I N T RO D U C T I O N
Breast  c ancer
Breast cancer is the most common form of cancer amongst women in Western countries, with 
over a million cases diagnosed each year. Over recent decades less invasive surgical techniques, 
such as breast-conserving surgery (BCS) and the sentinel node procedure for axillary nodal 
staging, have been developed with the aim of preserving healthy breast tissue and healthy 
lymph nodes, reducing morbidity and improving cosmetic outcome, all without compromising 
oncological outcomes.1-3
 Nevertheless, BCS has difficulties in obtaining tumour-free resection margins using a 
traditional palpation-guided procedure for palpable breast cancer with margin involvement in up 
to 41% of patients. This results in the need for additional treatment such as radiotherapy boost, 
re-excision or even mastectomy.4-6 These additional treatments are psychologically stressful and 
have a negative impact on the final cosmetic result. 7-9 
An important secondary goal of BCS is the achievement of a satisfactory cosmetic outcome; 
especially since patient survival rates are improving. A number of studies have shown that 
cosmetic outcomes in BCS have a marked bearing on psychological outcomes. Unfortunately, 
poor cosmetic outcomes are still observed in up to 40% of patients.10-14 Factors influencing 
cosmetic outcomes include the volume of resected breast tissue 15, the site of the tumour 16,17, 
postoperative wound complications18 and the amount of radiotherapy, including the radiotherapy 
boost.18-20 Cosmetic outcomes following BCS are mainly influenced by excision volumes, with 
large excision volumes generally resulting in less favorable cosmetic outcomes.21
The COBALT trial was designed to address these shortcomings in BCS by comparing 
ultrasound-guided surgery (USS) with the standard palpation-guided surgery (PGS). The 
oncological results showed a dramatic reduction of margin involvement, with tumour-involved 
margins for the invasive component in 3% of the USS group compared to 17% in the PGS 
group. Moreover, optimal excision volume was achieved by using USS, whereas PGS resulted in 
excision volumes over two times too large.8 Of the 13.000 patients diagnosed in the Netherlands 
each year, approximately 9000 patients have palpable breast cancer of which 75% can safely 
undergo BCS with adjuvant radiotherapy treatment.22
The improvements attributable to USS may potentially have a positive impact on the final 
cosmetic outcomes and patient satisfaction. The current analysis aims to assess the cosmetic 
outcomes and patient satisfaction of USS compared with PGS after one year of follow-up.
M E T H O D S
Tr ial  des ign and pat ient  populat ion
The COBALT trial was performed in accordance with the Declaration of Helsinki, guidelines 
for Good Clinical Practice, and the CONSORT statement.23 Central and local independent 
medical ethics review boards of the participating hospitals approved the study protocol 
(registered at http://www.TrialRegister.nl, number NTR2579).24
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The COBALT trial was a comparative, two-arm, parallel group, randomised controlled trial 
undertaken in six hospitals in the Netherlands between October 2010 and March 2012. Eligible 
patients were randomised in a 1:1 ratio to either USS or PGS.25 Patients eligible to participate in 
the COBALT trial were diagnosed with an early stage (T1-T2, N0-N1) palpable invasive breast 
cancer and were scheduled to undergo BCS. Women with preoperatively diagnosed DCIS, 
multifocal disease, a history of neo-adjuvant therapy, previous surgical treatment, or radiation 
therapy of the affected breast were excluded from the study. Patients who had invasive carcinoma 
with limited or extensive carcinoma in situ diagnosed postoperatively by the pathologist were 
not excluded.
S urgic al  Technique
Although the definition of tumour-free margins used in the current study was “no tumour cells 
at the margin”, the aim of both ultrasound-guided and palpation-guided surgery for all surgeons 
was to achieve complete tumour removal with a surgically feasible healthy tissue margins of up 
to 1 cm. The closure of the lumpectomy cavity did not involve oncoplastic surgery techniques, 
thus allowing seroma formation.
Calculated Resect ion R at ios  (CRR)
Excess volume resection was defined as a calculated resection ratio (CRR) and calculated by 
dividing the volume of each specimen by the optimal resection volume. The optimal resection 
volume is the spherical tumour volume plus an arbitrarily chosen, surgically feasible tumour-
free resection margin of 1 cm.7,26 In an ideal situation, the specimen volume is identical to the 
optimal resection volume and the CRR equals 1.0.
Patient  f ol low-up
Follow-up was performed at 3, 6 and 12 months after initial surgery and consisted of digital 
photographs of the breasts and patient self-evaluation. Digital photographs consisted of 
standardised 4-viewpoint pictures (one frontal, two oblique and one lateral picture of the breasts, 
from neck to waist), and were taken during regular outpatient clinic visits using a digital camera 
of at least 5-megapixel resolution.
S cor ing of  cosmet ic  outcome and pat ient  se l f-e valuat ion
The COBALT trial used subjective (panel- and self-evaluation) and objective (BCCT.core 
software) cosmetic outcome evaluation techniques. In all these methods, cosmetic outcome of 
the treated breast was compared to the untreated breast and scored by using the 4-point Likert 
scale, which classifies outcomes as excellent, good, fair or poor. “Excellent” meant identical 
to the untreated breast and “poor” indicated a marked difference with the untreated breast.27 
Patients who underwent mastectomy following primary surgery were scored as “poor” on all 
three evaluation methods.
a. Panel  e valuat ion
A three-member panel (one experienced breast surgeon and two laymen) evaluated the pictures. 
None of the panel members had performed surgery on the patients. Patient information and the 
study arm were blinded to the observers. The photographs were combined into a PowerPoint® 
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presentation of 30 to 90 slides. Each slide displayed 4 photographs of a patient at a specific 
follow-up time point. Breast shape or contour, breast volume, deformity, nipple position, the 
appearance of the surgical scar, skin alterations, and the overall cosmetic outcome were all scored.
b. Compute r ised  e valuat ion; BCCT.cor e
The Breast Cancer Conservative Treatment cosmetic results (BCCT.core) has been developed in 
recent years to facilitate cosmetic outcome assessment, improve reproducibility and to allow the 
comparison of the results from different breast clinics free of subjective individual scores.28 The 
software was used to assess the frontal photographs.
c . Pat ient  cosmet ic  se l f-e valuat ion
Patient self-evaluation was based on a composite questionnaire including questions on symmetry 
between the two breasts on different items including firmness of the breast, nipple position, 
breast contour, breast volume, appearance of the scar, final overall result and patient satisfaction 
with the appearance of the breast.
S tat ist ic a l  methods
Patient, tumour and treatment characteristics of both types of surgery were compared using the 
chi-squared test, Fisher’s exact test or the two independent sample t-test. Intraclass correlation 
coefficient (ICC) was calculated to obtain inter-observer reliability between the three panel 
members. The estimated consistency of agreement between the three observers at each follow-
up occasion was considered poor when ICC<0.40, fair when 0.40≤ICC<0.60, good when 
0.60≤ICC<0.75 and excellent when 0.75≤ICC<1.00.29 
All panel members’ scores were combined for each patient separately at a given follow-up time 
point by finding the mean overall cosmetic outcome score and rounding it to the nearest integer. 
A multilevel mixed effect proportional odds model for ordinal responses was used to model the 
odds of having a worse cosmetic outcome. Since the outcome was assessed at three different 
time points by three different methods of evaluation, each patient contributed 9 outcome 
measurements, and the patient was considered as a random effect in the model.
Candidate explanatory variables were study centre, type of surgery, follow-up occasion, method 
of evaluation, T stadium, BMI (kg/m2), age, re-excision (yes/no), and boost (yes/no). These 
variables were considered as fixed effects in the model and only those that were significant 
were retained in the final model. The effect of specimen volume on the cosmetic outcome 
was investigated separately, after excluding women who had undergone mastectomy after the 
primary surgery. The volume measurements were categorised into 2 groups (volume of more or 
less than 40cc), and were based on the median volume.  During revision of pathology reports, 
four specimens were identified with suspicious differences between volume and weight, and one 
specimen lacked volume measurement. Volumes of these specimens were therefore imputed 
using specimen weight (twice measured: in the operation theatre and by the pathologist). A 
separate model was run to investigate patient satisfaction with the appearance of their breast. 
The proportionality assumptions for all models were checked and fulfilled. 
All p-values were two-sided and a significance level of 5% was used. All analyses were performed 
using STATA version 13.
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RE S U LT S
Patient  and tumour  character ist ics  ( Table  1)
A brief overview of patient and tumour characteristics is provided in Table 1. For a complete 
overview of initial oncological results can be found in Krekel et al.8 Mean specimen weight, 
volume and CRR were significantly smaller in the USS group than in the PGS group (weight: 
38g vs. 52g, volume: 38cc vs. 53cc and CRR: 1.0 vs.1.7, all p<0.01). Additional therapy was 
more frequently required in the PGS group than the USS group (27% vs. 11%, p=0.038) and 
5 patients in the PGS group with tumour-involved margins underwent a mastectomy. Total 
missing data rates were 14% (18 patients) at 3 and 6 months, and 12% (14 patients) at one 
year. One patient refused to participate in follow-up, one patient had major complications due 
to chemotherapy and could not participate in follow-up, one patient refused follow-up after 3 
months and one patient was excluded from follow-up because she refused radiotherapy. The 
remaining missing data points per patient were due to the inability to attend the outpatient 
clinic visit despite several appointments. 
Table 1. Patient and tumour characteristics.
Palpation-guided 
surgery
Ultrasound-guided 
surgery
p*
Age (mean, 95% CI) 57.0 (54.6-59.4) 54.4 (51.9-56.8) 0.124 
BMI (mean,95% CI) 26.6 (25.4-27.8) 26.2 (25.0-27.4) 0.685 
Location of carcinoma
Upper outer
Upper inner
Lower outer
Lower inner
48 (70%)
7 (10%)
9 (13%)
5 (7%)
31 (48%)
12 (19%)
16 (25%)
5 (8%) 
0.079 
Weight specimen (mean, 95% CI) 51.9 (43.9-59.9) 37.8 (31.4-44.1) 0.007 
Volume specimen (mean, 95% CI)
53.1 (45.0-61.2) 37.9 (31.2-44.5) 0.004
Diameter tumour (mean, 95% CI) 2.0 (1.8-2.2) 2.0 (1.8-2.2) 0.983 
T-stadium
T1
T2
35 (51%)
34 (49%)
36 (56%)
28 (44%) 
0.523 
Calculated Resection Ratio (mean, 
95% CI)
1.7 (1.4-2.0) 1.0  (0.9-1.2) <0.001 
Additional therapy
None
Re-excision 
Mastectomy
Boost
50 (73%)
3 (4%)
5 (7%)
11 (16%)
57 (89%)
1 (2%)
0 (0%)
6 (9%)
0.038 
(0.016 for comparison 
additional therapy yes/no)
*chi-squared test, Fisher’s exact test or two independent sample t-test
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Inter-r ater  re l iabi l i t y  for  panel  e valuat ion
The estimated consistency of agreement between the three observers was fair for responses on 
the first follow-up occasion (ICC=0.59) and good for the next two occasions (ICC=0.69 at 6 
months; ICC=0.68 at 12 months).
Cosmetic  outcome inc luding mastectomies: USS vs . PGS. 
( Tables  2, 3 , 4)
USS resulted in better cosmetic outcomes than PGS, respectively 20% vs. 14% of the overall 
responses rated excellent. Only 6% of the responses were poor with USS, compared to 13% 
with PGS. Overall, a patient had a 45% reduced chance of a worse cosmetic outcome with 
USS as compared to PGS (OR=0.55, p =0.067). The odds of having a worse cosmetic outcome 
became significantly greater by 12 months (OR=2.57, p <0.001). When considering various 
evaluation methods, the odds of reporting a worse cosmetic outcome were lower for panel and 
self-evaluation than for BCCT.core software (Table 3). Furthermore, the odds of having a worse 
cosmetic outcome were 2.35 times higher for T2 tumours compared with T1 tumours (p=0.010). 
To elaborate on our findings, in Table 4 we report probabilities of scoring the breast as excellent, 
good, fair or poor. For all three evaluation methods the probability of an excellent or good score 
was clearly higher with USS than with PGS, and the cumulative probabilities of these responses 
were, respectively, 70% vs. 56% for BCCT.core, 81% vs. 69% for panel evaluation and 78% vs. 
66%, for patient self-evaluation.
Table 2. Overall percentages of overall cosmetic outcome and patient satisfaction categories.
Palpation-guided surgery Ultrasound-guided surgery
Cosmetic Outcome
Excellent
Good
Fair
Poor
14%
51%
22%
13%
20%
52%
22%
6%
Patient satisfation
Excellent
Good
Fair
Poor
26%
54%
7%
13%
43%
47%
8%
2%
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Table 3.  Odds ratios of having worse cosmetic outcome based on the proportional odds model for ordinal 
responses.
Odds Ratio (95% CI) p
Excision method
PGS
USS
1 (Ref )
0.55 (0.29-1.04) 0.067
Follow-Up
3 months
6 months
12 months
1 (Ref )
1.21 (0.88-1.66)
2.57 (1.86-3.55)
0.237
<0.001
Evaluation Method
BCCT.core
Panel
Self-evaluation
1 (Ref )
0.56 (0.41-0.77)
0.65 (0.47-0.88)
<0.001
0.006
T-stadium
T1
T2
1 (Ref )
2.35 (1.23-4.51) 0.010
BMI 1.08 (1.01-1.16) 0.020
Table 4. Response probabilities of the overall cosmetic outcome at one year follow-up after primary surgery. 
T-stadium is fixed at the sample proportions of T-stadium II and BMI is fixed at the means of BMI.
Palpation-guided surgery Ultrasound-guided surgery
BCCT.core
Excellent
Good
Fair
Poor
0.04
0.52
0.37
0.07
0.07
0.63
0.26
0.04
Panel evaluation
Excellent
Good
Fair
Poor
0.07
0.62
0.27
0.04
0.12
0.69
0.17
0.02
Self-evaluation
Excellent
Good
Fair
Poor
0.06
0.60
0.29
0.05
0.10
0.68
0.19
0.03
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Effect  of  volume on the  cosmet ic  outcome, mastectomies 
e xc luded ( Table  5)
The volume measurements were categorised into 2 groups (volume of more or less than 40cc). 
Excision volumes >40cc resulted in 2.78 higher odds of having worse outcome when compared 
to volumes ≤40cc (OR=2.78, p=0.002). When volume was included in the model as a covariate, 
the difference between the two types of surgery became non-significant (OR=1.18, p=0.574). 
However, of the lumpectomies performed with USS, only 20% had a volume larger than 40cc, 
while the figure for PGS lumpectomies was 56%. 
Patient  sat is fact ion ( Table.2)
After USS 90% of patients were very satisfied or satisfied with the appearance of their breasts, 
compared to 80% with PGS. The chances of being less satisfied were 86% lower after USS than 
after PGS, controlled for follow-up time points, T-stadium and BMI (OR=0.14, p=0.006).
Table 5. Odds ratios of having a worse cosmetic outcome based on the proportional odds model for ordinal 
responses (women who underwent mastectomy were excluded)
Odds Ratio (95% CI) p
Excision method
PGS
USS
1 (Ref )
1.18 (0.67-2.07) 0.574
Follow-Up
3 months
6 months
12 months
1 (Ref )
1.25 (0.90-1.72)
2.66 (1.91-3.70)
0.182
<0.001
Evaluation Method
BCCT.core
Panel
Self-evaluation
1 (Ref )
0.60 (0.44-0.83)
0.71 (0.52-0.97)
0.002
0.033
Volume (cc)
Category 1 (≤40)
Category 2(40>)
1 (Ref )
2.78 (1.49-5.18) 0.002*
BMI 1.07 (1.01-1.13) 0.018
*linear trend
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D I S C U S S I O N
Oncological outcomes are the primary endpoints of BCS. However, in recent years cosmetic 
outcome has gained increased interest. The primary results of the COBALT trial showed that 
USS significantly reduced margin involvement, while the amount of healthy breast tissue excised 
was smaller. Furthermore USS resulted in a reduction of additional treatments and healthcare 
costs.8,30 The present study shows that USS improves overall cosmetic outcomes at one year 
following surgery. “Excellent” or “good” outcomes were observed in 72% of patients who had 
undergone USS, and “poor” cosmetic outcomes in 6%. Women treated with PGS had a poor 
cosmetic outcome twice as often as women who underwent USS. 
Two studies evaluating cosmetic outcomes following BCS reported “excellent” or “good” scores 
in 68% to 93% of patients.31,32 These studies were retrospective, in contrast to the present 
randomised controlled trial (RCT), and used different evaluation methods (i.e. single observer 
evaluation). The 93% “excellent” or “good” overall cosmetic outcome score was obtained by 
patient self-evaluation; the most subjective evaluation method. The scores obtained with the 
BCCT.core software in these studies were similar to the scores obtained in the present study. 
Only one RCT described cosmetic outcomes with patient self-evaluation 3 years after radio-
guided seed localization (RSL) or wire localization (WL) for non-palpable carcinomas. 
“Excellent” and “good” scores were obtained in 80% and 76% of patients, with a “fair” and “poor” 
cosmetic outcome in 24% and 19%, respectively. Excision volumes and reoperations negatively 
influenced cosmetic results.33 
In our study, patients were “very satisfied or satisfied” with the appearance of their breast in 90% 
of cases after USS and in 80% after PGS. Which is higher than the 83% described by Losken 
at al. after oncoplastic surgery and higher than the reported 87% after BCS by Eichler et al.34,35
Different studies have shown that the rate of cosmetic failure is significantly higher if the size 
of the lump exceeds >50-70 cm³, regardless of breast size.19,20,36 In the present study only 20% of 
the volumes were >40cc in the USS group compared to 56% in the PGS group (breast size was 
not evaluated in this study). Other factors influencing cosmetic outcomes include the site of the 
tumour16,17, postoperative wound complications18 and the amount of radiotherapy, including the 
radiotherapy boost.18-20 In this study none of these factors appeared to be of significant influence 
on the overall cosmetic outcome; complication rates were low but the rate of women receiving 
boost radiotherapy was high due to national guidelines.
As a consensus on a gold standard for cosmetic outcome assessment is currently lacking and 
clear guidelines for the assessment of cosmetic outcomes have failed to emerge, current advice 
is that a range of objective and subjective evaluation methods should be used to evaluate the 
appearance of the breasts.13,28,37,38  Therefore, the present study used three different evaluation 
methods to obtain an overall cosmetic outcome.
The cosmetic outcome after one year seems to be a good predictor of final cosmetic outcome 
(although there are long-term effects of radiotherapy on breast appearance).20,39,40 Studies have 
reported that patients with moderate or poor surgical cosmetic outcome (a few months after 
surgery) have an increased risk of developing breast shrinkage or induration on the long term, 
and thereby underline the importance of reducing specimen volumes.21,39
A poor cosmetic outcome may negatively influence quality of life, and could have a marked 
bearing on the psychological outcome.10-13 Hau et al. demonstrated that patients with “fair” or 
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“poor” cosmetic outcome after BCS (at both 5 and 10 years follow-up) had significantly worse 
quality of life scores on an EORTC QLQ-C30 questionnaire.41 These considerations therefore 
predict that patients who underwent USS will have a better quality of life than those who 
underwent PGS. However, long-term follow-up of at least 3 years, including assessment of 
patient well-being, are expected in the coming years.
CO N C LU S I O N
USS for early-stage invasive breast cancer is superior to PGS as it significantly lowers margin 
involvement rates, the need for additional therapy and healthcare costs, and improves overall 
cosmetic outcome and patient satisfaction. Overall, “excellent” or “good” cosmetic outcome were 
reported for USS and PGS in 72% and 65% of cases, respectively. The improvements in cosmetic 
results achieved with USS are probably attributable to reductions in both additional therapy and 
excision volumes.
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A B S T RAC T
Aim of  the  sudy
The current study aims to assess margin status in relation to amount of healthy breast tissue 
resected in breast-conserving surgery (BCS) on a nationwide scale.
Methods
Using PALGA (a nationwide network and registry of histology and cytopathology in the 
Netherlands), all patients who underwent BCS for primary invasive carcinoma in 2012-13 
were selected (10,058 excerpts). 9276 pathology excerpts were analysed for a range of criteria 
including oncological margin status and distance to closest margin, specimen weight/volume, 
greatest tumour diameter, and with or without localisation method. Calculated resection ratios 
(CRR) were assessed to determine excess healthy breast tissue resection. 
Results
Margins for invasive carcinoma and in situ carcinoma combined were tumour-involved in 498 
(5.4%) and focally involved in 1021 cases (11.0%) of cases. Unsatisfactory resections including 
(focally) involved margins and margins ≤1mm were reported in 33.8% of patients. The median 
lumpectomy volume was 46 cc (range 1 – 807 cc; SD 49.18) and median CRR 2.32 (range 0.10 
– 104.17; SD 3.23), indicating the excision of 2.3 the optimal resection volume.
Conc lusion
The unacceptable rate of tumour-involved margins as well as margins ≤ 1mm in one third of all 
patients is also achieved at the expense of healthy breast tissue resection, which may carry the 
drawback of high rates of cosmetic failure. These data clearly suggest the need for improvement 
in current breast conserving surgical procedures to decrease tumour-involved margin rates while 
reducing the amount of healthy breast tissue resected.
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I N T RO D U C T I O N
Breast-conserving therapy (BCT) involves a combination of lumpectomy and adjuvant 
radiotherapy and is currently the treatment of choice for early stage breast cancer. The two 
main goals of breast-conserving surgery (BCS) are to obtain tumour-free resection margins 
and achieve good cosmetic outcomes and thereby maintain quality of life. Obtaining tumour-
free resection margins is important as it avoids the need for additional local treatments such as 
radiotherapy boost, re-excision or mastectomy.1-4 Internationally, palpable tumours and non-
palpable tumours are excised using different operative techniques. It should be stressed that 
the excision of palpable breast cancer is mostly based on the tactile (blind) skills of the surgeon, 
and that the excision of non-palpable breast cancer requires an intra-operative localisation 
method such as wire-guided excision, radio occult lesion localization (ROLL), iodine-125 seeds 
localisation or ultrasound guidance. 
Incidences for tumour-involved margins in BCS have been reported in literature worldwide in 
up to 40% of patients.3,5,6 7 However, direct comparison of studies is difficult due to the use of 
varying definitions for positive margins, for instance “close margin” is used for either a positive 
and negative margin. Internationally, close margins are defined as tumour cells ≤1mm from the 
resection margin.
In the United Kingdom previous guidelines recommended a margin >2mm, however current 
guidelines do not encompass a clear definition on margin status and they recommend breast 
units to have local guidelines regarding acceptable margin width.8 For instance Danish National 
Guidelines recommend tumour-free margins ≥2mm.9 Amongst others, Germany, Scotland 
and France, in contrast to the United Kingdom, have national and regional BCS guidelines on 
margin status which indicate that margins should be >1mm, and that patients with margins 
≤1mm should undergo additional surgery.10-12
Other countries, such as the Netherlands and the United States, have guidelines for BCS stating 
that tumour-free margins are all specimens without tumour-cells at the inked margins, and that 
these patients do not necessitate a re-excision.13,14 However, two surveys in the United States 
have reported that 85% of breast surgeons do not accept a margin ≤1mm.15,16 Another survey 
performed in 2014 by Parvez et al. describes that, respectively, only 20% and 8% of the responding 
Canadian and American breast surgeons would never recommend a re-excision when the tumour 
is <2mm of the closest margin, meaning that the remaining surgeons could recommend a re-
excision in patients with tumour negative margins.17 The latter results in re-excisions to attain 
wider clear margins although this is against the national breast cancer guidelines.18
Despite the international controversy regarding the definition of tumour margins, it is important 
to note that a tumour-free resection margin of >1mm is unrelated to local recurrence or overall 
survival, and local recurrence rates range from 2% to 5%.1,3,19-22
Although the secondary goal of BCS is a satisfactory cosmetic outcome, cosmetic failures still 
occur in up to 30% of cases.23-26 Factors influencing cosmetic outcomes include the volume of 
resected breast tissue27, the site of the tumour28,29, postoperative wound complications30 and the 
amount of radiotherapy, including the radiotherapy boost (which increases the total amount of 
Gy administered).30-32
Of these factors, the total lumpectomy volume has a major impact on cosmetic outcomes 
following BCS and is considered the main determinant.27,33 Literature shows that cosmetic 
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failure rates are significantly higher when a lump exceeds 50-85 cm³, regardless of the size of the 
breast.27,31-33 The lumpectomy volume is determined by the size of the tumour and the amount of 
healthy breast tissue resected. A way to quantify excess healthy breast tissue resection is by using 
the Calculated Resection Ratio (CRR).7
In recent years, indicators in breast cancer care have been formulated in a number of countries.34 
After a careful review of literature, quality indicators have been established from diagnostic 
work-up, to treatment and to follow-up. However, quality indicators for specimen volume, 
cosmetic outcome or quality of life are lacking. In the Netherlands quality indicators have been 
formulated in order to improve breast cancer care. One of the indicators is achieving tumour-
free margins for invasive breast cancer in at least 85% of patients, thereby fulfilling the primary 
goal of BCS. However, the secondary goal of achieving a satisfactory cosmetic outcome with 
BCS and issues such as excision volume or resection of excess healthy breast tissue are not 
addressed by any indicator. Therefore the Dutch national guidelines solely concentrate on the 
oncological outcomes whilst ignoring possible consequences due to excess healthy breast tissue 
resection, such as poor cosmetic outcomes. This exclusive focus on the primary goal of BCS 
has made the attainment of tumour-free resection margins paramount. While a large volume 
of resected tissue could improve the chances of achieving tumour-free resection margins, this 
approach may impair final cosmetic results.
A better understanding of this issue will require not only data on tumour involvement, but also 
data on the volume of healthy breast tissue resected – data that are currently lacking. 
The aim of this study is to determine margin status (including margins ≤1mm) in relation to 
specimen volume and the amount of healthy breast tissue resected in patients with invasive 
breast cancer who underwent BCS in the Netherlands.
M E T H O D S
1. Pat ient  se lect ion
All women with primary invasive breast cancer undergoing BCS in 2012 and 2013 were 
prospectively registered in PALGA (a nationwide network and registry of histology and 
cytopathology in the Netherlands) (a total of 10,058 excerpts).35 Patients with solely in situ 
carcinoma were excluded, as were patients who underwent only a lymph node or breast biopsy, 
patients who underwent a mastectomy or oncoplastic breast surgery, patients who received neo-
adjuvant treatment, patients with metastases and reports lacking margin status. This resulted in 
the analysis of 9276 pathology excerpts.
2. Breast  c ancer  patholog y  e xcer pts
The information as provided by the PALGA registry, according to National Dutch pathology 
guidelines, include: report identifier (encrypted patient identifiers ensuring patient privacy), date 
of specimen receipt, gender, age, pathology excerpt conclusion, pathological macroscopy report, 
excision method, tumour-involvement, type of carcinoma and greatest diameter of tumour. In 
the Netherlands, all pathology reports on breast conserving surgery should at least include a 
description of these items.
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Pat ients , t umours  and e xci s ion  methods
Pathology excerpts described several tumour types, which we categorised as invasive ductal 
carcinoma, invasive lobular carcinoma and “other” (all other tumour types).
Five excision methods were initially defined but we chose to group them as ‘excision without 
localization’ (standard lumpectomy, wide local excision and segmentectomy) and ‘excision with 
localization’ (majority wire-guided excision and minority iodine-125 seeds). Ultrasound-guided 
surgery and radio occult lesion localization (ROLL) were not described in pathology excerpts, 
and could theoretically be in both with and without localisation groups.
Marg in s tat us
According to Dutch national guidelines, resection margin status is categorised as tumour-
free, focally involved or as a tumour-involved margin. A tumour-free margin is defined as the 
absence of tumour cells at the inked margins of the specimen, focally-involved margins show 
an area of tumour cells ≤4 mm, while specimens with tumour-involved margins have grossly 
distinguishable tumour at the inked edge of the specimen.13 Close margins are defined as tumour 
cells ≤1mm from the closest margin and were also assessed, as internationally close margins may 
have clinical consequences such as re-excision or even mastectomy.8,10,12,36
As additional unexpected carcinoma in situ can be found during pathological examination, the 
present study also assessed margin status for patients with limited or extensive carcinoma in 
situ, in combination with the invasive carcinoma. Both the margin status for invasive carcinoma 
alone and margin status for invasive carcinoma and the in situ component were assessed and 
included in the analyses.
Calculat ion  of  the  volumes  and Calculated  Resect ion  R at ios  (CRR)
The weight or three-dimensional measurements of the resected specimens (length, width 
and height) were mentioned in the majority of pathological macroscopy reports. Specimen 
volumes could be derived from specimen weights, as studies have shown that breast specimen 
volumes (cubic centimeters) and weights (grams) are similar.37,38 When specimen weight 
was unavailable, specimen dimensions were used to calculate the volume of an ellipsoid 
[4/3π(length*width*height)] in order to obtain specimen volume.38,39
Excess volume resection was defined as a calculated resection ratio (CRR) and calculated by 
dividing the volume of each specimen by the optimum resection volume. The optimum resection 
volume as defined in our earlier studies is the spherical tumour volume plus an arbitrarily chosen, 
surgically feasible optimum tumour-free resection margin of 1 cm.7,38 In an ideal situation, the 
specimen volume is identical to the optimum resection volume and the CRR equals 1.0.
3. S tat ist ic a l  anal y ses
Data were analysed using the Statistical Package for the Social Sciences (SPSS statistical 
software, Version 21.0; IBM corp., USA). Patient, tumour and margin characteristics were 
compared using the chi-square test, Fisher’s exact test, Jonckheere-Terpstra test or Kruskal-
Wallis test with a Bonferroni correction in a post-hoc analysis. Nominal logistic regression was 
performed to compare the odds of having involved and focally-involved margins to the odds of 
having free margins. These analyses were performed to identify risk factors for margin status, 
and candidate factors were excision method, tumour type, patient age, greatest tumour diameter, 
lump volume and CRR. The results were considered significant at a 5% level of significance. 
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RE S U LT S
Patient  se lect ion
The study included all patients who underwent BCS in the Netherlands. A total of 28,698 
women diagnosed with primary invasive breast cancer in 2012-13.40 The database provided by 
PALGA included 10,058 excerpts on 9912 patients who underwent BCS for invasive breast 
cancer in the Netherlands in 2012-13. This means that 34.5% of patients with primary invasive 
breast cancer underwent BCS in 2012-13. After assessment for eligibility using the exclusion 
criteria, 9276 pathology excerpts were selected for analysis.
Patients , tumours  and e xcis ion methods  ( Table  1  and 3) 
Of the 9276 excerpts, the average patient age was 62 (range 24-97 years). Median tumour 
diameter was 1.4 cm (SD 0.77). Invasive ductal carcinoma (IDC) was the most prevalent 
carcinoma and was observed in 7781 specimens (83.9%) and invasive lobular carcinoma (ILC) 
was found in 832 (9.0%) of specimens. Regarding laterality, 51.1% of tumours were found in the 
left breast, 48.1% in the right breast and 0.7% of cases were unknown.
Surgery was aided by a tumour localization method in 2491 cases (26.9%). Tumour diameters 
were larger when localization methods were not used, 1.50 cm (SD 0.80), compared to 1.10 cm 
(SD 0.61) with use of iodine-125 seeds or wire-guided excision (p<0.001).
Margin status  for  invasive  c arcinoma onl y  ( Table  1)
Tumour-involved margins were reported in 323 (3.5%) and focally- involved in 626 (6.7%) 
cases. Close margins for invasive carcinoma (defined as tumour cells ≤1 mm of the margin) 
occurred in 1618 lumpectomies (17.4%). Tumour-involved margins and close margins for 
invasive carcinoma combined were therefore present in 27.6% of patients.
Excision of invasive ductal carcinoma was more successful in yielding tumour-free margins 
(90.9%) compared to invasive lobular carcinoma (77.4%). The use of either iodine-125 or wire-
guided excision resulted in small but significant differences in margin involvement (p=0.001). 
The use of localization resulted in a slightly higher rate of tumour-free margins (90.8%) than 
approaches without localization (89.4%). 
Margin status  for  invasive  c arcinoma and in  s i tu 
c arcinoma combined ( Table  2  and 4)
Margins for invasive carcinoma and in situ carcinoma combined were tumour-involved in 498 
(5.4%) and focally- involved in 1021 (11.0%) cases. Close margins for invasive carcinoma (defined 
as tumour cells ≤1 mm of the margin) occurred in 1618 lumpectomies (17.4%), combined with 
either invasive carcinoma or additional in situ carcinoma, (focally) involved margins or ≤1mm 
from the tumour occurred in 1519 lumpectomies (33.8%).
Again, the excision of IDC combined with additional DCIS resulted in a higher tumour-free 
margin rate (84.4%) than ILC combined with in situ carcinoma (73.9%). 
Unadjusted odds ratios of Excision Method and Max Tumour Diameter for tumour-involved 
and focally-involved margins differed when other prognostic factors were controlled for in the 
regression models, which might have been caused by potential confounding. The adjusted odds 
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Table 1. Tumour and margin characteristics for invasive carcinoma alone.
Tumour-free 
margins
Focally-involved 
margins
Tumour-
involved margins
p Total (in group 
percentage)
A ll specimens 8327 (89.8%) 626 (6.7%) 323 (3.5%) 9276 (100%)
Year
2012
2013
3577 (89.3%)
4750 (90.1%)
282 (7.0%) 
344 (6.5%)
145 (3.6%)
178 (3.4%)
0.4861 4004 (43.2%)
5272 (56.8%)
Excision method
Without Localization
With Localization
6065 (89.4%)
2262 (90.8)
454 (6.7%)
172 (6.9%)
266 (3.9%)
57 (2.3%)
0.0011 6785 (73.1%)
2491 (26.9%)
Tumour type
IDC
ILC
Other
7071 (90.9%)
644 (77.4%)
612 (92.3%)
488 (6.3%)
108 (13.0%)
30 (4.5%)
222 (2.9%)
80 (9.6%)
21 (3.2%)
<0.0011 7781 (83.9%)
832 (9.0%)
663 (7.1%)
Tumour stage
T1
T2
T3
6648 (92.0%)
1168 (82.5%)
11 (42.3%)
413 (5.7%)
211 (10.4%)
2 (7.7%)
168 (2.3%)
142 (7.0%)
13 (50.0%)
<0.0012 7229 (77.9%)
2021 (21.8%)
26 (0.3%)
Median greatest tumour 
diameter in cm (range 
; SD)
1.30 
(0.1-7.5 ; 0.72)
1.60 
(0.2-5.0 ; 0.82)
1.90
(0.4-10.0 ; 1.28)
<0.0014 1.40 
(0.1-10.0 ; 0.77)
Median age in years 
(range ; SD) 62 (24-97 ; 10.84) 61 (28-89 ; 10.81) 61 (26-91 ; 11.68) 0.3633 62 (24-97 ; 10.87)
Median lumpectomy 
volume in cc
(range ; SD)
47 (1-807 ; 48.76) 40 (3-485 ; 50.72) 40.32 (1-495 ; 
56.26)
<0.0013 46 (1 – 807 ; 49.18)
Median CRR
(range ; SD) 2.40 (0.10-104.17 
; 3.20)
1.78 (0.25-45.74 
; 2.82)
1.50 (0.36-69.00 
; 4.57)
<0.0014 2.32 (0.10 - 104.17 
; 3.23)
1Chi-square test 
2 Fisher’s exact test 
3 Kruskal-Wallis test 
4Jonckheere-Terpstra test
Abbreviations:  
IDC: Invasive Ductal Carcinoma 
ILC: Invasive Lobular Carcinoma
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Table 2. Tumour and margin characteristics for invasive carcinoma with additional DCIS included.
Tumour-free margins Focally-involved 
margins
Tumour-involved 
margins
p Total (in group 
percentage)
All specimens 7757 (83.6%) 1021 (11.0 %) 498 (5.4%) 9276 (100%)
Year
2012
2013
3343 (83.5%)
4414 (83.7%)
442 (11.0%) 
579 (11.0%)
219 (5.5%)
279 (5.3%)
0.9251 4004 (43.2%)
5272 (56.8%)
Excision method
Without Localization
With Localization
5667 (83.5%)
2090 (83.9%)
727 (10.7%)
294 (11.8%)
391 (5.8%)
107 (4.3%)
0.0101 6785 (73.1%)
2491 (26.9%)
Tumour type
IDC
ILC
Other
6569 (84.4%)
615 (73.9%)
573 (86.4%)
842 (10.8%)
124 (14.9%)
55 (8.3%)
370 (4.8%)
93 (11.2%)
35 (5.3%)
<0.0011 7781 (83.9%)
832 (9.0%)
663 (7.1%)
Tumour stage
T1
T2
T3
6179 (85.5%)
1571 (77.7%)
7 (26.9%)
742 (10.3%)
274 (13.6%)
5 (19.2%)
308 (4.3%)
176 (8.7%)
14 (53.8%)
<0.0012 7229 (77.9%)
2021 (21.8%)
26 (0.3%)
Median greatest tumour 
diameter in cm
(range ; SD)
1.30
(0.1-7.5 ; 0.71)
1.50
(0.1-5.2 ; 0.82)
1.60
(0.1-10.0 ; 1.19)
<0.0014 1.40
(0.1-10.0 ; 0.77)
Median age in years
(range ; SD)
62 (24-97 ; 10.81) 62 (28-89 ; 10.80) 60 (26-93 ; 11.80) 0.0163 62
(24-97 ; 10.87)
Median lumpectomy 
volume in cc
(range ; SD)
47.12
(1-807 ; 49.58)
41.23
(3-485 ; 45.45)
39.00
(1-495 ; 49.34)
<0.0014 46
(1 – 807 ; 49.18)
Median CRR
(range ; SD)
2.41
(0.10-104.17 ; 3.22)
2.04
(0.25-45.74 ; 2.87)
1.73
(0.36-69.00 ; 3.89)
<0.0014 2.32
(0.10 - 104.17 ; 
3.23)
 
1Chi-square test 
2 Fisher’s exact test 
3 Kruskal-Wallis test 
4Jonckheere-Terpstra test 
 
Abbreviations:  
IDC: Invasive Ductal Carcinoma 
ILC: Invasive Lobular Carcinoma
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Table 3.  Calculated Resection Ratios (CRR), lumpectomy volume and greatest tumour diameter for excision 
methods and tumour types.
Median Lumpectomy 
Volume (cc) (range)
p Median greatest 
tumour diameter 
(cm) (range ; SD)
p Median CRR
(range)
p
Excision method
Without Localization
With Localization
46.00 (1-807; 50.32)
46.08 (4-660; 45.91)
0.6931
1.50 (0.1 – 10,0; 0.80)
1.10 (0.1 – 7.5; 0.61)
<0.0011
2.14 (0.10-104.17; 2.97)
2.87 (0.41-91.15; 3.76)
<0.0011
Tumour type
IDC
ILC
Other
46.00 (1-807; 49.38)
48.76 (3-503; 52.38)
42.00 (4-306; 41.70)
<0.0011
1.40 (0.1 – 10,0; 0.74)
1.50 (0.1 – 7,0; 0.90)
1.20 (0.1 – 5.5; 0.82)
<0.0011
2.30 (0.10-104.17; 3.29)
2.44 (0.48-18.69; 2.43)
2.37 (0.24-49.32; 2.37)
0.4711
Tumour stage
T1
T2
T3
41.89 (1-754; 40.15)
66.00 (3-807; 65.91)
113.00 (41-348; 94.17)
<0.0012
1.20 (0.1 – 1.9; 0.42)
2.40 (2.0 – 4.9; 0.55)
5.50 (5.0 – 10.0; 0.77)
<0.0012
2.61 (0.10-104.17; 3.39)
1.56 (0.35-69.00; 2.14)
2.32 (0.10-104.17; 3.23)
<0.0011
 
1Kruskal-Wallis test 
2Jonckheere-Terpstra test 
 
Abbreviations: 
IDC: Invasive Ductal Carcinoma 
ILC: Invasive Lobular Carcinoma
ratio of involved margins did not differ significantly between excision methods with or without 
tumour localization tools (OR=0.94; p=0.63; CI 0.75-1.19). However, the adjusted odds ratio 
for focally involved margins differed significantly between excision methods and was lower 
when no localization tools were used (OR=0.79; p=0.002; CI 0.68-0.92).
When we compared involved margins between ILC and IDC, we found a significantly higher 
odds ratio for involved margins in ILC than IDC (OR=2.58; p<0.001; CI 2.00-3.33). Moreover, 
the odds ratio of having tumour-involved margins increased as tumour diameter increased 
(OR=2.19; p<0.001; CI 1.96-2.45), and decreased with age (OR=0.99; p=0.012; CI 0.98-1.00) 
and with lump volume (OR=0.99; p<0.001; CI 0.99-1.00). The odds ratio for focally-involved 
margins was higher for ILC than IDC (OR=1.57; p<0.001; CI 1.27-1.94) and also increased 
as greatest tumour diameter increased (OR=1.44; p<0.001; CI 1.31-1.58). The odds ratio was 
slightly lower for younger women (OR=0.99; p=0.012; CI 0.98-1.00) and for a smaller lump 
(OR=0.99; p<0.001; CI 0.99-0.99).
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Table 4.  Odds ratios for tumour-involved and focally-involved margins for both invasive carcinoma and 
DCIS.
Tumour-free vs tumour-involved margins
OR  (95% CI)
Univariate
p OR  (95% CI)
Multivariate
p
Excision method
Without localization
With localization
1.35 (1.08-1.68)
1 (Ref )
0.008 0.94 (0.75-1.19)
1 (Ref )
0.630
Tumour type
IDC
ILC
Other
1 (Ref )
2.69 (2.11-3.42)
1.08 (0.76-1.55)
<0.001
0.656
1 (Ref )
2.58 (2.00-3.33)
1.04 (0.71-1.51)
<0.001
0.851
Age 0.99 (0.98-1.00) 0.004 0.99 (0.98-1.00) 0.012
Max tumour diameter 1.83 (1.67-2.02) <0.001 2.19 (1.96-2.45) <0.001
Lump volume 1.00 (0.99-1.00) 0.003 0.99 (0.99-0.99) <0.001
Tumour-free vs focally-involved margins
Localization method
Without localization
With localization
0.91 (0.79-1.05)
1 (Ref )
0.211 0.79 (0.68-0.92)
1 (Ref )
0.002
Tumour type
IDC
ILC
Other
1 (Ref )
1.57 (1.28-1.93)
0.75 (0.56-1.00)
<0.001
0.047
1 (Ref )
1.57 (1.27-1.94)
0.78 (0.59-1.04)
<0.001
0.095
Age 0.99 (0.99-1.01) 0.884 1.00 (0.99-1.00) 0.731
Max tumour diameter 1.27 (1.17-1.38) <0.001 1.44 (1.31-1.58) <0.001
Lump volume 1.00 (0.99-1.00) <0.001 1.00 (0.99-1.00) <0.001
Resect ion volumes  and c alculated resect ion r at ios 
Median lumpectomy volume and median CRR were 46 cc (1 - 807 cc; SD 49.18) and 2.32 (0.10 
– 104.17; SD 3.23), respectively (Table 1).
Resection volumes were >50cc in almost half (42.3%) of all patients, and 35% of patients had 
a lumpectomy volume of more than 60cc. A CRR of 2.87 was found in the patient group 
that underwent surgery with tumour localization tools compared to 2.14 in the group without 
tumour localization tools (p<0.001), while the largest median tumour diameters in these groups 
were 1.10 cm and 1.50 cm, respectively (p<0.001)
The margin status of the various invasive carcinoma groups also showed differences in median 
lumpectomy volumes: the volume in the tumour-free group of 47cc was significantly higher 
compared to the 40cc found in both focally involved margins (post hoc p=0.02) and tumour-
involved margins (post hoc p<0.001). CRR was the greatest in the tumour-free margin group 
(2.40) compared to the focally involved margin (1.78) and the tumour-involved margin (1.50) 
groups and these medians were significantly decreasing across the three groups (p<0.001). 
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Different lumpectomy volumes were observed between margin status groups of the invasive 
carcinoma combined with additional in situ carcinoma: the tumour-free margin group showed 
the highest median volume of 47cc, the focally-involved margin group had the median volume 
of 41cc and the tumour-involved margin group had the smallest median of 39cc (p<0.001). 
The CRR was the highest in the tumour-free margin group (2.41), compared to the focally 
involved margin (2.04) and tumour-involved margin (1.73) groups. These differences were also 
significantly decreasing (p<0.001). 
D I S C U S S I O N
This nationwide study does not only address margin status but also focuses on its relation to 
lumpectomy volumes and amount of healthy breast tissue resected. 
Our results indicate that of all excisions for invasive carcinoma without additional carcinoma 
in situ, 10.2% resulted in tumour at the inked margin. According to Dutch national guidelines, 
these patients likely underwent additional therapy such as re-excision, radiotherapy boost or 
even mastectomy. With any BCS technique for tumour excision, the aim of the surgeon is to 
excise the tumour centrally in the specimen. This study also reported close margins (tumour 
distance to closest margin of ≤1mm) combined with tumour-involved margins, in 33.8% of cases, 
suggesting that one third of patients who underwent BCS had eccentrically located tumours in 
the lumpectomy specimen. The aim of breast cancer excision should be a central excision of the 
tumour surrounded by a reasonable amount of healthy breast tissue, and thereby these results 
indicate that current surgical approaches are lacking precision. For instance, palpable breast 
cancer surgery is exclusively based on the tactile (or blind) skills of the surgeon and results in a 
surgical failure rate in one third of patients over the years 2012-13.
An earlier Dutch study reported margin involvement rates for palpable and non-palpable tumour 
in 726 consecutive patients who underwent BCS for T1-T2 tumours in respectively 22.5% and 
17.4% of patients, and reported a median lumpectomy volume of 63cc and a calculated resection 
ratio (CRR) of 2.5, indicating resection of 2.5 times the ideal amount of healthy breast tissue. 
Higher tumour involvement rates are internationally described, for instance Park et al reported 
in 533 cases of BCS for invasive breast cancer, tumour involved margins in 12.4%, focally 
involved in 22.9% and close margins in 18.0% of patients.3,5 Nevertheless, margin status remains 
difficult to compare due to different definitions of tumour involvement and its implications for 
additional treatment.
A review by Lee et al. evaluated repeat surgery after BCS for T0-T2 breast cancer between 2004 
and 2010 in the United States, resulting in the inclusion of 241,597 patients. Although tumour 
free margins for invasive carcinoma were observed in 92% of patients, 23% of patients underwent 
additional surgery (62% re-excisions and 38% mastectomies). Unfortunately this study did not 
report margin width or close margins.41 Considering that 92% of patients had tumour free 
margins, ambiguities persist as to why 23% of patients underwent additional surgery. This may 
be explained by the study of the American Society of Breast surgeons on 6,725 patients who had 
undergone BCS. This study showed that 34% of 1,451 re-excisions were performed as a result of 
a margin <1mm, although no tumour was found at the inked margin.36
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Considering the definition of different countries on margin status for breast cancer, in the 
Netherlands and United States “no tumour at the inked margin” is considered a tumour free 
margin, contrasting with the German guidelines stating that tumour at ≤1mm from the inked 
margin is an indication to perform additional surgery to attain wider clear margins.8,10,13 
Moreover the Netherlands and US differentiate between focally positive and positive margins, 
where a radiotherapy boost can be administered for focally positive margins and re-excision is 
not mandatory but can be considered on a case-by-case basis. 
Hence, margin width remains a subject of debate, and internationally there seems to be a lack 
of standardization on the definition of margin status and a considerable variation in clinical 
consequences, with re-excisions commonly performed in cases of close margins. Two separate 
surveys performed in the United States have reported that up to 15% of surgeons would accept 
any negative margin lacking tumour cells, whereas 28% and 78%, respectively, would prefer
1 mm or 2 mm.15,16 The endeavour to obtain wider margins unfortunately results in repeat 
surgery in patients with no tumour cells at the inked margin.42 This clearly reveals that surgeons 
aim at excising breast cancer centrally in the specimen.
Although margin width remains a subject of debate, several studies have shown that an increased 
risk of local recurrence is only associated with tumour cells at the inked margin, and more 
specifically, that increasing margin width did not affect local recurrence rates.43,44 Given the 
variation in clinical consequences when close margins are observed, it is incontestable that the 
guidelines of BCS of different countries have not complied with the results of the studies on 
local recurrence rates in case of close margins.
The current study reported a median excision volume of 46cc after BCS with a high CRR 
(median 2.3), which indicates that two and a half times the ideal and surgically feasible amount 
of healthy breast tissue is currently being removed. Even in case of tumour-involved margins, an 
excess healthy breast tissue resection is observed (CRR=1.5).
Resection volume and its relation to cosmetic outcome has been a major issue in BCS in recent 
years. A number of studies have shown that larger excision volumes significantly influence breast 
and nipple retractions, lifting of the breast, breast volume and breast contour. Cosmetic failure is 
also significantly higher if the size of the lump exceeds 60cc, regardless of breast size.27,29,31-33,45,46 
In the present study 35% of patients had a lumpectomy volume of more than 60cc. Applying 
an ideal lumpectomy volume (maximum tumour diameter plus a 1 cm margin, CRR=1) to 
our data set, the ideal excision volume should exceed 60cc in only 5% of patients. Achieving 
optimal resection volumes (CRR=1) could theoretically reduce cosmetic failure rates. Despite 
the frequent excision of excessive amounts of healthy breast tissue, the results of the present 
study show that tumour-involved margins still occur in 16% of BCS patients. Additionally, 
close margins for invasive breast cancer in 19.4% of the tumour-free margin group suggest that 
eccentric excision of tumours is common.
A range of approaches to excision all resulted in comparable rates of tumour-free resection 
margins (including additional in situ carcinoma). This study demonstrates that BCS with 
tumour-free margins is observed in 84% of cases, but achieved at the cost of - and we would 
argue, excessive - amounts of healthy breast tissue excision. In the past years new surgical 
techniques have been developed combining BCS with plastic surgery techniques and are 
referred to as oncoplastic surgery. Advocates of oncoplastic breast conserving surgery highlight 
that wider tumour excisions could reduce margin involvement. However, a systematic review on 
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oncoplastic surgery showed tumour-free margins after oncoplastic surgery occur in 78% to 93% 
of excisions.47 The studies included in this review clearly show that higher lumpectomy volumes 
and greater amounts of healthy breast tissue excision do not result in higher rates of tumour-free 
margins.
Other techniques and devices have been developed, such as the MarginProbe (Dune Medical 
Devices, Zug, Switzerland), for ex-vivo specimen margin assessment after tumour excision for 
both invasive carcinoma and in particular DCIS. The MarginProbe enables immediate re-excision 
if tumour is detected at the margins and claims to result in fewer secondary interventions.48 
Ex-vivo ultrasound assessment of the surgical specimen performed by Olsha et al. and Eichler 
and colleagues, resulted in tumour-free margins in 95% and 96% of patients, respectively.49,50 
However, major improvements could be achieved by continuous tumour visualization, guiding 
the surgeon through surgery.
The use of visual guidance during excision, as opposed to removing a tumour solely based on the 
tactile sense, is known to improve surgical management, as it allows real-time feedback to the 
surgeon and enables immediate decision-making regarding the extent of excision.51
As early as in 2001, Moore et al. performed a prospective study to evaluate ultrasound-guided 
surgery (USS) in women with palpable invasive ductal breast cancer which resulted in only 
3% tumour-involved margins with USS compared with 29% palpation-guided surgery (PGS) 
(p<0.05).52 The manifold benefits of ultrasound-guided surgery have been described extensively 
and specifically in terms of improved margin clearance, fewer re-excision procedures, and 
smaller excision volumes.6,39,53-56 Furthermore, a multicentre randomised controlled COBALT 
trial, comparing PGS with USS for palpable T1–T2 invasive breast cancer, showed significant 
improvements in both tumour-involved margins and excision volumes with USS. Margin 
involvement was present in only 3.1% of patients (versus 17.0% with PGS) and a 38cc mean 
excision volume was obtained (versus 58cc with PGS), together with a CRR of exactly 1.0 
(versus 1.7 with PGS). The use of intra-operative ultrasound also resulted in a significant 
reduction in re-excisions, mastectomies and irradiation boost, reduced health care costs and 
increased cosmetic results compared with PGS.37,57 A recent survey by Sclafani et al. reported 
that 39% of breast surgeons believe to be adequately trained in breast ultrasound.58 This rate 
could easily be improved according to Krekel et al. who demonstrated that breast surgeons can 
be trained in USS in a fairly short period, achieving tumour-free margins and reducing both 
lumpectomy volume and CRR after only 8 procedures.59
The results of the current study show that there is still considerable room for improvement in 
BCS. To achieve the dual goals of a CRR=1 and a reduction in tumour-involved margins, we 
believe that all US-visible T1-T2 tumours should be excised using USS. A limitation of USS 
may be that some tumours are not visible with ultrasound.
In recent years quality indicators for breast cancer surgery have been established in the 
Netherlands. Amongst others, the United States National Consortium of Breast Centres 
(NCBC) and the European Society of Breast Cancer Specialists (EUSOMA), indicate that 
positive margin rates and re-operation should be quality indicators.34,60,61 However accepting 
positive margin rate as a quality indicator is controversial as this may results in larger excision 
volumes, increased mastectomy rates and thereby poor cosmetic outcomes, as stated by the 
American Society of Breast Surgeons.62 The Dutch Breast Cancer Audit (NBCA), in dialogue 
with the Dutch Association of Surgical Oncology, has formulated quality indicators including 
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tumour-free margins for invasive breast cancer in at least 85% of patients. This study shows that 
this goal is achieved at the expense of the increase of healthy breast tissue resection, an outcome 
predicted by the American Society of Breast Surgeons as a result of the quality indicator on 
margin involvement. This is also corroborated by the fact that only 35% of patients have received 
BCS in the Netherlands in 2012 and 2013, which is lower than the figure of 50% for BCS 
reported by the Dutch Breast Cancer Audit in 2011.63
Intraoperative ultrasound guidance and the adoption of excess healthy breast tissue resection 
(CRR) as a quality indicator could result in improved breast cancer care and increased numbers 
of BCS procedures compared to mastectomies.
The current study was entirely based on pathological findings after primary BCS for invasive 
breast cancer, and not on the clinical aspects of breast cancer surgery. Therefore, results did 
not include further clinical patient characteristics or information on additional treatment in 
cases with (focally-) involved margins. Unfortunately USS was not mentioned as an excision 
method in the PALGA database. Therefore this group could not be retrieved from the available 
data, although we suspect that USS data may have been incorporated in the PGS, WLE and 
segmentectomy groups.
In conclusion, tumour-involved margins in invasive and in situ carcinoma occur in 16% of cases 
with excessive resection of healthy breast tissue (>2 times optimal). Although this rate of margin 
involvement is 20-40% lower as compared to earlier literature, unsatisfactory resections with 
margins ≤1mm were reported in 33.8% of cases. The amounts of healthy breast tissue currently 
resected in order to obtain tumour-free margins probably result in high rates of cosmetic failure. 
This study clearly shows that current BCS lacks surgical precision. Intra-operative ultrasound 
guided surgery could resolve these conflicting goals by increasing tumour-free margin rates and 
decreasing the amount of healthy breast tissue resection (CRR=1), while reducing health care 
costs. Iodine-125 visualization seems to be a promising technique for the tumour-free resection 
of breast cancer (93.2%) in tumours invisible to ultrasonography.
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A B S T RAC T
O bject ive
The primary objectives of this systematic review on oncoplastic breast surgery (OPBS) were 
to evaluate the oncological and cosmetic outcomes of OPBS. The secondary objectives were to 
assess morbidity, quality of life, and applied algorithms.
Bac kground
Breast-conserving therapy (BCT) has become the standard of care, and survival is now excellent. 
Consequently, the focus of BCT has increasingly shifted to cosmetic outcome, quality of life, 
and patient satis- faction. Nonetheless, excision of certain tumours still presents a considerable 
challenge. Specialised approaches combining oncological surgery and plastic surgery techniques 
are collectively referred to as OPBS. A summary of OPBS outcomes would facilitate decision-
making and best treatment selection by both clinicians and patients.
Methods
Using specific inclusion and exclusion criteria to analyze 2090 abstracts on the topic of OPBS 
published between 2000 and 2011, the authors evaluated each study with respect to design and 
outcomes.
Results
A total of 88 articles were identified for potential inclusion and reviewed in detail by the lead 
authors. No randomised controlled trials were identified. Eleven prospective observational or 
comparative studies fulfilled inclusion criteria and were selected. In these studies, 80% to 93% 
of the tumours were invasive. Tumour-free resection margins were observed in 78% to 93%, 
resulting in a 3% to 16% mastectomy rate. Local recurrence was observed in 0% to 7% of the 
patients. Good cosmetic outcome was obtained in 84% to 89% of patients. However, most studies 
showed significant weaknesses including lack of robust design and important methodological 
shortcomings, negatively influencing generalizability.
Conc lusions
This systematic review reveals that current evidence supporting the efficacy of OPBS is based 
on poorly designed and underpowered studies. Given the increasing importance and application 
of OPBS, there is a pressing need for robust comparative studies, including both randomised 
controlled trials and well-designed, multicentre prospective longitudinal studies.
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I N T RO D U C T I O N
Histor y  and descr ipt ion of  oncoplast ic  surger y
Breast cancer is the most common form of cancer in women, with a worldwide estimated 
incidence of 1.38 million patients per year.1 Several trials have compared the efficacy of 
mastectomy to breast-conserving surgery (BCS) followed by eradication of residual tumour 
cells by radiotherapy (referred to as breast-conserving therapy [BCT]) and found that disease-
free and overall survival are equivalent.  The latter approach has become the standard of care for 
early-stage breast cancer and under Dutch guidelines, 75% of breast cancer patients qualify for 
BCT. 2-6
The primary goal of tumour excision using BCS is to achieve tumour-free resection margins. 
Despite the best surgical efforts, tumour-involved surgical margins still occur in 20-40% of 
all tumour excisions, leading in many cases to additional boost radiation, re-excision or even 
mastectomy.7-10 Local recurrence rates range from 2% to 5%. 4,9,11-13 It should also be noted that 
a tumour-free resection margin of >1mm is unrelated to local recurrence or overall survival.7 
Although an important secondary goal in BCS is to achieve a satisfactory cosmetic outcome, a 
factor crucial to patient satisfaction and quality of life, poor cosmetic outcomes are still observed 
in up to 40% of patients. 14-17
Many localised tumours can be successfully treated by standard lumpectomy, but some lesions 
are difficult to excise without the risk of cosmetic deformity and/or margin involvement. In 
some cases, cosmetically favourable results can be difficult to obtain and an example of this is in 
patients with large breast tumours in relation to breast size. Specialised approaches to resection 
with concomitant reconstruction have been developed over the past decades and are now referred 
to as oncoplastic breast surgery (OPBS). These new surgical approaches combine oncological 
resection with plastic surgery techniques in a single procedure. Advocates of oncoplastic 
surgery in breast cancer emphasise the freedom to perform wider tumour excisions, potentially 
reducing margin involvement and thereby retreatment resulting in lower local recurrence rates, 
in combination with adjuvant therapies. Another advantage of OPBS is the possibility to allow 
the excision of larger tumours without compromising cosmetic outcome.
OPBS is based on two broad techniques; i) volume-displacement using (dermo)glandular 
transposition of breast tissue into the resection site;  ii) volume replacement using autologous 
tissues to compensate the volume loss following tumour resection. Diverse oncoplastic techniques 
are practised under the umbrella of these two forms of oncoplastic surgery, but in all cases, the 
surgeon should prepare for postoperative tumour bed localisation by using clips to mark the 
tumour bed.
Volume displacement
Volume displacement is generally used to correct small or moderate defects following 
tumourectomy and these techniques reduce the risk of a localised defect through glandular or 
dermoglandular redistribution of breast tissue.
While a wide variety of oncoplastic volume displacement techniques have been described in the 
literature, the most frequently encountered techniques are the following.18-21
Glandular rotation is a method of parenchymal redistribution that can be used in almost every 
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location in the breast in cases of tumourectomy without skin resection. The skin is undermined 
in order to mobilise the whole quadrant and the lateral glandular flaps of the defects can then 
easily be approximated for suturing into the defect.
Nipple-areolar complex elevation or centralisation can be used to correct the nipple asymmetry 
that may occur when the central volume of the breast needs to be mobilised towards the defect. 
The central portion of the breast is undermined, separating the nipple-areola complex from the 
underlying breast tissue, and then sutured into the defect.
The round block technique is often used in breasts with moderate ptosis or hypertrophy, with 
tumour localisation in the periareolar region. This technique involves drawing circles of two 
different diameters around the nipple and resecting the intervening skin. This allows good 
access to the tumour site and facilitates quadrant resection. Reshaping is achieved by partially 
dissecting breast tissue off the pectoralis muscle, while preserving the major perforating vessels 
in order to preserve vascularisation of the breast.
The radial technique can be used when the tumour is located in the medial or lateral quadrants. 
Skin resection is performed in a radial manner followed by a large quadrantectomy until the 
deep pectoral plane is reached. Partial undermining of the skin allows glandular rotation into 
the defect. Nipple-areolar complex centralisation can prevent upward or median deviation of 
the nipple.
Oncoplastic mamma reduction is probably the oldest OPBS technique and is often used in 
patients with large breasts for whom smaller breasts are perceived as a positive outcome. This 
technique allows wide excisions and depending on the location of the tumour, a lower or upper 
pedicled flap is preferred, using the same technique in the opposite breast.
Volume replacement
Volume replacement corrects a defect by replacement of the patient’s own tissue from a distant 
site. Volume replacement techniques are mainly used when a large resection volumes is required 
in relatively small breasts. In such cases the defect cannot be corrected by volume displacement 
due to a lack of remaining breast tissue. Several different approaches to volume replacement have 
been described, including myocutaneous, myosubcutaneous and adipose flaps;
Latissimus dorsi myocutaneous flap (LD) is indicated in small-breasted women. This 
myocutaneous autologous reconstruction technique uses the latissimus dorsi muscle and 
overlying skin to replace areas of excised tissue volume. A skin island with underlying muscle is 
prepared and pivoted under the axilla whilst maintaining the blood supply of the flap.22
Latissimus dorsi myosubcutaneous flap or latissimus dorsi mini flap (LDm) is indicated in small-
breasted women where the skin overlying the tumour can be preserved but where replacement of 
the excised tissue volume needs to take place to preserve symmetry and improve cosmetic results. 
The LDm technique is similar to the LD technique, except that the skin overlying the LD is not 
used in this particular reconstruction.23
Other more complex oncoplastic volume replacement techniques for partial breast reconstruction 
have been described, using free flap reconstruction and microvascular anastomosis. These 
techniques include the transverse rectus abdominus myocutaneous flap (TRAM), the deep 
internal epigastric perforator flap (DIEP), the superficial inferior epigastric artery flap (SIEA), 
the superior gluteal artery perforator flap (SGAP), and the omental flap. Further techniques can 
be found in oncoplastic and plastic surgery literature.
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How the  inter vent ion might  work
Oncoplastic breast surgery should only be considered when an unfavourable cosmetic 
outcome is expected with standard BCS. The choice of the technique should rely on a 
well-defined algorithm that take into account the tumour size in relation to breast size, 
location of the tumour and minimal postoperative complications. The primary focus 
in breast cancer surgery should be the effective treatment of the breast cancer and the 
oncological outcome should always prevail over the desired cosmetic results. In Attainment 
of tumour-free resection margins in OPBS is more important than ever, as remodelling 
or direct reconstruction impedes re-excision in case with positive resection margins. 
Aims of  this  sy stemat ic  re vie w
Oncoplastic surgery has rapidly gained acceptance and is now widely practiced.24 An extensive 
body of literature has accumulated over the past decade, claiming that oncological, cosmetic and 
psychological benefits can be achieved through immediate oncoplastic reconstruction during 
BCS.25,26 A summary of the evidence from this literature could help clinicians and patients 
understand both oncological and cosmetic outcomes, and issues of morbidity and quality of life, 
thus allowing informed decisions on the most appropriate surgical technique for the treatment 
of a specific breast cancer case.
The primary objectives of this systematic review were to evaluate the oncological and cosmetic 
outcomes of OPBS. The secondary objectives were to assess morbidity, quality of life and applied 
algorithms.
M E T H O D S
Relevant studies were identified using computerised bibliographic searches of MEDLINE, 
EMBASE, and the Cochrane database (November 2011) and supplemented by a manual 
search of reference lists and the review of “epub ahead of print” articles. A comprehensive search 
was performed using the following search terms: breast-conserving surgery, oncoplastic breast 
surgery, partial breast reconstruction, reduction mammoplasty, partial mastectomy, immediate 
reconstruction and cosmesis. Additional keywords and further logical combinations of these and 
related terms were used to maximise sensitivity. The search included all study designs.
The search was limited to articles published in English between 2000-2011 and involving 
women with breast cancer undergoing immediate reconstruction after breast conserving surgery. 
A manual cross-reference search of the bibliographies of relevant articles was conducted to 
identify studies not found through the computerised search. Randomised controlled clinical 
trials (RCTs), prospective observational or comparative studies with an oncoplastic operated 
patient group greater than 25 individuals were considered. Articles describing appropriate 
and recognised OPBS techniques were included (either volume displacement or volume 
replacement). No other restrictions were applied on selection.
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Data  e xtr act ion
Two review authors (MHK, NMAK) independently evaluated titles and abstracts to assess 
eligibility in terms of outcome measures and study design. The authors were blinded to each 
others’ results during the review process and findings were then compared. Articles for which 
agreement could not be reached were reassessed to achieve consensus. Four studies were 
reassessed due to differing evaluations of study design, and 3 of these articles were subsequently 
excluded from the review.
RE S U LT S
Literature  search (F igure  1)
Titles and abstracts of 2090 citations were identified from the MEDLINE, EMBASE and 
Cochrane searches. Following appraisal of the inclusion criteria, 88 articles were identified for 
potential inclusion and reviewed in detail. A total of 76 articles were excluded, leaving 12 articles 
to form the basis of this systematic review. 
OP BS methodologic al  character ist ics  ( Table  1)
St udy  D esig n
No RCTs were identified during the selection process. As Veiga et al. used the same study 
population in articles from 2010 and 2011, we considered both articles as one study.27,28 Of 
these 11 studies, 7 were prospective observational studies and 4 were prospective comparative 
studies. Three studies compared OPBS with BCT, and 1 study compared OPBS with reduction 
mammaplasty for macromasty. All the trials were single centre studies.
St udy  Populat ion
All studies recruited patients from a single clinical institution and tended to towards small 
sample sizes. Four of the studies included less than 100 patients in the OPBS group and none of 
the remaining 7 studies exceeded 200 patients. A total of 998 patients were treated using OPBS 
techniques in these prospectively monitored studies and the predominant histotype was invasive 
ductal carcinoma. The mean or median tumour size ranged from 22mm to 34mm.
Breast  surgeons  and plast ic  surgeons
The majority of the operations was performed by breast surgeons, only occasionally assisted by 
plastic surgeons. Surgery was conducted without the assistance of a plastic surgeon in 6 studies. 
The first 15 patients in the study by Clough et al. were operated on by both a breast surgeon 
and a plastic surgeon. Other studies noted that breast surgeons had received plastic surgery 
training. Rusby et al. even described using volume replacement techniques (in particular the 
LDm-technique) by a trained breast surgeon without the help of a plastic surgeon.
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Figure 1. Literature diagram
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Reference Type of study Groups Speciality Technique Number of 
patients
Follow-up (months) Age (years)
Bong et al., 2010 Prospective 
observational
OPBS Breast Surgeon BM, PM, MWPM 167 NR Mean 55.6 (Range 33-85)
Chan et al., 2009 Prospective 
observational
OPBS Specialist Surgeon NAC, GR 162 1-3 Mean 52 (Range 20-96)
Clough et al., 
2003
Prospective 
observational
OPBS Breast Surgeon (First 15 
by Plastic Surgeon)
RMsp, RMpp, 
other techniques
101 Median 46 (Range 
7-168)
Mean 53 (Range 31-91)
Giacalone et al., 
2010
Prospective 
comparative
OPBS
Quadrantectomy
Surgeons trained in breast 
and plastic surgery
1. RM, RB
2. Quadrantectomy
31
43
NR 1. Mean 51.3 (SD 12.1)
2. Mean 58.5 (SD 1.7)
Gulcelik et al., 
2011
Prospective 
Comparative
OPBS
Macromasty
NR 1. RMip, RMsp
2. RMip, RMsp
101
 
185
Every 3 months, f irst 
year
1. Mean 52.2
2. Mean 44.8
Range or SD per group not 
specif ied
Kaur et al., 2005 Prospective 
comparative
OPBS
Quadrantectomy
1.Breast Surgeon and 
Plastic Surgeon
2. Breast Surgeon
1. RMip, RMsp, 
RB, LD
2. Quadrantectomy
30
30
Less than 24 months 1. Mean 48.73
(Range: 30-75)
2. Mean 55.76
(Range 34-81)
Meretoja et al., 
2005
Prospective 
observational
OPBS Surgeons trained in breast 
and plastic surgery.
79/90 operated on by 3 
surgeons
NAC, GR, RM, 
central resection, M
90 Median 26
(Range 6-52)
Mean 57 (Range 37-80)
Rietjens et al., 
2007
Prospective 
observational
OPBS Breast Surgeon and Plastic 
Surgeon
RMsp, RMip, RB, 
LD, SI
148 Median 74
(Range: 10-108)
2 patients lost
Mean 50 (Range 31-71)
Rusby et al., 2008 Prospective 
observational
OPBS Breast Surgeon LDm 110 Median 41.1
(Range: 21.1-82.0)
Mean 49.5 (SD 9.3)
Veiga et al., 2010 
and 2011
Prospective 
comparative
OPBS
BCT
Breast Surgeon and Plastic 
Surgeon
Solely local f laps 
or breast reduction 
techniques, 11=RM
45
42
6 and 12 1. Median 52
(Range: 33-72)
2. Median 48
(Range 34-71)
Yang et al., 2011 Prospective 
observational
OPBS Breast Surgeon and Plastic 
Surgeon
Superiorly located 
breast cancers, RB, 
BM, TRM, GR, 
PM
58 Mean 21 Mean 46 +- 10.4
NR: Not Reported
SD: Standard Deviation
OPBS: OncoPlastic Breast Surgery
BM: Batwing Mastopexy
GR: Glandular Rotation technique
LD: Latissimus Dorsi musculocutaneaous f lap
LDm: Latissimus Dorsi minif lap, musculosubcutaneaous f lap
RB: Round Block technique
M: Mastectomy, planned or converted
MWPM: Modif ied Wise Pattern Mastopexy
NAC: Nipple Areolar Complex centralisation or elevation
PM: Parallelogram Mastopexy
RM: Reduction Mammaplasty without specif ication of used pedicle
RMip: Reduction Mammaplasty inferior pedicle technique
RMpp: Reduction Mammaplasty posterior pedicle technique
RMsp: Reduction Mammaplasty superior pedicle technique
SI: reconstruction with Silicon Implant
TRM: Tennis Racket Method
Table 1. Study characteristics.
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Surgeon
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RMip: Reduction Mammaplasty inferior pedicle technique
RMpp: Reduction Mammaplasty posterior pedicle technique
RMsp: Reduction Mammaplasty superior pedicle technique
SI: reconstruction with Silicon Implant
TRM: Tennis Racket Method
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OP BS tec hniques  appl ied  and indic at ions
A wide variety of OPBS techniques have been developed and over 10 different techniques were 
used in the reviewed studies. Overall, the most commonly employed were volume displacement 
techniques, in particular reduction mammoplasties and glandular rotation techniques.
Clough et al. used the reduction mammaplasty with superior pedicle technique (RMsp) in 
83% of the cases, followed by a concomitant contralateral mammaplasty in 88% of cases. Other 
techniques included posterior pedicle technique (3%), and the free nipple graft (6%).
Contralateral breast surgery was performed concomitantly by Rietjens et al. in all cases of 
their series.29 Kaur et al. performed an immediate contralateral reduction mammaplasty in 
27 patients (90%) of the oncoplastic group. Other studies performed immediate contralateral 
symmetrisation in fewer cases.
None of the studies described whether concomitant contralateral breast surgery for 
symmetrisation was planned preoperatively or chosen for during the operation. In most cases, 
the choice for an OPBS technique was based purely on the location of the tumour as described 
in oncoplastic literature, without use of a validated algorithm.
Fol low-up
Mean or median follow-up ranged from 1 month to 74 months.
Oncologic al  outcomes  ( Table  2)
Marg in Involvement
Any literature review of the oncological outcomes resulting from OPBS should consider the 
limitations of the reported studies. It is important to note that the accepted definition of 
tumour-free margins is at least a 1mm distance between the cut edge of the specimen and the 
outer limit of the tumour. Greater distances are not associated with lower local recurrence rates, 
despite the aim of OPBS to excise greater volumes of breast tissue even for smaller tumours.7,8,10 
Few of the studies reviewed heeded the internationally accepted descriptions of free margins, 
close margins and focally involved margins. Moreover, many were inconsistent in their reporting 
of tumour and specimen size, the rate of invasive tumours, and in particular, the oncoplastic 
technique employed.
In this review, we compared the 20% to 40% positive margin rate achieved with regular BCS 
to the margin involvement results of OPBS, using the margin involvement outcomes of 7 
prospective studies in which they were described.29-35 These studies used varying definitions of 
close margins, but they were mostly defined as a 1mm or 2mm distance between the cut edge of 
the specimen and the outer limit of the tumour.
In summary, in these 7 OPBS studies 77% to 95% of all tumours were invasive breast cancers. 
Furthermore, the use of OPBS resulted in tumour-free margins in 78% to 93% of cases; close 
margins in 3% to 13% and positive margins in 0% to 10%, resulting in a need for mastectomy 
in 3% to 16% of all cases. Specimen weight range in these studies was wide, ranging from 157g 
to 948g.
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L oc al  r ecur r ence
A follow-up of at least 2 years was considered relevant for the assessment of local recurrence. 
Furthermore both patient and tumour characteristics should be described when reporting 
local recurrence, so that non-invasive tumours (benign or DCIS) and patients who previously 
underwent mastectomy can be excluded. Unfortunately, methodological problems are still 
hampering many reports.
Seven studies reported local tumour recurrence, with a mean or median follow-up ranging from 
1 month to 74 months. Four of these studies described tumour recurrence with mean and median 
follow-up periods of >24 months. 29,30,33,36 These studies indicate that a mean or median follow-
up of more than 24 months allows the identification of local recurrence at rates ranging from 0% 
to 7%. Although the follow-up varied considerably, ranging from 10 to 108 months, the number 
of patients with a minimum follow-up of at least 24 months was not described. Only Rusby and 
colleagues noted the exclusion of mastectomies from local recurrence rate calculations, although 
they did not mention the exclusion of non-invasive tumours when reporting local recurrence.33
Cosmetic  outcomes  ( Table  3)
The cosmetic outcomes of OPBS were adequately reported in only 4 studies, and while 3 of these 
described the method of cosmetic evaluation, no uniform or validated method was used.30,36-38 
Veiga et al. described the method of cosmetic outcome assessment but did not describe results 
numerically. 28 
Together, these four studies reported good cosmetic outcomes following OPBS in 84% to 89% 
of patients. Nevertheless, there was wide variation in both the manner of assessment of cosmetic 
outcome and the moment of cosmetic assessment. A detailed description of the used methods 
used and the results for cosmetic outcome can be found in Table 3.
Patient  sat is fact ion
Only one study described patient satisfaction and Chan et al. used a single question related to 
patient satisfaction with the appearance of their breast.37 Of 162 patients, 94% were satisfied 
or very satisfied with the appearance of their breasts. However, patient satisfaction dropped 
significantly when the percentage of breast volume excised was greater than 20% of the whole 
breast.
Q ualit y  of  l i fe
Quality of life outcomes were only described in the study by Veiga et al.27 These authors compared 
the results following OPBS with the results following BCS, using two validated questionnaires 
(Short Form-36 and the Rosenberg-EPM Self-Esteem Scale). Twelve months postoperatively, 
the oncoplastic group showed significantly higher scores than in the BCS group on the items 
health perception, vitality, social functioning, role emotional and mental health.
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Reference Number of 
patients
Groups Histotype Tumour size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Bong et al., 2010 167 OPBS IDC=127
ILC=5
DCIS=33
MC=2
Invasive: 80.2%
< 2 cm = 74 (55.2%)
> 2 cm = 60 (44.8%)
Close or involved = 37/167 (22.2%)
Re-excision = 17 (10%)
Mastectomy = 11 (7%)
Radiotherapy = 3 (2%)
Plan to reoperate = 3 (2%)
ALN status reported NR NR
Chan et al., 2010 162 OPBS Invasive or in situ carcinoma Median 25 (6-50)
30g (3-184g)
NR NR NR NR
Clough et al., 20 03 101 OPBS IDC=66
IDC+DCIS=18
ILC=9
DCIS=7
Paget=1
Invasive 94%
Mean 32 (10-70)
T class in table2
Free: 90 (89%)
Focal: 4 (4%)
Extensive: 3 (3%)
Unknown: 4 (4%)
Mastectomy = 6 (6%)
Boost = 5 (5%)
13 (13%)
5 year metastasis 
free survival 82.8% 
(72.5 – 93.2%)
5 year actuarial local 
recurrence 9.4% (1.8-
16.9%)
8 died 8%
5 year  overal l survival 
95.7 % (91 – 100%)
Giacalone et al., 2010 1. 31
2. 43
1. OPBS
2. Quadrantectomy
1:
IDC=10
ILC= 1
DCIS=8
ILC+EIC=12
Invasive: 77%
2:
IDC= 19
ILC= 3
DCIS= 6
ILC+EIC= 15
Invasive: 86%
1:
5-20mm=20
20-30mm=8
30-40mm=1
>40mm=2
Specimen Volume: 190cc (32-945)
2:
5-20mm=25
20-30mm=14
30-40mm=3
>40mm=1
Specimen Volume: 99cc (12-463)
1:
Free: 24 (77%)
Close*: 4 (13%)
Positive: 3 (10%)
2:
Free: 29 (67%)
Close*: 7 (16.5%)
Positive: 7 (16.5%)
NR NR NR
Gulcelik et al., 2011 1. 101
2. 185
1. OPBS
2. Macromasty
NR Stage I and II
Breast volumes described
1:
Positive: 6 (6%)
Re-excision = 3 (3%)
Mastectomy = 3 (3%)
NR NR NR
Kaur et al., 20 05 1. 30
2. 30
1. OPBS
2. Quadrantectomy
NR only DCIS involvement
1: 
DCIS= 4 
2:
DCIS= 11
Tumour size was identical in both 
groups
1.
pTis: 4
pT1: 18
pT1: 2 (bifocal)
pT2: 6
1:
Free: 25 (83%)
Close*: 4 (13%)
Positive: 1 (3%)
2:
Free: 17 (57%)
Close*: 10 (33%)
Positive: 1 (3%)
Unknown: 2 (7%)
3 patients None NR
Meretoja et al., 2010 90 OPBS IDC=48
ILC=18
DCIS=7
Other type or mixed = 17
Invasive 92%
NR Inadequate margin and required 
mastectomy: 11 (16%)
3 (3%) No local or distant 
recurrences
One died (1%)
R ietjens et al., 20 07 148 OPBS DCIS = 11 (7%)
Invasive tumours= 137 (93%)
1-10mm=18
11-20mm=65
21-30mm=42
>30mm=19
Mean 22mm
Negative: 135 (91%)
Close*: 5 (3%)
Focally involved with DCIS: 8 (5%) 2 
reoperations
Contralateral Br: 5 mastectomies due 
to new BrCa during FU
19 (13%) 5 (3%) 11 died (7%)
Rusby et al., 20 08 110 OPBS IDC=81
ILC=11
DCIS=6
Other type or mixed = 12
Invasive 95%
36/115 multifocal
Mean tumour size: 34 (SD 18)
Weight 157 (SD 87)
115 patients for frozen section:
Free: 107 (93%)
Close*: 3 (3%)
(2 reexcisions and 1 mastectomy)
Positive: 5 (5%)
(all mastectomies)
More patients 
alive with distant 
metastasis
1 (1%) 9 died of breast cancer 
(8%)
Veiga et al., 2010 1. 45
2. 42
1. OPBS
2. BCS
NR NR NR NR 1. local: 2 (2%)
2.NR
NR
Veiga et al., 2011 1. 45
2. 42
1. OPBS
2. BCS
NR 1. T1-T2: 41
    T3: 4
2. T1-T2: 42
    T3: 3
NR NR 1. local: 1 (1%)
2. NR1
NR
Yang et al., 2011 58 OPBS NR
Invasive: 83%
Stage 0 n=10 (17%0
Stage I n=32 (55%)
Stage IIa n=10 (17%)
Stage IIb n=6 (10%)
84g (29-140g)
NR NR No local recurrences NR
 
* Close margins were def ined as those with tumour cel ls between the cut edge of the specimen and the outer limit of the tumour ≤2mm
Table 2. Oncological outcomes.
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Reference Number of 
patients
Groups Histotype Tumour size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Bong et al., 2010 167 OPBS IDC=127
ILC=5
DCIS=33
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Invasive: 80.2%
< 2 cm = 74 (55.2%)
> 2 cm = 60 (44.8%)
Close or involved = 37/167 (22.2%)
Re-excision = 17 (10%)
Mastectomy = 11 (7%)
Radiotherapy = 3 (2%)
Plan to reoperate = 3 (2%)
ALN status reported NR NR
Chan et al., 2010 162 OPBS Invasive or in situ carcinoma Median 25 (6-50)
30g (3-184g)
NR NR NR NR
Clough et al., 20 03 101 OPBS IDC=66
IDC+DCIS=18
ILC=9
DCIS=7
Paget=1
Invasive 94%
Mean 32 (10-70)
T class in table2
Free: 90 (89%)
Focal: 4 (4%)
Extensive: 3 (3%)
Unknown: 4 (4%)
Mastectomy = 6 (6%)
Boost = 5 (5%)
13 (13%)
5 year metastasis 
free survival 82.8% 
(72.5 – 93.2%)
5 year actuarial local 
recurrence 9.4% (1.8-
16.9%)
8 died 8%
5 year  overal l survival 
95.7 % (91 – 100%)
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2. 43
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30-40mm=1
>40mm=2
Specimen Volume: 190cc (32-945)
2:
5-20mm=25
20-30mm=14
30-40mm=3
>40mm=1
Specimen Volume: 99cc (12-463)
1:
Free: 24 (77%)
Close*: 4 (13%)
Positive: 3 (10%)
2:
Free: 29 (67%)
Close*: 7 (16.5%)
Positive: 7 (16.5%)
NR NR NR
Gulcelik et al., 2011 1. 101
2. 185
1. OPBS
2. Macromasty
NR Stage I and II
Breast volumes described
1:
Positive: 6 (6%)
Re-excision = 3 (3%)
Mastectomy = 3 (3%)
NR NR NR
Kaur et al., 20 05 1. 30
2. 30
1. OPBS
2. Quadrantectomy
NR only DCIS involvement
1: 
DCIS= 4 
2:
DCIS= 11
Tumour size was identical in both 
groups
1.
pTis: 4
pT1: 18
pT1: 2 (bifocal)
pT2: 6
1:
Free: 25 (83%)
Close*: 4 (13%)
Positive: 1 (3%)
2:
Free: 17 (57%)
Close*: 10 (33%)
Positive: 1 (3%)
Unknown: 2 (7%)
3 patients None NR
Meretoja et al., 2010 90 OPBS IDC=48
ILC=18
DCIS=7
Other type or mixed = 17
Invasive 92%
NR Inadequate margin and required 
mastectomy: 11 (16%)
3 (3%) No local or distant 
recurrences
One died (1%)
R ietjens et al., 20 07 148 OPBS DCIS = 11 (7%)
Invasive tumours= 137 (93%)
1-10mm=18
11-20mm=65
21-30mm=42
>30mm=19
Mean 22mm
Negative: 135 (91%)
Close*: 5 (3%)
Focally involved with DCIS: 8 (5%) 2 
reoperations
Contralateral Br: 5 mastectomies due 
to new BrCa during FU
19 (13%) 5 (3%) 11 died (7%)
Rusby et al., 20 08 110 OPBS IDC=81
ILC=11
DCIS=6
Other type or mixed = 12
Invasive 95%
36/115 multifocal
Mean tumour size: 34 (SD 18)
Weight 157 (SD 87)
115 patients for frozen section:
Free: 107 (93%)
Close*: 3 (3%)
(2 reexcisions and 1 mastectomy)
Positive: 5 (5%)
(all mastectomies)
More patients 
alive with distant 
metastasis
1 (1%) 9 died of breast cancer 
(8%)
Veiga et al., 2010 1. 45
2. 42
1. OPBS
2. BCS
NR NR NR NR 1. local: 2 (2%)
2.NR
NR
Veiga et al., 2011 1. 45
2. 42
1. OPBS
2. BCS
NR 1. T1-T2: 41
    T3: 4
2. T1-T2: 42
    T3: 3
NR NR 1. local: 1 (1%)
2. NR1
NR
Yang et al., 2011 58 OPBS NR
Invasive: 83%
Stage 0 n=10 (17%0
Stage I n=32 (55%)
Stage IIa n=10 (17%)
Stage IIb n=6 (10%)
84g (29-140g)
NR NR No local recurrences NR
 
* Close margins were def ined as those with tumour cel ls between the cut edge of the specimen and the outer limit of the tumour ≤2mm OPBS: OncoPlastic Breast Surgery
BCS: Breast Conserving Surgery
DCIS: Ductal Carcinoma In Situ
IDC: Invasive Ductal Carcinoma
NR: Not Reported
ILC: Invasive Lobular Carcinoma
AIDH: Atypical IntraDuctal Hyperplasia
EIC: Extensive Intraductal Component
MC: Mucinous Carcinoma
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Operat ive  t ime, postoperat ive  stay  and complic at ions 
( Table. 4)
Operative time was reported in 3 studies.30,32,38 In these studies, OPBS required more time than 
standard BCT, with a reported mean duration of at least twice that of regular BCS (1 hour and 
30 minutes vs 45 minutes). Concomitant contralateral symmetrisation was an important factor 
requiring more operative time.
Most patients undergoing regular BCS leave the hospital on the day of the operation. This 
contrasts strongly with the average postoperative stay of 3 to 6 days following OPBS.30,32,34,38
Early complications (<2 months postoperatively) and late complications (>2 months 
postoperatively) were described in 7 studies.29,30,32-34,36,38 Complication rates varied widely among 
studies and an early complication rate of 20% in the OPBS group was the most commonly 
described effect.
Postop er at ive  t reatment
Several studies described the administration of adjuvant chemotherapy and postoperative 
radiotherapy according to local protocols. Clough et al. reported that a number of patients 
underwent preoperative radiotherapy until 1994, an approach that has since been abandoned 
due to poor cosmetic results.30 Radiotherapy boost for margin involvement was mentioned in 
3 studies.29,30,32 However, none of these studies provided their definition of a tumour bed in 
the context of the larger volume of radiotherapy boost was required for the larger wound bed 
resulting from OPBS.
D I S C U S S I O N
Although oncological safety remains the primary concern, breast cancer surgery today is 
increasingly focussing on improved cosmetic outcomes. Oncoplastic surgery has evolved to 
meet this need and the extensive body of literature published in recent years demonstrates 
the widespread use of these techniques. This systematic review was stimulated by the need for 
an objective evaluation of the diverse aspects of current approaches to oncological safety and 
cosmetic outcomes in oncoplastic procedures.
Despite the current popularity of oncoplastic techniques, this systematic review failed to 
identify a single randomised controlled trial evaluating the effectiveness of OPBS, leaving 
only a relatively small number of prospective observational and comparative studies of sub-
optimal quality to be considered. Methodological disparities between these studies made the 
direct comparisons of results difficult, with some comparative studies even including patients 
undergoing quadrantectomy as their BCS controls, despite the fact that this is not standard 
procedure for patients undergoing BCS. Few studies reported both oncological and cosmetic 
outcomes with sufficient follow-up (of at least 2 years). Furthermore, a complete description 
of the used OPBS techniques, radiation techniques and adjuvant systemic therapy were not 
reported in all studies, even though these factors have the potential to influence oncological and 
cosmetic outcomes.
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Only Clough et al.30 presented fairly complete data and used satisfactory methodology for 
assessment of oncological and cosmetic outcomes. The incomplete reporting of current data 
and the low number of published studies might be related to the fact that OPBS is a relatively 
new approach, this conclusion being supported by the restriction of available literature to the 
last decade.
Breast  surgeons  and plast ic  surgeons
One of the problems faced by oncoplastic surgeons is the division of the surgical procedure into 
two parts (oncological and reconstructive), and the difficulty in combining techniques from 
different specialties in OPBS. Some papers described collaborations between breast surgeons 
and plastic surgeons when performing OPBS, whereas others described the performance of 
the procedure by breast surgeons trained in plastic surgery. No clear guidelines are currently 
available on requirements for performance of OPBS by breast surgeons, especially with regard to 
immediate reconstruction. Despite this lack, it is clear that a plastic surgeon, or a breast surgeon 
with plastic surgery training - thus with an extensive knowledge of volume displacement and 
replacement techniques - should always take part in any reconstruction.
Indic at ions  and character ist ics  of  the  inter vent ions
It is often reiterated that accurate preoperative evaluation of both the tumour and patient 
characteristics are key components in the success of any oncoplastic operation for breast cancer. 
However, current decision making in OPBS appears to depend predominantly on surgeon 
preference.
Most papers in this review describe volume displacement procedures, with a predilection for 
bilateral reduction mammaplasty in patients with large or ptotic breasts. Volume replacement 
techniques are mainly used in the management of smaller breasts. Besides invasive tumours, 
these studies also noted that younger patients with extensive DCIS should be candidates for 
delayed-immediate reconstruction, due to patient risk factors related to positive margin rate and 
tumour recurrence.
Oncologic al  results
One proposed benefit of OPBS is the ability to achieve wide surgical margins, with a greater 
chance of obtaining tumour-free resection margins than with standard BCS. It is therefore 
surprising to note that tumour-free margins ranged from 78% to 93% with OPBS, resulting 
in a conversion to mastectomy in 3% to 16% of all OPBS cases. The large specimen volumes 
described in these studies (with mean weight ranging from 157g to 948g), do not therefore 
always guarantee the attainment of tumour-free surgical margins.
Overall, the oncological results of the studies evaluated for this review corroborate the 
retrospective work of Fitoussi et al., which is the single largest retrospective study, describing 
the oncological and cosmetic outcomes of 540 patients over a period of two decades.39 This 
study described clear margins in 438 patients (81%), focal involvement in 77 patients (14%) and 
tumour-involved margins in 25 patients (5%). Eleven patients underwent re-excision (2%), 40 
patients received an additional radiotherapy boost (7%) and 51 patients required a mastectomy 
(9% overall).
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Reference Cosmetic results Cosmetic evaluation method Quality of life Quality of life evaluation 
method
Patient satisfaction
Chan et al., 2010 Patients:
Nearly identical 40%
Slightly different 45%
Clearly different 14%
Distorted 1%
Surgeons:
Nearly identical 41%
Slightly different 48%
Clearly different 11%
Distorted 0%
4 item questionnaire:
1. Satisfaction with appearance
2. Comparison with untreated breast
3. Same treatment?
4. Further surgery or reshaping?
1-3 months after surgery, before 
chemotherapy and radiotherapy
NR NR 60% very satisf ied
34% satisf ied
5% acceptable
1% dissatisf ied
Satisf ied when percentage 
of breast volume excised 
was <20%
Clough et al., 2003 Acceptable results (excellent, 
good or fair), 88% at 2 years
82% at 5 years
Patients who received preop 
RT vs postop RT, worse 
results (42.9% vs. 12.7%) 
p<.002
No table, no exact 
description. 
Score from 1-5 on 5 parameters:
1. Volumetric symmetry
2. Shape of breast mounds
3. Symmetry of NAC placement
4. Ipsilateral and contralateral scars
5. Post irradiation sequelae
3 people evaluating: a surgeon and 2 
nonmedical raters
Mastectomies were excluded.
NR NR NR
Meretoja et al., 2005 Acceptable cosmetic results 
84% of the time
NR NR NR NR
Veiga et al., 2010 and 
2011
Higher scores for the 
oncoplastic group than the 
BCT group
Photos preop, 6 months and 12 
months postop.  4 independent raters, 
modif ied Garbay criteria. 2 breast 
surgeons, 2 plastic surgeons and 
didn’t participate in surgery.
Signif icantly higher scores in 
oncoplastic group 12 months 
postop regarding:
1. Health perception
2. Vitality
3. Social functioning
4. Role emotional
5. Mental health
Medical Outcomes Study 
36-item Short-Form Health 
Survey Questionnaire
NR
Rosenberg Self Esteem 
scale was used
Yang et al., 2011 Surgeon:
Excellent 31%
Good 52%
Fair 15%
Bad 2%
Patient:
Excellent 38%
Good 45%
Fair 15%
Bad 2%
At 12 months post operatively. 
Overall result evaluated
1. Global aspect, two breasts
2. Shape
3. Size
4. Scars
5. NAC position and shape
6. Breast symmetry
7. Post irradiation sequelae
Scale from excellent to bad (4-1)
Patient appraisal also recorded
NR NR NR
Table 3. Cosmetic outcomes, quality of life and patient satisfaction.
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Reference Cosmetic results Cosmetic evaluation method Quality of life Quality of life evaluation 
method
Patient satisfaction
Chan et al., 2010 Patients:
Nearly identical 40%
Slightly different 45%
Clearly different 14%
Distorted 1%
Surgeons:
Nearly identical 41%
Slightly different 48%
Clearly different 11%
Distorted 0%
4 item questionnaire:
1. Satisfaction with appearance
2. Comparison with untreated breast
3. Same treatment?
4. Further surgery or reshaping?
1-3 months after surgery, before 
chemotherapy and radiotherapy
NR NR 60% very satisf ied
34% satisf ied
5% acceptable
1% dissatisf ied
Satisf ied when percentage 
of breast volume excised 
was <20%
Clough et al., 2003 Acceptable results (excellent, 
good or fair), 88% at 2 years
82% at 5 years
Patients who received preop 
RT vs postop RT, worse 
results (42.9% vs. 12.7%) 
p<.002
No table, no exact 
description. 
Score from 1-5 on 5 parameters:
1. Volumetric symmetry
2. Shape of breast mounds
3. Symmetry of NAC placement
4. Ipsilateral and contralateral scars
5. Post irradiation sequelae
3 people evaluating: a surgeon and 2 
nonmedical raters
Mastectomies were excluded.
NR NR NR
Meretoja et al., 2005 Acceptable cosmetic results 
84% of the time
NR NR NR NR
Veiga et al., 2010 and 
2011
Higher scores for the 
oncoplastic group than the 
BCT group
Photos preop, 6 months and 12 
months postop.  4 independent raters, 
modif ied Garbay criteria. 2 breast 
surgeons, 2 plastic surgeons and 
didn’t participate in surgery.
Signif icantly higher scores in 
oncoplastic group 12 months 
postop regarding:
1. Health perception
2. Vitality
3. Social functioning
4. Role emotional
5. Mental health
Medical Outcomes Study 
36-item Short-Form Health 
Survey Questionnaire
NR
Rosenberg Self Esteem 
scale was used
Yang et al., 2011 Surgeon:
Excellent 31%
Good 52%
Fair 15%
Bad 2%
Patient:
Excellent 38%
Good 45%
Fair 15%
Bad 2%
At 12 months post operatively. 
Overall result evaluated
1. Global aspect, two breasts
2. Shape
3. Size
4. Scars
5. NAC position and shape
6. Breast symmetry
7. Post irradiation sequelae
Scale from excellent to bad (4-1)
Patient appraisal also recorded
NR NR NR
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Table 4. Operative time, post-operative stay and complications.
Reference Groups Operative time Post-operative stay Early complications
(<2 months after surgery)
Late complications
(>2 months after surgery)
Clough et al., 2003 OPBS Mean 2 hours (Range 86-162 minutes)
Contralateral RM in 88% of patients
Mean 6 days (Range 2-12 days) DWH: 9%
AS: 4% 
PH: 2%
AB: 2%
BS: 1%
PSN: 1%
4% required reoperation
FN: 3%
BF: 3%
HS: 3%
Giacalone et al., 2010 OPBS
Quadrantectomy
1. Mean 117 minutes (SD 48.1)
Contralateral RM in 34% of patients 
2. Mean 80.8 minutes (SD 31.5)
1. Mean 5.1 days (SD 2.7)
2. Mean 4.7 days (SD 2.5)
1.  PSN: 68%
     DWH: 16%
     PH: 6%
2.  PH: 7% 
     DWH: 2%
NR
Gulcelik et al., 2011 OPBS
Macromasty
NR Mean 4.4 days in both groups 1.  BS: 5%
     DWH: 4%
     SSI: 3%
     D: 4%
     PH: 2%
     PSN: 1%
2.  BS: 6%
     DWH: 4%
     D: 4%
     SSI: 2%
     PH: 2%
NR
Meretoja et al., 2005 OPBS NR NR PH: 3% 
DWH and SSI: 13%
9% required reoperation
NR
Rietjens et al., 2007 OPBS NR NR SSI: 5%
PH: 3%
PSN: 1%
Other: 2%
NR
Rusby et al., 2008 OPBS NR NR Unspecif ied: 5% NR
Yang et al., 2011 OPBS Mean 1.5 hours Mean 3-4 days D: 3% 
PSN: 2%
Radiation burn: 2%
BCT: Breast Conserving Therapy
NR: Not Reported
OPBS: OncoPlastic Breast Surgery
RM: Reduction Mammaplasty
SD: Standard Deviation
AB: Abscess
AS: Axillary Seroma
BF: Breast Fibrosis
BS: Breast Seroma
D: Dehiscence
DWH: Delayed Wound Healing
FN: Fat Necrosis
HS: Hypertrophic Scarring
PH: Postoperative Hematoma
PSN: Partial Skin Necrosis
SSI: Surgical Site Infection
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Table 4. Operative time, post-operative stay and complications.
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Historical data from major studies describe a variety of approaches to the treatment of margin 
involvement following BCS; Jacobson et al.40 allowed two excisions and obtained a mastectomy 
rate of only 0.83%. Fisher et al.4 allowed only a single attempt before proceeding to mastectomy 
and reported a 10% mastectomy rate.
As OPBS allows wider margins, margin involvement in up to 22% of the cases seems very 
disappointing, especially when considering that clear margins in OPBS are a prerequisite for 
direct reconstruction and that a second excision may be hampered by the displacement of 
mammary tissue.
Local recurrence rates of the prospective studies included in our review (0% to 3%) are similar 
to the previously reported 2% to 5% local recurrence rates with BCT.4,13 The prospective studies 
selected described survival rates between 92% and 99%. However, local recurrence was observed 
in 7% of cases in the large retrospective study of Fitoussi et al. with a 5-year survival rate of 93% 
and an overall and disease-free survival rate of 88% after OPBS with additional treatment.39 A 
possible explanation for this difference may be the follow-up time of 5 years that was achieved 
by Fitoussi et al., compared with the approximatly 24 months follow-up in the studies in this 
review.
Cosmetic  results
According to Vrieling et al.41 and personal experience, the most appropriate time to assess cosmetic 
outcome is at least 2 years postoperatively, due to the long-term effects of radiation. Frequently 
used methods to evaluate cosmetic outcome are patient self-evaluation, panel evaluation, and 
Breast Retraction Assessment (BRA). Patient self-evaluation is valuable because the subjective 
experience of the patient is central to assessment of quality of life. However, patients consistently 
report better scores than professionals.42,43 A very reliable alternative is panel-evaluation, which 
consists of evaluation of 4-point view pictures of the breasts by a panel of six professionals and 
non-professionals.16,44 A truly objective method is the measuring of changes in breast symmetry 
with BRA. In general, a combination of cosmetic assessment methods will produce the most 
reliable results. 
Oncoplastic surgery claims to improve cosmetic results by integrating plastic surgery techniques 
immediately after oncological resection of the tumour. Interestingly, cosmetic outcomes were 
reported in only 4 of 11 studies; these studies reported good cosmetic outcomes in 84% to 89% 
of patients. Only one of these four studies showed appropriate evaluation of cosmetic results, 
that of Clough et al., using an independent panel format and a follow-up time of at least 2 
years.30
Fitoussi et al. retrospectively used the same cosmetic evaluation method as Clough et al., with 
a panel made up of a surgeon, a nurse and a layman, using a five-point scale from excellent to 
poor.39 The cosmetic outcome in this retrospective study was satisfactory in 98% of patients at 
12 months, and in 90% of patients at 5 years following surgery.
Although there is a large disparity in follow-up periods and cosmetic evaluation methods 
between the prospective studies described here, the cosmetic outcomes following OPBS seem 
encouraging, compared to the 60% to 80% rate of acceptable cosmetic results generally achieved 
with standard BCT.
These studies also differed with regard to the timing of contralateral symmetrisation. Immediate 
contralateral breast symmetrisation was often part of OPBS procedures, despite an earlier report 
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by Gray et al. describing an association between breast irradiation in large breasted or heavy 
women and greater retraction at 5 years and an inferior overall cosmetic result. 45 It is worth 
noting that Fitoussi and colleagues performed symmetrisation 6 months after lumpectomy 
following neoadjuvant treatment, as they suspected an unpredictable effect of radiotherapy on 
the breast and a fluctuation of body weight during chemotherapy, although these effects were 
not objectified in the study. 39
Postop er at ive  t reatment
Radiotherapy is an essential adjunct to BCS. Both whole breast irradiation and additional 
radiotherapy boost in BCT reduce the risk of local recurrence in all patient groups by 50%.46 
While OPBS might theoretically present a problem for radiotherapy boost in terms of volume 
delineation as translation or rotation of the boundaries of the surgical cavity is often performed, 
none of the articles described the method of radiotherapy boost administration i.e. the definition 
of the tumour bed or the administration of larger boost volumes. Some papers mentioned 
the placement of surgical clips by the surgeon at the time of tumour resection, marking the 
boundaries of the surgical cavity. In their review on quality indicators of radiotherapy for breast 
cancer, Poortmans et al. stated that the position of surgical clips can be misleading in cases where 
oncoplastic surgical techniques are used, especially where the boost region is not the entire 
surgical cavity but the rim of residual breast tissue that surrounded the primary tumour.47 This 
often results in larger boost volumes than actually necessary and potentially leading to greater 
fibrosis and poorer cosmetic results. 47,48
As OPBS is increasingly performed, new techniques and solutions are being proposed to resolve 
the problem of greater boost volumes. Kirova et al. described a multidisciplinary approach 
for precise localisation of the breast tumour bed by placement of three or more clips into the 
tumour bed and a detailed report of the surgical procedure. 49 They also proposed deformation 
maps using deformable image fusion software to obtain a better definition of the tumour bed.50 
However, the size of OPBS boost volumes compared to those used in BCT, and the concomitant 
long-term oncological and cosmetic outcomes have yet to be published.
Nevertheless, an ideal tumour bed volume may be difficult to achieve, due to the use of 
remodelling techniques in OPBS on a larger part of the breast than the tumour bed alone. The 
greater challenge in the administration of radiotherapy boost may in part explain the higher 
local recurrence rate of 6.8% described by Fitoussi et al. (compared to 2% to 5% in BCT).39
Postoperative surveillance is not significantly affected by the rearrangement of mammary 
tissue, according to Losken et al.51 These results corroborate with the findings of Roberts et al. 
concerning the incidence of abnormal mammograms after reduction mammography and these 
authors stated that, despite the substantial mobilisation of tissue, postoperative mammography 
did not lead to more diagnostic interventions compared to non-operative controls.52 Finally, 
little evidence is available to suggest that greater complications following OPBS lead to delayed 
administration of chemotherapy and radiotherapy with only Meretoja et al. reporting no delays 
in adjuvant treatments.36
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CO N C LU S I O N S
 
A standard claim for OPBS is that it allows wider resection margins, thereby improving 
oncological outcomes, while achieving a good cosmetic result with the breast. Surprisingly, this 
systematic review showed that large specimen volumes do not guarantee tumour-free surgical 
margins and OPBS results in only a slight improvement of clear margins when compared to 
the historical data on BCT. Moreover, as the size of the microscopically tumour-free resection 
margin is unrelated to local recurrence or overall survival, there is no need to excise a large 
volume of adjacent breast tissue with a tumour.7-10 As adequate administration of an additional 
radiotherapy boost is more difficult following OPBS, it is reasonable to conclude that surgeons 
should be reticent when considering OPBS techniques.Thus, more stringent patient selection is 
required and greater attention should be paid to tumour characteristics and localisation in order 
to minimise the incidence of positive margins.
Although the emerging role of OPBS holds promise, many questions remain. The first of these 
is that current indications for oncoplastic surgery are unclear. No uniform algorithm exists 
for OPBS, and decision-making often depends on surgeon preference. This is an important 
issue, as oncoplastic procedures require more extensive surgery with additional operation time 
and higher costs. The ability to identify patients at risk for poor cosmetic outcome at time of 
consultation would allow more informed choices in surgery. A uniform management algorithm 
is clearly required, and its use would help surgeons to adequately inform patients at the time 
of consultation on the surgical approach most likely to provide an optimal cosmetic result and 
highest possible patient satisfaction.
Secondly, adequate tumour resection should receive greater attention and oncoplastic surgery in 
particular should strive to minimise the incidence of positive margins, as these will often prompt 
a subsequent mastectomy.
The results of OPBS could be improved by the use of intra-operative tumour localisation tools to 
visualise the breast cancer during the surgery. Ultrasound guidance during surgery is known to 
be the most accurate imaging modality currently available and is reported to result in high rates 
of tumour-free resection margin. Results of an ongoing randomised controlled trial (COBALT) 
comparing ultrasound-guided surgery to traditional palpation-guided surgery for palpable breast 
tumours, including an assessment of the cosmetic outcome of either technique, are expected 
soon.53  This study hypothesises that the intra-operative use of ultrasound during standard BCS 
allows smaller excision volumes and an improved cosmetic outcome. If the tumour volume to 
mammary volume ratio is low, ultrasound-guided surgery might be sufficient to achieve both 
tumour-free surgical margins and a good cosmetic result. Consequently, the future of BCS may 
lie in ultrasound-guided surgery where it is possible to achieve reduced margin involvement 
and better cosmetic results, through minimising resection volumes. OPBS can be applied in 
cases where high excision volumes / breast volume ratios are expected, even with the use of 
intra-operative ultrasound. In these cases, the breast may still be preserved and a good cosmetic 
outcome achieved, ensuring an improvement of quality of life and overall psychological well-
being of the patients.
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Implic at ions  for  research
A variety of algorithms for OPBS have been proposed with patient selection based on tumour 
location, tumour size and breast size.54-56 Patients with tumours in the lower quadrants were 
offered oncoplastic surgery more frequently, since these tumours are prone to poor cosmetic 
outcomes in regular BCS.
Although the various algorithms are well described and appear useful, they have yet to be studied 
in a well-designed, randomised controlled trial comparing OPBS with BCS.
While conducting a randomised trial could help obtain valuable evidence, many authors 
maintain that randomisation is neither feasible nor ethical when there is a clear preference for 
one treatment option over another (on the part of either the patient or surgeon).57,58
As this review clearly shows that there is currently insufficient evidence to support OPBS over 
BCS, we feel that randomisation between standard BCS and OPBS following a predefined 
algorithm, is easily defensible.
In conclusion, prior to the worldwide introduction of OPBS, reliable randomised clinical trials 
should be conducted to compare both the oncological and cosmetic outcomes of OPBS with 
standard BCS.
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Tumour-free margins
5.4% tumour-involved margins
11% focally-involved margins
17,4% margins ≤1mm
Breast-conserving surgery was 
performed in 9276 patients 
over 2012 and 2013
Ultrasound-guided surgery
could decrease healthcare costs
by € 1,001,655 per year
The Netherlands
In Dutch patients a median of 
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S U M M A RY
Breast cancer is the most common form of cancer in women, with an estimated worldwide 
incidence of 1.38 million cases per year. Due to improvements in screening, the majority of 
breast cancer patients today present at an early stage and the tumours seen at first presentation 
are relatively small (diameter <5cm). 
A number of trials have been conducted to compare the efficacy of mastectomy to that of breast-
conserving surgery (BCS), followed by whole breast irradiation to eradicate microscopic residual 
disease (also referred to as breast-conserving therapy). These trails demonstrated that the two 
approaches are equivalent in terms of disease-free and overall survival. Mastectomy has since 
declined and breast conserving therapy (BCT) is now the standard procedure for early-stage 
breast cancer, with 75% of breast cancer patients qualifying for BCT according to Dutch breast-
cancer guidelines.
The goals of BCT are to deliver low local recurrence rates and equivalent survival rates to 
mastectomy, while achieving an acceptable cosmetic outcome. Despite the best surgical efforts, 
tumour-involved surgical margins still occur in 20-40% of all tumour excisions, leading in many 
cases to additional boost radiation, re-excision or even mastectomy. Nevertheless, the current 
5-year survival rates after BCT for early stage breast-cancer are excellent (>95%), and local 
recurrence rates range from 2% to 5%.
Although an important secondary goal in BCS is to achieve a satisfactory cosmetic outcome, a 
factor crucial to patient satisfaction and quality of life, poor cosmetic outcomes are still observed 
in up to 40% of patients. Against a background of excellent survival rates, the focus of BCS is 
now shifting towards improving cosmetic outcomes.
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Chapter 2. Ultrasound-guided surgery (USS) could potentially improve tumour-free margin 
rates and cosmetic outcomes of BCS for palpable breast cancer. This prospect led to the initiation 
of the COBALT trial in 2010, with the primary goal the comparison of ultrasound-guided 
surgery to the standard for palpable breast cancer, palpation-guided surgery (PGS), in terms of 
margin status and extent of healthy breast tissue resection.
COBALT was a randomized clinical trial that recruited patients with palpable T1-T2 invasive 
breast cancer between October 2010 and March 2012, in 6 medical centres in the Netherlands. 
Participants were randomly assigned to either USS or PGS. The primary outcomes were surgical 
margin involvement (classified as tumour-free, focally positive, or positive), and excess healthy 
tissue resection, defined by a calculated resection ratio (CRR) (derived from excision volumes 
and tumour diameters). A CRR of 1 indicated excision of the ideal amount of healthy breast 
tissue, whereas a CRR of 2 indicated excision of twice the ideal amount. In total, 134 patients 
were randomly assigned to USS (n = 65) or PGS (n=69). A dramatic difference in margin 
involvement was seen: only 2 (3%) of the 65 patients in the ultrasound-guided surgery group 
showed tumour-involved margins, compared to 12 (17%) of the 69 patients in the palpation-
guided surgery group. USS also resulted in reduced excision volumes, 38 cc vs. 58 cc and 
reduced CRR, 1.0 vs. 1.7 in PGS. These findings showed that continuous intraoperative tumour 
visualisation with USS can deliver significantly lower rates of tumour-involved resection margins 
in palpable breast cancer excision, thus reducing the need for additional interventions such as 
re-excision, mastectomy or radiotherapy boost. 
“ C o n t i n u o u s  i n t r a o p e r a t i v e  t u m o u r  v i s u a l i s a t i o n 
b y  u l t r a s o u n d - g u i d e d  s u r g e r y  a c h i e v e s  a 
s i g n i f i c a n t l y  l o w e r  r a t e  o f  t u m o u r - i n v o l v e d 
r e s e c t i o n  m a r g i n s  d u r i n g  p a l p a b l e  b r e a s t  c a n c e r 
e x c i s i o n”
Chapter 3. The ultrasound system required for USS entails certain costs, but as shown in chapter 
2, USS reduces the need for additional therapies. An economic evaluation of the COBALT trial 
was initiated to assess the costs and benefits of USS compared to PGS. On the cost side, resource 
use related to baseline treatment was taken into account (the ultrasound system) and on the 
benefit side resource use related to additional treatments was included (re-excision, mastectomy 
and the costs of hospitalisation). In terms of costs, the mean difference in costs per patient was 
€193, with higher costs in the USS group. On the benefit side, the mean difference in costs 
per patient was €349 due to additional treatments, with higher costs in the PGS group. This 
resulted in overall costs that were €154 lower in the USS group compared to the PGS group. 
We therefore conclude that the reduction in the rate of tumour-involved margins with USS 
compared to PGS leads to a reduction in healthcare costs.
“ U l t r a s o u n d - g u i d e d  s u r g e r y  f o r  p a l p a b l e  b r e a s t 
c a n c e r  l e a d s  t o  a  r e d u c t i o n  i n  h e a l t h c a r e  c o s t s ”
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Chapter 4. Despite the increasing interest in the evaluation of cosmetic outcomes following 
breast-conserving therapy (BCT) over recent decades, no consensus has yet been reached 
on the optimal approach to cosmetic evaluation. In chapter 4 we compare the strengths and 
weaknesses of the BCCT.core cosmetic outcome evaluation software to those of a 10-member 
panel from diverse backgrounds. Digital photographs of 109 consecutive patients after BCT for 
primary T1-T2 invasive breast cancer were evaluated for 7 items by a panel consisting of 2 breast 
surgeons, 2 residents, 2 laypersons and 4 plastic surgeons. All photographs were then objectively 
evaluated using the BCCT.core software, and an overall cosmetic outcome score was reached 
using a four-point Likert scale (poor, fair, good and excellent). Based on the mean BCCT.core 
software score, 41% of patients had fair or poor overall cosmetic results (10% poor), compared 
with 51% (14% poor) scored by panel evaluation. The mean overall BCCT.core scores and mean 
overall panel scores showed substantial agreement (weighted kappa: 0.68). By contrast, analysis 
of the evaluation of scar tissue revealed large discrepancies between the BCCT.core software and 
the panel. In conclusion, although software analysis of scar tissue shows room for improvement, 
overall the BCCT.core represents a valid and efficient alternative to panel evaluation.
“ B CC T. c o r e  c o s m e t i c  e v a l u a t i o n  s o f t w a r e 
r e p r e s e n t s  a  v a l i d  a n d  e f f i c i e n t  a l t e r n a t i v e  t o  p a n e l 
e v a l u a t i o n”
Chapter 5. In light of the significant reduction in both margin involvement and excision volumes 
achieved by USS in the COBALT trial, this chapter describes our efforts to determine whether 
USS also leads to improvements in cosmetic outcome and patient satisfaction when compared 
to standard palpation-guided surgery (PGS).
The same 134 patients with T1-T2 invasive breast cancer included in the COBALT trial 
were analysed (65 USS patients and 69 PGS patients). Cosmetic outcomes were assessed by a 
three-member panel, by the computerized BCCT.core software and by patient self-evaluation, 
including evaluation of patient satisfaction. Time points for follow-up were 3, 6 and 12 months 
after surgery. Overall cosmetic outcome and patient satisfaction were scored on a 4-point Likert 
scale (poor, fair, good and excellent). USS achieved better cosmetic outcomes, with 20% excellent 
overall and only 6% rated as poor, whereas 14% of PGS outcomes were rated excellent and 13% 
as poor. USS also showed consistently lower odds for poorer cosmetic outcomes (OR=0.55, 
p=0.067) than PGS. The chance of having a worse outcome was significantly increased by a 
larger lumpectomy volume; a volume >40cc showed odds 2.78 times higher for a worse outcome 
than a volume ≤40cc. USS also resulted in a higher patient satisfaction compared with PGS.
“ U S S  d e l i v e r s  b e t t e r  o v e r a l l  c o s m e t i c  o u t c o m e s 
a n d  p a t i e n t  s a t i s f a c t i o n  t h a n  P G S ”
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Chapter 6. As demonstrated in the COBALT trial, USS can significantly improve margin 
involvement rates and the extent of healthy breast tissue resection. However, objective results on 
margin involvement and resection of healthy breast tissue during BCS are currently lacking in 
the Netherlands. Therefore, this chapter describes the assessment of margin status in relation to 
the amount of healthy breast tissue resected in breast-conserving surgery (BCS) on a nationwide 
scale. Using PALGA (a national network and registry of histology and cytopathology in the 
Netherlands), we selected all patients who underwent BCS for primary invasive carcinomas 
during 2012-13 (10,058 excerpts). Pathology excerpts (n=9276) were then analysed for a range 
of criteria including oncological margin status and distance to closest margin, specimen weight/
volume, greatest tumour diameter, and with or without use of a localisation method. Calculated 
resection ratios (CRR) were assessed to determine excess healthy breast tissue resection. Margins 
for invasive carcinoma and in situ carcinoma combined were tumour-involved in 498 cases 
(5.4%) and focally-involved in 1021 cases (11.0%). Unsatisfactory resections, including (focally) 
involved margins and margins ≤1mm, were reported in 33.8% of cases. The median lumpectomy 
volume was 46 cc (range 1 – 807 cc; SD 49.18) and median CRR 2.32 (range 0.10 – 104.17; 
SD 3.23), indicating the excision of 2.3 times the optimal resection volume. This unacceptably 
high rate of tumour-involved margins, in addition to margins ≤ 1mm in one third of all patients, 
occurs at the expense of healthy breast tissue resection and thus potentially carries a risk of high 
rates of cosmetic failure.
“ I n  t h e  N e t h e r l a n d s ,  t h e r e  i s  a  n e e d  f o r 
i m p r o v e m e n t  i n  t h e  c u r r e n t  b r e a s t - c o n s e r v i n g 
s u r g i c a l  p r o c e d u r e s  t h a t  a i m  t o  d e c r e a s e  t u m o u r -
i n v o l v e d  m a r g i n  r a t e s  w h i l e  r e d u c i n g  t h e  a m o u n t 
o f  h e a l t h y  b r e a s t  t i s s u e  r e s e c t e d ”
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Chapter 7. Referred to as oncoplastic breast surgery (OPBS), new surgical approaches combine 
oncological resection of breast cancer with plastic surgery techniques in a single procedure. 
In this systematic review we evaluated the oncological and cosmetic outcomes of OPBS. The 
secondary objectives were assessment of morbidity, quality of life and applied algorithms. 
Using specific inclusion and exclusion criteria to analyse 2090 abstracts on the topic of OPBS, 
published between 2000 and 2011, the authors evaluated each study with respect to design 
and outcomes. A total of 88 articles were identified for potential inclusion and reviewed in 
detail by the lead authors. No randomised controlled trials were identified. Eleven prospective 
observational or comparative studies fulfilled inclusion criteria and were selected. In these 
studies, 80% to 93% of the tumours were invasive. Tumour-free resection margins were observed 
in 78% to 93%, resulting in a 3% to 16% mastectomy rate. Local recurrence was observed in 
0% to 7% of the patients. Good cosmetic outcome was obtained in 84% to 89% of patients. 
However, most studies showed significant weaknesses such as lack of robust design which, 
together with important methodological shortcomings, negatively influenced generalizability. 
Given the increasing importance and application of OPBS, there is a pressing need for robust 
comparative studies, including both randomized controlled trials and well-designed, multicentre 
prospective longitudinal studies. 
“ T h i s  s y s t e m a t i c  r e v i e w  r e v e a l s  t h a t  c u r r e n t 
e v i d e n c e  s u p p o r t i n g  t h e  e f f i c a c y  o f  o n c o p l a s t i c 
b r e a s t - c o n s e r v i n g  s u r g e r y  i s  d e r i v e d  f r o m  p o o r l y -
d e s i g n e d  a n d  u n d e r p o w e r e d  s t u d i e s ”
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Radicale resecties
5,4% irradicale resecties
11% focaal irradicale resecties
17,4% marges ≤1mm
9276 patiënten ondergingen 
een borstsparende operatie in 
2012 en 2013
Echogeleide chirurgie kan de
kosten in de zorg met 1.001.655 € per 
jaar verlagen
Nederland
Een mediaan van 2,34 keer de
ideale hoeveelheid gezond borstweefsel 
was verwijderd in deze patiënten
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S A M EN VAT T I N G
Borstkanker is de meest voorkomende vorm van kanker bij vrouwen, met een wereldwijde 
incidentie van 1,38 miljoen vrouwen per jaar. De meerderheid van de borstkankerpatiënten 
presenteert zich in een vroeg stadium (maximale tumor diameter <5cm). Verschillende studies 
hebben de doeltreffendheid van de borstamputatie vergeleken met borstsparende chirurgie 
gevolgd door radiotherapie (ook wel borstsparende behandeling genoemd). Deze studies laten 
zien dat voor beide technieken de (ziektevrije) overleving gelijk is. Omdat de borst behouden 
kan blijven en de overleving gelijk blijft, is een borstsparende operatie de standaard behandeling 
geworden van borstkanker in een vroeg stadium. De Nederlandse richtlijnen geven aan dat 
75% van alle borstkanker patiënten in aanmerking zouden moeten kunnen komen voor een 
borstsparende behandeling.
Naast de bovengenoemde doelen van de borstsparende behandeling wordt ook een acceptabel 
cosmetisch resultaat nagestreefd. Ondanks de inzet van oncologisch chirurgen, blijft er in 
20-40% van de gevallen tumorweefsel achter in de borst en spreekt men van een irradicale 
resectie van borstkanker. In deze gevallen moeten vrouwen extra radiotherapie krijgen, opnieuw 
geopereerd worden om het achtergebleven stuk tumor te verwijderen, en in de ergste gevallen 
een borstamputatie ondergaan. Toch is de 5-jaarsoverleving na een borstsparende behandeling 
uitstekend (>95%), en treedt er een lokaal recidief op bij maar 2-5% van de patiënten. Ondanks 
dat een acceptabel cosmetisch resultaat behaald dient te worden, hetgeen sterke invloed heeft 
op patiënttevredenheid en kwaliteit van leven, wordt een slecht cosmetisch resultaat beschreven 
in tot wel 40% van de patiënten. De goede overleving na borstsparende chirurgie heeft ervoor 
gezorgd dat de aandacht voor een goed cosmetisch resultaat is toegenomen.
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Hoofdstuk 2.  Echogeleide borstsparende operaties zouden de irradicaliteit en de hoeveelheid 
verwijderd gezond borstweefsel kunnen terugdringen. Daarom is in 2010 de COBALT-studie 
van start gegaan om echogeleide excisie van het palpabel borstkanker (het constant visualiseren 
van de tumor gedurende de operatie) te vergelijken met de standaard blinde palpatiegeleide 
excisie die uitsluitend gebaseerd is op de tastzin. De primaire uitkomstmaten waren de radicaliteit 
(hoe vaak de tumor in zijn geheel verwijderd was bij de eerste operatie), en de hoeveelheid 
verwijderd gezond borstweefsel. Van oktober 2010 tot maart 2012 zijn er in 6 ziekenhuizen 
134 patiënten geïncludeerd, die willekeurig werden toegewezen aan de echogeleide groep of de 
palpatiegeleide groep. Om de hoeveelheid verwijderd gezond borstweefsel vast te stellen werd 
er gebruikt gemaakt van de CRR, waarbij CRR=1 de ideale hoeveelheid verwijderd gezond 
borstweefsel aangeeft, en CRR=2 twee keer te veel verwijderd gezond borstweefsel aangeeft. 
Van de 134 patiënten zaten er 65 in de echogeleide groep en 69 in de palpatiegeleide groep. Een 
groot verschil in tumorvrije marges werd gezien, waarbij in 97% van de echogeleide excisies de 
tumor in zijn geheel verwijderd was vergeleken met 83% in de palpatiegeleide groep. Het volume 
verwijderd borstweefsel was ook verlaagd  in de echogeleide groep (respectievelijk 38 vs. 58 cc), 
en het CRR was in de echogeleide groep 1,0 vergeleken met 1,7 in de palpatiegeleide groep. 
Deze resultaten laten duidelijk zien dat echogeleide chirurgie,  door het constant visualiseren 
van de tumor gedurende de operatie, de afwijking vaker in zijn geheel verwijdert. Hierdoor is er 
minder noodzaak voor een hernieuwde ingreep zoals een re-excisie of borstamputatie. Daarnaast 
werd er bijna 2x minder gezond borstweefsel verwijderd, hetgeen mogelijk het cosmetische 
resultaat van de borst zal bevorderen vergeleken met de palpatiegeleide chirurgie.
“ H e t  c o n s t a n t  v i s u a l i s e r e n  v a n  d e  t u m o r  b i j  e e n 
e c h o g e l e i d e  b o r s t s p a r e n d e  o p e r a t i e  v e r g e l e k e n 
m e t  d e  s t a n d a r d  p a l p a t i e g e l e i d e  o p e r a t i e ,  z o r g t 
v o o r  e e n  d r a s t i s c h e  a f n a m e  v a n  a c h t e r g e b l e v e n 
t u m o r w e e f s e l  t e r w i j l  h e t  g e z o n d  b o r s t w e e f s e l 
s p a a r t ”
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Hoofdstuk 3. Het gebruik van een echoapparaat gedurende de operatie brengt kosten met 
zich mee, maar verlaagt het aantal hernieuwde ingrepen na een borstsparende operatie. In 
dit hoofdstuk onderzoeken we of de kosten van de aanschaf van een echoapparaat opwegen 
tegen de baten die het echoapparaat met zich meebrengt. De kosten zijn de aanschaf van een 
echoapparaat, en de baten zijn de besparing door het vermijden van  hernieuwde ingrepen zoals 
extra radiotherapie, een re-excisie of zelfs een mastectomie. Hiervoor werden bijvoorbeeld de 
kosten van een operatiekamer, personeel en ziekenhuisverblijf meegenomen. Uit deze studie 
bleek dat echogeleid opereren gemiddeld €193 aan kosten per patiënt met zich meebrengt. 
Daarentegen zorgen de kosten van hernieuwde ingrepen in de palpatiegeleide groep voor 
gemiddeld €349 aan extra kosten per patiënt. Uit deze analyse blijkt dat er gemiddeld €154 per 
patiënt aan kosten bespaard kan worden indien vrouwen een echogeleide borstsparende operatie 
ondergaan in plaats van de palpatiegeleide operatie.
“ D e  v e r m i n d e r i n g  v a n  h e r n i e u w d e  i n g r e p e n  n a 
e c h o g e l e i d e  b o r s t s p a r e n d e  c h i r u r g i e  v e r g e l e k e n 
m e t  p a l p a t i e g e l e i d e  c h i r u r g i e  z o r g t  v o o r  e e n 
s i g n i f i c a n t e  k o s t e n d a l i n g  i n  d e  z o r g ”
Hoofdstuk 4. Ondanks de toegenomen aandacht voor het cosmetische resultaat na 
borstsparende operaties, bestaat er nog geen gouden standard voor de beoordeling hiervan. In 
dit hoofdstuk vergelijken wij het oordeel van een panel van 10 beoordelaars met een objectieve 
beoordelingssoftware genaamd de BCCT.core. Digitale foto’s van 109 opeenvolgende patiënten 
na borstsparende chirurgie werden beoordeeld op 7 onderdelen door een panel bestaande uit 2 
oncologisch chirurgen, 2 assistenten in opleiding tot chirurg, 2 leken en 4 plastisch chirurgen. 
Alle foto’s werden tevens beoordeeld door de BCCT.core software op dezelfde schaal als het 
panel: de 4 punts Likert schaal (slecht, matig, goed en perfect). De BCCT.core gaf in 41% van 
de gevallen een slecht tot matig cosmetisch resultaat aan (slecht in 10%), terwijl het panel 51% 
van de foto’s slecht totmatig beoordeelde (14% van de foto’s slecht). De scores gegeven door 
het panel en de BCCT.core software kwamen substantieel met elkaar overeen (gewogen kappa 
van 0,68). De BCCT.core software had moeite met de beoordeling van het litteken vergeleken 
met het panel. Ondanks de slechte beoordeling van het litteken, lijkt de BCCT.core een goed 
alternatief voor panel beoordeling van het cosmetisch resultaat na borstsparende ingrepen.
“ D e  B CC T. c o r e  s o f t w a r e  v o o r  h e t  b e o o r d e l e n 
v a n  h e t  c o s m e t i s c h  r e s u l t a a t  n a  b o r s t s p a r e n d e 
i n g r e p e n  l i j k t  e e n  g o e d  a l t e r n a t i e f  v o o r  d e  m e e r 
a r b e i d s i n t e n s i e v e  p a n e l  b e o o r d e l i n g ”
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Hoofdstuk 5. Gezien de afname in het achterblijven van tumorweefsel na echogeleide 
borstsparende operaties in vergelijking met palpatiegeleide operaties, en de vermindering in de 
hoeveelheid weggehaald gezond borstweefsel, wordt er in dit hoofdstuk onderzocht of echogeleide 
operaties ook leiden tot een verbeterd cosmetisch resultaat en grotere patiënttevredenheid 
vergeleken met palpatiegeleide chirurgie. Dezelfde 134 van de COBALT-studie werden 
beoordeeld op verschillende tijdstippen na de operatie (echogeleid=65 patiënten en palpatie 
geleid=69 patiënten). Cosmetische resultaten werden beoordeeld aan de hand van foto’s, door 
de BCCT.core software, een panel bestaande uit 6 leden en door patiënt-zelfevaluatie. De 
beoordelingstijdstippen waren 3, 6 en 12 maanden na de operatie. Het cosmetisch resultaat werd 
met de verschillende methoden allen op de 4-punts Likert schaal beoordeeld (slecht, matig, goed 
en perfect). Echogeleid opereren resulteerde in 20% perfecte cosmetische resultaten en maar 
6% slechte resultaten, terwijl palpatiegeleide operaties in 14% perfecte cosmetische resultaten 
had en 13% slechte resultaten. De echogeleide operaties hadden een 0,55 kleinere kans om een 
slechter cosmetisch resultaat te hebben dan de palpatiegeleide groep. Er was ook een kans op 
een slechter cosmetisch resultaat wanneer het volume van het weggehaalde stuk borst >40cc was. 
Tevens was er sprake van een betere patiënttevredenheid in de echogeleide groep.
“ E c h o g e l e i d e  b o r s t s p a r e n d e  o p e r a t i e s 
v o o r  p a l p a b e l  b o r s t k a n k e r  l e i d e n  t o t  e e n 
b e t e r  c o s m e t i s c h  r e s u l t a a t  e n  e e n  h o g e r e 
p a t i ë n t t e v r e d e n h e i d  v e r g e l e k e n  m e t  d e  s t a n d a a r d 
p a l p a t i e g e l e i d e  t e c h n i e k”
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Hoofdstuk 6. De COBALT-studie laat duidelijk zien dat er door echogeleid opereren minder 
tumorweefsel achterblijft in de borst terwijl er ook minder gezond borstweefsel onnodig 
wordt verwijderd. In dit hoofdstuk wordt onderzocht hoe de huidige stand van zaken is in 
heel Nederland met betrekking tot radicaliteit (achtergebleven tumorweefsel) na de initiële 
borstsparende operatie. Hiervoor werden de verslagen van de weefselonderzoeken van de 
patholoog na de borstsparende operaties gebruikt. Tevens werd onderzocht hoeveel gezond 
borstweefsel werd verwijderd. Voor deze studie werd gebruik gemaakt van de PALGA 
database (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief ) om alle verslagen van 
weefselonderzoeken na borstsparende ingrepen in 2012 en 2013 voor invasief borstkanker te 
analyseren (10.058 verslagen). Uiteindelijk werden 9276 verslagen onderzocht op tumorvrije 
marges, kortste afstand van tumor tot dichtstbijzijnde marge, weefselgewicht en volume, grootste 
tumordiameter en of er gebruikt was gemaakt van een lokalisatie methode bij het verwijderen 
van de tumor. Ook in deze studie werd de CRR gebruikt om de hoeveelheid verwijderd gezond 
borstweefsel te beschrijven. Voor invasieve tumoren gecombineerd met in situ carcinomen 
(voorlopercellen van kwaadaardige tumoren) bleef er in 498 (5,4%) van de gevallen tumor achter 
in de borst, en in 1021 (11,0%) van de verslagen werd beschreven dat een klein deel van de tumor 
achterbleef in de borst. Deze getallen gecombineerd met de gevallen waarbij de tumor ≤1mm 
van de dichtstbijzijnde marge waren, leverden in 33,8% van de verslagen een onbevredigend 
excisieresultaat op. Het mediane weefselvolume was 46cc en een mediaan CRR van 2,32 werd 
berekend, wat aangeeft dat er 2,3 keer te veel gezond borstweefsel werd verwijderd. Dat er bij 
een derde van de patiënten een inadequate resectie plaatsvond in 2012 en 2013 terwijl er te veel 
gezond borstweefsel werd verwijderd is een zorgwekkende constatering. Hoogstwaarschijnlijk 
heeft dat ook slechte cosmetische resultaten ten gevolg.
“ I n  N e d e r l a n d  i s  e r  e e n  d r i n g e n d e  n o o d z a a k  o m 
d e  k w a l i t e i t  v a n  d e  b o r s t s p a r e n d e  o p e r a t i e s  t e 
v e r b e t e r e n  d o o r  d e  t u m o r  v a k e r  i n  z i j n  g e h e e l  t e 
v e r w i j d e r e n  e n  m i n d e r  g e z o n d  b o r s t w e e f s e l  w e g  t e 
n e m e n”
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Hoofdstuk 7. Oncoplastische chirurgie (OPC) voor borstkanker is een relatief nieuw concept. 
Bij OPC wordt borstsparende chirurgie gecombineerd met plastisch chirurgische technieken. 
Hierdoor zou het mogelijk zijn grotere tumoren toch te opereren door middel van borstsparende 
ingrepen. OPC heeft als doel de oncologische veiligheid te waarborgen en adequate cosmetiek 
te bewerkstelligen. Voornamelijk het laatste decennium is er veel literatuur verschenen over de 
oncologische en cosmetische resultaten van OPC. Het doel van deze studie is om de radicaliteit, 
de lokale recidiefkans en de cosmetiek van OPC te vergelijken met de historische resultaten van 
mammasparende chirurgie in de vorm van een systematische review.
Er werd gezocht in de elektronische databases van Medline, Embase en de Cochrane Library. 
Inclusiecriteria waren prospectief gerandomiseerde studies met meer dan 25 patiënten per groep, 
gepubliceerd vanaf het jaar 2000 in een Engelstalig tijdschrift. 2087 artikelen werden gevonden 
en 167 werden geselecteerd op abstract om nader beoordeeld te worden door de twee reviewers. 
Geen enkele prospectief gerandomiseerde studie werd gevonden. 12 prospectieve studies werden 
geïncludeerd in deze studie. In de geanalyseerde artikelen waren 80% tot 93% van de tumoren 
invasief en werden tumorvrije marges beschreven in 77% tot 93% van de gevallen. 3% tot 10% 
van de excisies waren irradicaal en 3% tot 13% focaal irradicaal. Dit leidde in 5% tot 12% van 
de artikelen tot een mastectomie. Bij een gemiddelde follow-up van >36 maanden ontstond 
een lokaal recidief bij 3% tot 5% van de patiënten. Slechts 1 studie beschrijft een lokaal recidief 
percentage na 5 jaar follow-up: 9,4%. Cosmetiek werd beschreven in 6 artikelen. Acceptabele tot 
goede cosmetische resultaten variëren tussen 82% en 89%. Hoewel OPC veel aandacht krijgt, 
is er geen prospectief gerandomiseerde studie uitgevoerd die gebaseerd is op een algoritme. 
Oncologische resultaten van OPC met betrekking tot radicaliteit lijken beter in vergelijking 
met de historische groepen behandeld met conventionele mammasparende therapie. Echter, 
de lokale recidiefkans is hoog in vergelijking met de huidige 3% 5-jaar lokaal recidiefkans bij 
mammasparende chirurgie. Bemoeilijkte toediening van radiotherapie speelt hier mogelijk een 
rol in. Concluderend is wat betreft oncologisch en cosmetisch resultaat bij OPC nog winst te 
behalen, en moet er dringend gekeken worden welke patiënten in aanmerking zouden moeten 
komen voor OPC om overbehandeling te voorkomen.
“ D e z e  s y s t e m a t i s c h e  r e v i e w  l a a t  d u i d e l i j k  z i e n 
d a t  e r  o n v o l d o e n d e  w e t e n s c h a p p e l i j k  b e w i j s  i s  o m 
o n c o p l a s t i s c h e  i n g r e p e n  r o u t i n e m a t i g  u i t  t e  v o e r e n 
v o o r  a l l e  b o r s t s p a r e n d e  i n g r e p e n”
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Berges saines
5,4% berges atteintes
11% berges focalement atteintes
17,4% berges de ≤1mm
9276 patientes ont reçu une 
chirurgie conservatrice du sein 
en 2012 et 2013
L’exérèse échographique peut
diminuer les coûts de la santé
publique de 1.001.655 € par an
Pays-Bas
La médiane de 2,32 fois la quantité idéale 
de tissu sain a été enlevé dans ces patientes
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R É S U M É
Le cancer du sein est la le cancer féminin le plus commun avec une incidence mondiale estimée 
de 1,39 million de patientes par an. La majorité des femmes se présente à un stade peu avancé 
(tumeurs avec un diamètre inférieur à 5 cm). Certaines études ont comparé l’efficacité de la 
mastectomie avec la chirurgie conservatrice (ablation de la tumeur avec une marge de tissu 
sain autour) suivie de radiothérapie pour éradiquer les cellules cancéreuses microscopiques. Ces 
études ont prouvé qu’après la mastectomie ou la chirurgie conservatrice, les patientes ont une 
survie similaire. Ainsi la chirurgie conservatrice est devenue le standard pour le cancer du sein 
à un stade peu avancé, et le référentiel Néerlandais indique que 75% des femmes atteintes du 
cancer du sein peuvent bénéficier de la chirurgie conservatrice du sein suivie de radiothérapie.
Le but de la chirurgie conservatrice pour le cancer du sein est d’avoir la même survie qu’après 
une mastectomie, tout en ayant un résultat cosmétique acceptable. Malgré les meilleurs efforts 
chirurgicaux, la tumeur est présente dans les berges de l’exérèse chez  20 à 40% des patientes 
qui doivent recevoir plus de radiothérapie, ou subir une ré-exérèse ou même une mastectomie. 
Malgré cela, le taux de survie 5 ans après la diagnostic est bon (>95%).
Le but secondaire important de la chirurgie conservatrice du sein est d’atteindre un résultat 
cosmétique acceptable, ce qui est indispensable à une bonne qualité de vie. Malheureusement, 
jusqu’à 40% des patientes après la chirurgie conservatrice du sein ont un mauvais résultat 
cosmétique. Vu le bon taux de survie, la chirurgie conservatrice du cancer du sein se concentre 
de plus en plus sur le résultat cosmétique. 
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Chapitre 2. L’échographie pour guider l’exérèse dans la chirurgie conservatrice du cancer du 
sein invasif et palpable, pourrait améliorer le taux de berges saines. Ainsi l’étude COBALT a 
été initiée afin de comparer l’exérèse standard guidée par palpation du chirurgien (PGS) avec 
l’exérèse échographique (USS), en terme de berges saines, et afin de voir si la précision de 
l’échographie résulte en une réduction d’enlèvement de tissu sain.
La COBALT est une étude randomisée pour laquelle étaient recrutées toutes les femmes avec 
une tumeur invasive palpable inférieure à 5 cm de diamètre, entre octobre 2010 et mars 2012 
dans 6 hôpitaux aux Pays-Bas. Les participantes étaient randomisées pour recevoir une exérèse 
guidée par palpation ou guidée par échographie. Les buts primaires étaient l’analyse des berges 
chirurgicales (saines, focalement atteintes, ou atteintes par la tumeur) et du tissu sain enlevé, 
défini par un ratio d’exérèse calculé (CRR : dérivé du volume de la tumeur et du volume de 
l’exérèse). Un CRR de 1 indique une marge de tissu sain idéal autour de la tumeur, alors qu’un 
CRR de 2 indique une ablation deux fois trop importante de tissu sain. Au total, 134 patientes 
étaient incluses dans l’étude dont 69 ont eu une exérèse guidée par palpation et 65 une exérèse 
guidée par échographie. Une grande différence de berges saines fut constatée, 97% pour l’exérèse 
échographique et 83% pour l’exérèse guidée par la palpation. L’USS résultait aussi en un CRR de 
1 comparé à 1,7 pour le groupe PGS, avec un volume de 38 cc par rapport à 58 cc respectivement. 
Cette étude a montré que la visualisation de la tumeur durant l’exérèse avec l’aide de l’échographie 
permet d’obtenir un taux de berges saines élevé comparé à l’exérèse guidée par la palpation. Cela 
induit aussi un nombre réduit de thérapies additionnelles comme des ré-exérèses, mastectomies 
et radiothérapies additionnelles. 
“ La visual i sat i on cont i nue de  la  t u meu r  p endant 
l ’e xérèse  éc h og r aph i q ue  pe r m et  d ’obt enir  u n t au x  de 
berges  saine s  pl us  é l e vé  q u’a vec  l ’e xérèse  gu idée  p ar 
l a  pal pat ion”
Chapitre 3. Le cout de l’exérèse échographique semble plus élevé car il faut tenir compte de 
l’achat d’un échographe. Mais comme nous l’avons vu dans le chapitre 2, l’exérèse échographique 
induit moins de thérapies additionnelles. Pour plus de précisions, une évaluation économique 
est faite dans ce chapitre en comparant les coûts et les bénéfices des deux méthodes d’exérèse. 
Les coûts de l’exérèse échographique (achat d’un appareil échographique), et les coûts des ré-
exérèses, mastectomies ou radiothérapies additionnelles ont été calculés. En moyenne, l’exérèse 
échographique coûtait un prix par patient supérieur de 193 euros à l’exérèse guidée par la 
palpation. En revanche, l’augmentation du nombre de thérapies additionnelles dans le groupe 
de l’exérèse guidée par la palpation engendrait un coût supérieur de 349 euros en moyenne par 
patient par rapport à l’exérèse échographique. Il en résultait une différence de coûts par patient 
entre les deux groupes de 154 euros, au bénéfice de l’exérèse échographique.
“ Moins  d e  th é r api e s  ad d i t i o nnel les  ap rès  l ’e xérèse 
éc hog r aph i q ue  par  r appor t  à  l ’e xérèse  gu idée  p ar  la 
palpat i on, i nd ui t  une  rédu ct ion de  coû t ”
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Chapitre 4. Malgré plus d’attention pour le résultat cosmétique après la chirurgie conservatrice 
du sein, aucun consensus n’a été atteint sur la meilleure méthode pour évaluer le résultat 
cosmétique. Dans ce chapitre, nous étudions les points forts et les faiblesses du logiciel BCCT.
core pour évaluer le résultat cosmétique du sein, comparé à un pannel de 10 membres. Les 
photos digitales de 109 patientes après la chirurgie conservatrice pour cancer du sein T1T2 ont 
été évaluées sur 7 points par un pannel de 2 chirurgiens du sein, 2 chirurgiens en formation, 2 
personnes sans expérience en médecine, et 4 chirurgiens plasticiens. Toutes les photos étaient 
évaluées objectivement par le logiciel, utilisant le même système Lickert de 4-points pour le 
résultat cosmétique final (mauvais, moyen, bien et parfait). Le logiciel donnait 41% de résultats 
comme mauvais ou moyens (10% mauvais), comparé à 51% (14% mauvais) par le pannel de 10 
personnes. Le jugement moyen du logiciel et du panneau pannel étaient substantiellement en 
accord (kappa pesé: 0.68). Malheureusement, l’évaluation de la cicatrice montrait de grandes 
différences entre les deux techniques. Même si les analyses de la cicatrice doivent être améliorées, 
le logiciel BCCT.core représente un bon moyen pour évaluer facilement le résultat cosmétique 
après chirurgie conservatrice du sein.
“ L e log ic i e l  B CCT.core  re p résent e  u n bon mo yen 
pour  é valu e r  f aci l e me nt  l e  résu lt at  cosmét iqu e ap rès 
c h i r ur g i e  conse r vat r ice  du  sein”
Chapitre 5.  Compte tenu de la réduction du pourcentage de berges atteintes grâce à l’exérèse 
échographique et la réduction en volume de sein enlevé, ce chapitre examine si ces résultats ont 
des effets sur le résultat cosmétique un an après la chirurgie, par rapport à l’exérèse guidée par la 
palpation.
Les mêmes 134 patientes ont été étudiées dans la COBALT (USS=65 et PGS=69). Un pannel 
de 3 membres et le logiciel BCCT.core évaluaient le résultat cosmétique, incluant la satisfaction 
des patientes avec le résultat cosmétique. Les différents stades d’évaluation étaient à 3, 6 et 12 
mois après la chirurgie. Le résultat cosmétique était évalué sur le système Lickert de 4-points 
(mauvais, moyen, bien et parfait). L’échographie donnait de parfaits résultats chez 20% des 
patientes et seulement 6% de mauvais résultats, et PGS donnait 14% de résultats parfaits 
et 13% de mauvais résultats. Les chances d’avoir un résultat cosmétique défavorable étaient 
significativement plus grandes lorsque le volume de l’exérèse est supérieur à 40cc, 2.78 fois plus 
grandes comparées à un volume d’exérèse inférieur à 40cc. L’exérèse échographique donnait un 
pourcentage de satisfaction plus élevé chez les patients.
“ L’e xérè se  é c h og r aph i q ue donne u n résu lt at 
cosmé t i q ue  me i l l e ur  e t  u n p ou rcent age  de 
sat isfact i on d e  pat i e nte s  plu s  éle vé  p ar  r ap p or t  à 
l ’e xé rè se  gui d é e  par  la  p alp at ion”
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Chapitre  6. L’exérèse échographique peut améliorer le taux de berges atteintes de tumeur et réduire 
le volume de tissu sain enlevé, comme les chapitres précédents l’ont montré. Malheureusement, 
des chiffres objectifs sur le taux de marges atteintes aux Pays-Bas manquent. Ce chapitre vise à 
analyser le taux de berges atteintes par la tumeur et le montant de volume de tissu sain enlevé 
après chirurgie conservatrice du sein aux Pays-Bas. Pour cela la base de données pathologique 
et nationale PALGA est utilisée. Toutes les patientes ayant eu une opération conservatrice pour 
un cancer du sein invasif aux Pays-Bas entre 2012 et 2013 ont été incluses (10.058 fichiers). 
Résultant dans l’analyse de 9276 rapports de pathologie pour un nombre de critères incluant 
l’atteinte des berges, distance minimale de la tumeur à la berge la plus proche, poids ou volume 
de l’exérèse, diamètre maximal de la tumeur et exérèse avec ou sans technique de localisation. Le 
ratio d’exérèse calculé fut défini par la quantité de tissu sain enlevé. Les berges pour les tumeurs 
invasives combinées avec les cancers in situ étaient atteintes dans 498 cas (5,4%) et focalement 
atteintes dans 1021 cas (11,0%). Des exérèses non satisfaisantes incluant les berges atteintes, 
focalement atteintes ou la tumeur a ≤1mm étaient observés dans 33,8% des cas. De ces 9276 
rapports, la médiane de volume était 46cc et la médiane de CRR était 2,32, indiquant l’exérèse 
de 2,3 fois trop de tissu sain. Le nombre inacceptable de berges atteintes et de tumeur à ≤ 1mm 
dans un tiers des patientes combiné avec l’exérèse de trop de tissu sain, montre que la chirurgie 
conservatrice du sein doit être améliorée, et pourrait même expliquer des résultats cosmétiques 
non satisfaisants.
“Aux Pay s-B as, i l  f aut  absolu ment  améliorer  la 
tec hnique d e  c h i r ur g i e  conser v at r ice  t el le  qu’el le  est 
réal isée  act ue l l e me nt, af i n  de  rédu ire  le  nombre  de 
berges  atte i nte s  par  l a  t umeu r  t ou t  en diminu ant  la 
q uant i té  d e  t i ssu  sain  enle vé ”
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Chapitre 7. De nouvelles approches chirurgicales combinent l’exérèse du cancer du sein avec la 
chirurgie plastique par une technique destinée à améliorer le résultat cosmétique : la chirurgie 
oncoplastique conservatrice. Cette revue systématique de la littérature vise à inventorier les 
résultats oncologiques et cosmétiques après la chirurgie oncoplastique conservatrice. Le but 
secondaire est d’inventorier la morbidité, la qualité de vie et les algorithmes de chirurgie appliqués. 
Utilisant des critères d’inclusion et d’exclusion spécifiques pour analyser les 2090 résumés 
d’articles parus sur la chirurgie oncoplastique conservatrice entre 2000 et 2011, les auteurs ont 
évalué chaque article. Un total de 88 articles étaient identifiés pour une inclusion potentielle et 
étaient examinés par les deux premiers auteurs de cet article. Aucun article randomisé n’a été 
identifié. Onze études prospectives observationnelles ou comparatives satisfaisaient aux critères 
d’inclusion. Dans ces études, 80 à 93% de tumeurs étaient invasives. Les berges étaient saines 
dans 78 à 93% des patientes, résultant en 3 à 16% des patientes en une mastectomie. De bons 
résultats cosmétiques étaient obtenus dans 84 à 89% des patientes. Malheureusement, un grand 
nombre de ces études montraient des faiblesses, comme un manque de méthodologie et un faible 
échantillonnage dans les groupes étudiés, empêchant de pouvoir généraliser ces résultats. Compte 
tenu de l’application de plus en plus fréquente des techniques oncoplastiques, il faut absolument 
mettre en place de grandes études comparatives prospectives et des études randomisées.
“Cette  re vue  sy sté mat i q ue  d e  l i t t ér at u re  mont re  qu e 
la  c hir urg i e  oncopl ast i q ue  conser v at r ice  est  ju squ’ à 
présent  b asé e  sur  d e s  pe t i tes  ét u des  manqu ant  de 
mé th od olog ie ”
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Discussion and future perspectives
9
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C U RREN T  S TAT E  O F  B RE A S T-
CO N S ERV I N G  S U RG ERY
The thesis has shown that surgical accuracy in breast-conserving surgery for invasive breast 
cancer is clearly inadequate, and especially so regarding margins ≤1mm. As our nationwide 
PALGA study shows, this conclusion also extends to The Netherlands, where an unacceptably 
high rate of tumour-involved margins and excision of large volumes of healthy breast tissue are 
the norm. This lack of accuracy subsequently requires additional re-excisions, radiotherapy or 
even mastectomies. 
Attempts by the surgeon to achieve tumour-free margins often lead to the resection of excess 
healthy breast-tissue, increasing the chances of a poor cosmetic outcome. It is indisputable that 
these additional therapies and poor cosmetic outcomes represent an extra burden for breast 
cancer patients.
“ T h e  c u r r e n t  s u r g i c a l  a c c u r a c y  i n
b r e a s t - c o n s e r v i n g  s u r g e r y  i s  c l e a r l y  i n a d e q u a t e ”
B RE A S T  CA N C ER  Q UA LI T Y 
I N D I CATO R S
Over the past decade, quality indicators for breast cancer treatment have been implemented in 
several countries in Europe, including the Netherlands.1 Our analysis of nationwide PALGA 
pathology reports showed 16.4% margin involvement in invasive carcinoma combined with 
ductal carcinoma in situ (DCIS), despite the resection of large volumes of healthy breast-
tissue. A number of countries such as Germany, Scotland and France consider margins ≤1mm 
as inadequate and recommend that these patients undergo additional surgery.2-4 When close 
margins were taken into account in the PALGA database, over a third of all patients (33.8%) in 
the Netherlands underwent an inadequate resection. In addition to the very high level of poor 
resections, the calculated resection ratio for all patients in the PALGA study was 2.32, meaning 
that well over twice the optimal amount of healthy breast-tissue is being excised by Dutch 
surgeons.
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The Dutch Healthcare Inspectorate (IGZ) state in their latest breast cancer guideline that for 
the purposes of margin involvement registration, focally-involved margins can be counted as 
tumour-free margins.5 Taking this view, margin-involvement following a first breast-conserving 
operation over 2012 and 2013 in the Netherlands would be only 5.4% for invasive carcinoma 
combined with DCIS.  This reported margin-involvement rate thus complies with the 
implemented quality indicators of a tumour-free margin rate of 85% per hospital (the NBCA 
uses the same definition of margin involvement as the IGZ).6
However, and as detailed by the American Society of Breast Surgeons, accepting the positive 
margin rate as a quality indicator remains controversial and is open to dispute because it may 
result in larger excision volumes, re-excisions and increased mastectomy rates.7 As such, a 
quality indicator that solely considers margin involvement stimulates breast surgeons to excise a 
wider margin of healthy breast-tissue and is therefore counter-productive for the final cosmetic 
outcome.
“ Q u a l i t y  i n d i c a t o r s  o n  m a r g i n  i n v o l v e m e n t  f o r 
T 1 - T 2  b r e a s t - c o n s e r v i n g  s u r g e r y  s h o u l d  b e ,  a t  t h e 
v e r y  l e a s t ,  a c c o m p a n i e d  b y  a  r e s t r i c t i o n  i n  h e a l t h y 
b r e a s t - t i s s u e  r e s e c t i o n ,  f o r  e x a m p l e  a  C R R  o f  1 ” 
“ Fo c a l l y - i n v o l v e d  t u m o u r  m a r g i n s  s h o u l d  n o t  b e 
a c c e p t e d  a s  a n  a d e q u a t e  r e s e c t i o n”
In the PALGA study the median excision volume was 46cc, but more importantly, 34% of 
patients had an excision volume >60cc. It is known that cosmetic failure is significantly higher 
if lump size exceeds 60cc, regardless of breast size.8-14 From this we can conclude that 34% of all 
patients who received BCS in the Netherlands in 2012 and 2013 were at risk for a poor cosmetic 
outcome. If these patients had undergone image-guided surgery, the chances of having a CRR>1 
would have been substantially lower and patients would have had a lower risk for cosmetic 
failure. Cosmetic failure after BCS remains a problem worldwide and is still observed in up to 
40% of patients, and is probably accompanied by psychological distress.15
“ I f  a l l  B C S  i n  2 0 1 2 - 2 0 1 3  h a d  a c h i e v e d  a  C R R  o f 
1 ,  o n l y  5 %  r a t h e r  3 4 %  o f  p a t i e n t s  w o u l d  h a v e  b e e n 
e x p o s e d  t o  t h e  r i s k  o f  a  p o o r  c o s m e t i c  o u t c o m e ”
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A N  I M P EN D I N G  D E TO U R  I N 
B RE A S T- CO N S ERV I N G  S U RG ERY
Oncoplastic breast-conserving surgery (OPBS) combines a wide local excision of the breast 
tumour, generally removing large volumes of healthy breast tissue, followed by reconstructive 
techniques. This approach is claimed to achieve a reduction in margin involvement and good 
cosmetic outcomes. Despite a lack of scientific evidence for OPBS and a clearly defined 
algorithm that has withstood clinical trials, OPBS has proliferated and is being implemented 
by ‘vocal advocates’ in more and more departments of surgery. However, the scientific evidence 
is still insufficient to justify the routine implementation of OPBS in early stage breast cancer. 
In fact, one could state that in some cases OPBS is little more than an excuse to excise large 
amounts of healthy breast tissue, using the plastic surgeon to reconstruct the defect. By contrast, 
an initial accurate excision guided by ultrasonography, with the goal of achieving a CRR of 
1, would have offered a perfectly adequate procedure for most patients, without the resulting 
increase in healthcare costs.
Our systematic review on OPBS identified studies describing tumour-involved margins in up 
to 22% of patients.16 More recent and detailed reports have since been published. A very recent 
manuscript by Clough et al. (an acknowledged expert in the field of OPBS) appeared in late 2015 
in the Annals of Surgical Oncology, describing OPBS results in their department.17 The study 
describes OPBS procedures for T1 tumours in 78 patients, T2 in 100 patients and T3 tumours 
in 14 patients, with tumour-involved margins in 5%, 16% and 43% of patients, respectively. A 
mean tumour-involved margin rate of 12% was observed, resulting in a 9% mastectomy rate. 
OPBS does not seem to improve margin involvement for lobular carcinomas, as the margin 
involvement rate was 28%. This new study on OPBS corroborates our findings detailed 
in chapter 7, and does not show an improvement compared to previous results.  Moreover, 
referring to the COBALT trial, Clough et al. appropriately conclude that OPBS in combination 
with continuous ultrasound-guidance could reduce both margin involvement and unnecessary 
resection of healthy breast-tissue, thereby optimizing cosmetic results. 
As stated earlier, studies describing the cosmetic outcomes of OPBS are scarce. Moreover, when 
OPBS studies actually describe cosmetic outcome, they often lack good evaluation methods for 
cosmetic outcomes, which makes them difficult to evaluate. 
The weight of evidence regarding margin involvement and improved cosmetic outcomes with 
USS suggests that OPBS only has a place where USS fails to achieve acceptable cosmetic 
outcomes despite the small excision volumes. Analysis of cases with poor cosmetic outcomes 
following USS could help identify patients who might benefit from OPBS. Other drawbacks 
of OPBS are the complicated administration of radiotherapy, as OPBS techniques include 
local advancement flaps. Furthermore, performing OPBS increases the length of the surgical 
procedures and requires an additional plastic surgeon for reconstruction of the breast, leading to 
a considerable increase in healthcare costs.
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In addition to the lack of evidence supporting the widespread implementation of OPBS, the 
number of patients receiving BCS per year would make it impractical. Surgeons should therefore 
be reticent in the implementation of OPBS in routine daily practice until well-defined and 
scientifically-proven algorithms are developed. Although an illusion may be created amongst 
patients that OPBS represents better care compared to BCS alone, current OPBS outcomes do 
not justify this optimism or support the performance of OPBS procedures.
“ O n c o p l a s t i c  s u r g e r y  s h o u l d  o n l y  b e  i m p l e m e n t e d 
f o r  T 1 - T 2  b r e a s t  c a n c e r  p a t i e n t s  o n c e  i t  h a s 
p r o v e n  t o  b e  s u p e r i o r  t o  u l t r a s o u n d - g u i d e d
b r e a s t - c o n s e r v i n g  s u r g e r y  i n  w e l l - d e s i g n e d 
r a n d o m i z e d  c o n t r o l l e d  t r i a l s ”
“ I n t r a - o p e r a t i v e  u l t r a s o u n d - g u i d a n c e  f o r
b r e a s t - c o n s e r v i n g  s u r g e r y  r e s u l t s  i n  p o o r  c o s m e t i c 
o u t c o m e s  i n  o n l y  6 %  o f  p a t i e n t s ”
Another trend in BCS is neo-adjuvant chemotherapy (NACT), which is increasingly employed 
in breast cancer patients who have an indication for systemic chemotherapy at the time of 
presentation based on primary tumour characteristics. Two main factors justify use of NACT: 
large tumours can be downstaged to avoid a mastectomy and facilitate breast-conserving surgery, 
or if a poor cosmetic outcome is anticipated, a large tumour can be downstaged in order to 
improve the cosmetic outcome.18-22 
Unfortunately it is not possible to predict the response of a tumour to NACT beforehand. Studies 
should therefore examine which tumour types and which hormonal or genetic configurations 
of breast tumours most often result in tumour-free resection margins with acceptable cosmetic 
outcomes. As cosmetic outcomes and patient satisfaction following NACT have not yet been 
described in the literature, NACT should therefore only be implemented to downstage tumour 
size once the procedure is proven effective by careful, well-designed studies of oncological 
outcomes, cosmetic outcomes, patient satisfaction and cost-effectiveness.
“ S t u d i e s  o n  t h e  o n c o l o g i c a l  a n d  c o s m e t i c  o u t c o m e s 
o f  N AC T  c o u l d  h e l p  i d e n t i f y  t h o s e  t u m o u r s  t h a t 
s h o u l d  b e  t r e a t e d  w i t h  B C S  a n d  w h i c h  p a t i e n t s 
c o u l d  d e r i v e  g r e a t e s t  b e n e f i t  f r o m  m a s t e c t o m y 
w i t h  r e c o n s t r u c t i o n”
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U LT RA S O U N D - G U I D ED  S U RG ERY 
F O R  T H E  EXC I S I O N  O F 
N O N - PA LPA B LE  B RE A S T  CA N C ER
The excision of non-palpable tumours requires surgical aids and options available to the surgeon 
include wire-guided excision (WGE), radio occult lesion localisation (ROLL), radioactive 
iodine-125 seed localisation or ultrasound-guided surgery (USS).
A randomized controlled trial by Rahusen et al. showed that USS resulted in significantly fewer 
tumour-involved margins compared with WGE (4% and 18% respectively). However this study 
did not describe tumour involvement for additional ductal carcinoma in situ.23 Two other trials 
demonstrated the superiority of ROLL over WGE in terms of margin involvement and ease 
of use.24,25 In 2011, a multicentre retrospective study corroborated the above results and showed 
tumour-involved margins for non-palpable invasive breast cancer excision with ROLL in 25.0%, 
with WGE in 21.4% and with USS in only 3.8% of patients. Including both invasive carcinoma 
and unexpected ductal carcinoma in situ, this study reported involved margin with ROLL in 
31.3%, with WGE in 26.5% and with USS in 17.3% of patients.26 A systematic review by 
Lovrics et al. (2011) reported use of iodine-125 seed localisation leading to tumour-involved or 
close margins in invasive carcinoma and DCIS in up to 27% of patients.27 These results therefore 
strongly suggest that USS is the most accurate method for excision of non-palpable breast-
cancer, although a one-to-one comparison of iodine-125 seed localisation and USS has not yet 
been performed in a randomized controlled setting.
All the above-mentioned techniques have their own specific technical difficulties. For instance, 
when performing WGE the radiologist places the wire in the middle of tumour under 
ultrasound-guidance or mammography the day before surgery. The position of the wire is 
checked by mammography in 2 directions. It is a requirement that the wire remains in place until 
the operation, and cases of displacement during mobilisation or transection of the wire during 
the operation have been described.28-30 Local complications due to WGE include bruising of 
the breast and pneumothorax has been described in a limited amount of cases.31 Following 
lumpectomy and while the patient is kept under general anaesthesia, the specimen is sent to the 
radiology department to confirm correct excision of the tumour and that the entire tumour is 
contained within the specimen. 
For ROLL and iodine-125 the radiologist places the technetium (Tc 99m) solution or iodine-125 
seed under ultrasound or stereotactic guidance. The iodine-125 seed localisation technique uses a 
titanium seed containing iodine-125. The radiologist loads the seed into an 18-gauge needle and 
places it near to or within the tumour.32 After iodine-125 seed implantation, a mammography 
in two directions is used to confirm correct placement. In both ROLL and iodine-125, seed 
localisation requires use of the same gamma-ray detector during surgery as for the sentinel node 
procedure. 
Due to the use of radioactive material, these procedures also involve special care and specific 
protocols in accordance with a hospital’s license for use of radiation in medical procedures and 
under Dutch law.33 ROLL and iodine-125 seed localisation are performed under the direct 
responsibility of the Nuclear Medicine Department. In some cases, patients have to undergo 
the injection of the Tc 99m or iodine-125 seed at a Nuclear Medicine Department of another 
hospital, if the hospital performing the surgery lacks such a department. 
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Wire-guided excision
 Top left: pre-operative placing of the wire using mammography.
 Top right: mammographies to check the correct placement of the wire. 
 Bottom left: the wire in the lumpectomy specimen
 Bottom right: X-ray of the specimen in order to check if the tumour is inside
It is fair to conclude that WGE, ROLL and iodine-125 seed localisation result in additional 
procedures, the increased use of anaesthetics and greater discomfort, while evidently increasing 
healthcare costs. Furthermore, these patients are exposed to additional radiation when placement 
of the device is checked. It should also be noted that the radiologist places the device under 
ultrasound guidance when the tumour is visible by ultrasonography. Almost all palpable breast 
tumours are visible by ultrasonography. Only a small percentage of patients have a breast tumour 
that is not visible to ultrasonography. Non-palpable mammographically detected breast tumours 
can be visualised in 62% of cases with ultrasonography, and the sensitivity increases to 76% if 
lesions consisting entirely of microcalcifications were excluded.34
Thus, when tumours are invisible to ultrasonography, surgical aids should be placed under 
stereotactic guidance.
Iodine-125 seed localisation
 A small titanium seed containing iodine-125
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Of the above described localisation methods, USS is the only method that can inform the surgeon 
about the tumour delineation in the breast parenchyma. In our opinion, USS for non-palpable 
breast lesions should be used for all echogenic tumours (thus the vast majority). In practical terms, 
a portable ultrasound device is used in the operating theatre, with assistance from a radiologist 
and the preoperative diagnostic ultrasound images. This means that the patient does not have 
to undergo any additional procedures before the lumpectomy. Furthermore, ultrasonography is 
absolutely free of radiation, in contrast to iodine-125 seed localisation and ROLL. However, one 
should be especially vigilant in the case of lobular carcinomas as these tumours can a present a 
problem for USS in terms of ill-defined margins. However, even on the case of palpable lobular 
carcinomas, the COBALT trial demonstrated a reduction in margin involvement in the USS 
group compared to the PGS group.
“A l l  b r e a s t  t u m o u r s  v i s i b l e  w i t h  u l t r a s o n o g r a p h y 
s h o u l d  b e  e x c i s e d  u n d e r  u l t r a s o u n d  g u i d a n c e ”
Ultrasound-guided surgery
 The surgeon continuously visualises the tumour during the entire procedure
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I M P LEM EN TAT I O N  O F 
U LT RA S O U N D - G U I D ED  S U RG ERY 
I N  DA I LY  P RAC T I C E : N O 
EXC U S E S  P ER M I S S I B LE
Ultrasonography is already part of the armamentarium of many professions, such as construction 
workers detecting water pipes and fisherman using USS-related sonars. In the medical profession 
ultrasonography is no longer the sole preserve of the radiologist, as more and more specialists 
apply ultrasonography in daily practice. A broad spectrum of practitioners, including urologists, 
gynaecologists, anaesthesiologists, liver surgeons and cardiothoracic surgeons, has been trained 
to perform simple ultrasonography during their clinical procedures. One common example is 
the use of ultrasound by anaesthesiologists to place central catheters in large arteries or veins. 
However, it is important to remember that use of ultrasonography as a diagnostic tool should in 
most cases be reserved for the experienced radiologist.
Because surgeons do not use ultrasound to diagnose new lesions, but simply as a guide during 
an operation, in our opinion less expensive ultrasound machines could suffice for intra-operative 
ultrasound guidance. Today, remarkably cheap medical ultrasound probes such as the Uprobe-2® 
that can be directly connected to an Iphone® or Ipad® device can be bought on Ebay for 
approximately $2000. The fact that cheaper devices provide lower image resolution should not 
be a problem, as the tumour is already diagnosed and is always defined with outstanding image 
quality and resolution by a trained radiologist before the operation. Furthermore, technology 
in the operating theatre allows the surgeon to compare the tumour during surgery to the high-
resolution diagnostic images provided by the radiologist.
The wireless U-probe-2 ultrasound
 This probe can be connected to a range of iOS and Android devices such as tablets.
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Of the 13000 patients diagnosed each year with breast cancer in the Netherlands, approximately 
9000 have a palpable tumour and could undergo USS without the physical presence of a 
radiologist in the operating room.10 However, it is advisable to have the opportunity to consult 
a radiologist when necessary.
The widespread implementation of USS could greatly reduce the percentage of tumour-involved 
margins, decrease the need for additional therapy and increase cosmetic outcome, thereby 
reducing healthcare costs.35 
A recurring question is the ease with which one can learn USS. Studies have shown that 
surgeons who apply USS achieve tumour-free margins in their very first procedure and require 
only 8 procedures to obtain a CRR of 1.36 Furthermore, a recent American survey by Sclafani et 
al reported that 39% of breast surgeons believe to be adequately trained in breast ultrasound.37 
As such, we would encourage all breast surgeons to learn the USS technique and by so doing 
improve their surgical precision.
In conclusion, this thesis has highlighted many facets of current advances in breast-conserving 
surgery, whereby improved cosmetic outcome and reduced morbidity take a prominent place. 
By limiting excess healthy breast tissue resection and thus reducing poor cosmetic outcome 
rates, thereby increasing patient satisfaction and lowering healthcare costs, intra-operative use 
of ultrasonography in breast-conserving surgery fulfils the Hippocratic oath: “NIL NOCERE”. 
In my opinion the developments highlighted in this thesis mark the dawn of a new era in breast 
cancer surgery.
“ T h e r e  a r e  n o w  n o  e x c u s e s  f o r  a  l a c k  o f  r o u t i n e 
i m p l e m e n t a t i o n  o f  u l t r a s o u n d - g u i d e d  e x c i s i o n  i n 
b r e a s t - c o n s e r v i n g  s u r g e r y ”
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Letter to the editor. A response to: “The CUBE Technique:
Continuous Ultrasound-Guided Breast Excision”
187
Dear editor, 
We read the article “The CUBE Technique: Continuous Ultrasound-Guided Breast Excision”, 
published in August 2014 by Tummel et al.1 We congratulate the authors with their study 
and the positive results concerning intra-operative ultrasonography for breast cancer surgery. 
However, if the authors had performed a review of the literature on this subject, they would have 
realised that the described technique is actually not as ‘novel’ as they opine. Over the past years, 
our study group has extensively published on this subject, resulting in a multicentre, randomised 
controlled trial including 134 patients.2 Although the term “CUBE” is a novel name indeed, 
the technique itself is an exact copy of the technique we repeatedly described and is already 
known.3-7 It is needless to say that it would have been appropriate for the authors to refer to 
our studies while presenting their results, and we are somewhat disappointed that the Journal 
did revise the literature list on behalf of the authors. We recommend to the authors to repeat 
our randomised controlled trial on the use of intra-operative ultrasound, so we can convince 
all surgical oncologists to use this excellent technique in their operating theatre. It would be 
highly appreciated if the authors could respond to our letter and we are waiting for their reply. 
Thank you for your time and attention. 
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DANKWOORD
Allereerst wil ik alle patiënten bedanken die mee hebben gedaan aan de COBALT studie. 
Zij hebben het vertrouwen gehad in de onderzoeksgroep om te objectiveren of de resultaten 
van de echogeleide chirurgie voor palpabel borstkanker superieur zijn aan die van de 
standaard operatie. Daarnaast zijn zij bereid geweest om alle vragenlijsten in te vullen en om 
gefotografeerd te worden. De enorme hoeveelheid aan data heeft er toe geleid dat wij goede 
en klinisch relevante artikelen hebben kunnen schrijven die in toonaangevende internationale 
tijdschriften zijn verschenen. Het is mijn hoop dat hierdoor de bortstkankerzorg wereldwijd 
zal verbeteren!
Prof. dr. S. Meijer, promotor. Beste Professor Meijer, wat ben ik blij dat u mij het vertrouwen 
heeft gegeven om Nicole op te volgen. Uw gedrevenheid en kritische blik vertaalden zich in lange 
research-besprekingen waarin wij onze manuscripten en artikelen grondig doornamen. De 
lange telefonische gesprekken die we hadden als er een deadline was voor een subsidieaanvraag 
of artikel, zijn het bewijs van uw tomeloze toewijding. Als geen ander weet u de essentie in een 
stuk naar voren te brengen. Uw enthousiasme en nauwgezetheid werkten dan ook aanstekelijk, 
hetgeen heeft geleid tot een reeks manuscripten waaronder dit proefschrift, iets waar wij 
samen ontzettend trots op kunnen zijn. U heeft mij gevormd tot een arts die onafhankelijk een 
mening kan vormen, creatief kan denken en nieuwe wetenschappelijke ontwikkelingen kan 
beoordelen. U zei altijd dat ik patiënten de behandeling moest geven alsof het mijn familie was. 
Ik denk dat dit de essentie is van wat ik van u heb geleerd, en dat dit altijd van invloed zal zijn 
op mijn carrière als specialist. Ik ben ontzettend blij dat ik bij u kan promoveren.
Dr. M.P. van den Tol, co-promotor. Lieve Petrousj, wat heb ik genoten van de tijd dat wij 
samen hebben mogen werken. Je opgewektheid en enthousiasme zorgden altijd voor een 
ontzettend leuke sfeer op de OK. Je kwam regelmatig  met nieuwe ideeën voor artikelen die 
telkens goed uitpakten. Als geen ander wist je nieuwe invalshoeken te vinden, niet alleen in 
het onderzoek maar ook op het persoonlijk vlak. Ik heb je betrokkenheid altijd erg op prijs 
gesteld! Je blijdschap bij elke nieuwe publicatie maar ook  je steun en optimisme in tijden van 
tegenspoed. Je ging hierbij altijd direct op zoek naar een goede oplossing, en die vond je dan 
ook snel.  Ik ben heel erg blij dat ik bij Prof. Meijer en jou onderzoek heb mogen doen, jullie 
vullen elkaar perfect aan.
Prof. dr. H.J. Bonjer, afdelingshoofd chirurgie VUmc. Beste Professor Bonjer, zonder uw 
betrokkenheid en vertrouwen in onze onderzoekslijn had ik niet zo lang full-time kunnen 
werken aan de COBALT-studie. U vond het altijd erg belangrijk dat de lijntjes tussen 
onderzoekers en bazen kort waren, daar bent u uitermate goed in geslaagd onder andere door 
het creëren van de onderzoekskamer. Ik ben u erg dankbaar voor de goede tijd die ik op de VU 
heb mogen doorbrengen.
Geachte leden van de promotiecommissie, Prof. dr. J.H.G Klinkenbijl, Prof. dr. Ir., J.J.M. 
van der Hoeven, Prof. dr. M. Hamdi, Prof. dr. C. Van Kuijk en Prof. dr. H.J. Bonjer, 
hartelijk dank voor de tijd die u heeft genomen om mijn proefschrift te beoordelen.
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Geachte opponenten, hartelijk dank voor het deelnemen in de oppositie.
Nicole Krekel, paranimf. Lieve Nicole, wat was ik blij om van jou het onderzoek over te 
nemen! Een goed lopende studie met prachtige resultaten. En wat was het fijn dat je in het 
begin de stukken die ik toen schreef op zo een voortreffelijke manier corrigeerde. Jij haalde de 
punten er uit die prof. Meijer en Petrousj sowieso anders wilden. Jouw doorzettingsvermogen 
en doortastendheid zijn altijd een voorbeeld voor mij geweest. Er was nooit een twijfel dat jij 
mijn paranimf zou worden, en ik ben je erg dankbaar dat je die functie voor mij wilt bekleden.
Olvert Berkhemer, paranimf. Beste Ol, studiegenoot, jaargenoot, ex-huisgenoot, collega bij 
BIS, mede-onderzoeker, collega arts-assistent in opleiding tot Radioloog en bovenal goede 
vriend. De opsomming van alle benamingen die je hebt laat zien hoeveel wij hebben gedeeld. 
Wat ben ik blij dat je mijn paranimf bent! Ondanks dat ik een prachtig onderzoek heb, moet ik 
zeggen dat jij wel de meest succesvolle onderzoeker bent die ik ken. Onmisbaar aan mijn zijde 
tijdens de verdediging.
José Volders. Beste José, ik ben erg onder de indruk  van het feit dat jij naast je opleiding 
ontzettend hard aan het werk bent gegaan om de laatste follow-up van de COBALT-studie 
af te ronden. Het was een genoegen en een opluchting dat jij mij kwam helpen om opnieuw 
de gehele database door te lopen van onze PALGA studies. Met jouw enthousiasme en 
doorzettingsvermogen denk ik dat je als een speer je promotieonderzoek afrond! Ik kijk er naar 
uit om nog veel met je te mogen publiceren.
Karin Nielsen. Lieve Karin, wat hebben we toch een heerlijke tijd gehad op de onderzoekskamer 
en wat was het fijn om dezelfde promotor en co-promotor te delen. Dank je voor alle gezelligheid 
en hulp.
Deelnemende chirurgen van de COBALT; beste Alexander Lopes Cardozo, Anne Marie 
Bosch, Wilfred de Roos, Henk van der Veen, Sandra Muller, Herman Rijna, Louise de 
Widt en Pieter Poortman. Hartelijk dank voor het meedoen aan de trial en, voor sommigen 
onder jullie, voor het implementeren van de echogeleide chirurgie in jullie ziekenhuis. Ik kan 
mij voorstellen dat het jullie ook voldoening geeft om te zien dat deze operatietechniek zulke 
ontegenzeggelijke resultaten teweeg brengt.
Alle afdelingen chirurgie die deel hebben genomen aan de COBALT-studie, beste secretaresses 
en mammacare, hartelijk dank voor jullie hulp tijdens de inclusies en follow-up. 
Lieve Margôt de Graaf, jouw komst kwam als geroepen om mee te helpen aan de 
dataverzameling. Ik ben je heel erg dankbaar voor al het rondreizen naar de verschillende 
deelnemende ziekenhuizen om patiënten te zien; iets  waar je altijd rustig de tijd voor nam. 
Daarnaast vond ik het altijd erg leuk om met je af te spreken om de laatste stand van zaken door 
te nemen. Ook na mijn vertrek van de VU hebben wij elkaar regelmatig met  veel plezier gezien 
voor een lunch. Als geen ander ben jij betrokken bij de COBALT-studie.
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Beste Elly de Lange, hartelijk dank voor al je statistische hulp gedurende mijn 
promotieonderzoek, en voor het goed opzetten van nieuwe studies.
Kasia Józwiak. Dear Kasia, while doing clinical work it was rather difficult to find a statistician 
who could help us with our analyses. Thankfully you were just around the corner in the NKI/
AVL, and after I was finished with my work on the ward, it was always a great pleasure to 
meet you in your office. You never stopped searching for the right analysis for our manuscripts, 
which eventually resulted in the publication of our articles in high-impact papers.
Beste Veerle Coupé, Judith Bosmans en Caroline Terwee, jullie expertise in epidemiologie 
gecombineerd met kostenanalyses en het valideren van vragenlijsten waren onmisbaar in het 
schrijven van onze artikelen. Heel veel dank voor al het geduld en de uitleg, jullie bijdrage 
heeft de methodologie van deze artikelen erg sterk gemaakt.
Beste Derek Rietveld, hartelijk dank voor alle tijd en je duidelijke uitleg, zonder jou was de 
radiotherapie voor borstkanker niet zo inzichtelijk voor mij geweest.
Beste overige co-auteurs, Ellis Barbé, Liesbeth Bergers, Frank Bloemers, Mark-Bram 
Bouman, Marlon Buncamper, Joger Jacobs, Frank Niessen, Collin Sietses, Hay Winters, 
Roos de Wit en Babs Zonderhuis, hartelijk dank voor al jullie input, beoordelingen en 
enthousiasme. Het was een waar genoegen om met jullie samen te werken.
Mark Osinga. Hartelijk dank voor het mogelijk maken van de studie. Jij hebt geholpen om 
de onderzoekslijn van de COBALT-studie op te starten, en wij zijn erg blij dat het nog steeds 
zijn vruchten afwerpt.
Toshiba Medical Systems, Bianca Hesselius en Marcel Boschker. Het lenen van een extra 
echoapparaat was echt nodig voor de goede logistiek van de studie. Ik stel jullie enthousiasme 
en toewijding zeer op prijs. We komen elkaar in de toekomst vast nog vaker tegen.
Beste Annet Nielsen, ik ben ontzettend blij dat je plaats hebt willen nemen in het 
beoordelingspanel met mijn moeder en Prof. Meijer. Bedankt voor je tijd en moeite.
Beste reseachers, lieve Gabor, Joanna, Marjolein, Nikki, Dieuwertje, Renske, 
Erienne, Saskia, Wouter en Jennifer, wat hebben wij een onvergetelijke tijd gehad op de 
onderzoekskamer. We hebben hoogtepunten en dieptepunten met elkaar gedeeld. Een tijd om 
nooit te vergeten. Ik hoop dat we nog heel vaak een reünie hebben samen.
Beste medewerkers van de afdeling heelkunde VUmc, Ilse Kruit, Wendy Kolk, Rita Blom en 
Ron de Hoon. Dank voor jullie oprechte betrokkenheid, hulp en gezelligheid.
Oud collega’s van de heelkunde VUmc, hartelijk dank voor de tijd op de afdeling, de leuke 
skivakanties en het meermaals samen winnen van de Chirurgencup.
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Beste collega’s van het NKI/AVL, lieve Henriette, Jony, Arne, Caroline, Cecile, Eva, 
Jacqueline, Jonas, Lisette, Marije B, Marije P, Nick, Roel, Tessa, Niels, Reinder, Matthijs 
en tweemaal Rosa bedankt voor de fantastische tijd die ik heb gehad in het AVL. Wat was het 
gezellig met z’n allen op de artsenkamer, tijdens de overdracht en bij de borrel.
Beste Arend en Jos, hartelijk dank voor mijn tijd in het AVL, jullie begeleiding, geduld en 
uitleg. Alle overige stafleden, fellows en AIOSen, WANhoofden, verpleegkundigen en 
medewerkers van het AVL,  ik heb erg genoten van mijn leerzame ANIOS periode bij jullie, 
dank daarvoor.
Beste Martijn en Caroline, wat heb ik een geluk gehad om jullie als collega’s te mogen hebben.
Beste dr. Montauban van Swijndregt, alle stafleden, AIOS, fellows, Hanny en overige 
medewerkers van de afdeling Radiologie van het Onze Lieve Vrouwe Gasthuis, wat ben ik 
ontzettend blij dat ik bij jullie in opleiding mag. Ik kijk ontzettend uit naar de samenwerking 
de komende jaren.
Dear dr. Bayley, it was always a pleasure working with you. Your editing of our manuscripts 
resulted in clearer texts and helped us convey our message more effectively. 
Beste Harm, hartelijk dank voor het maken van de app voor mijn proefschrift. Hij ziet er super 
mooi uit!
Beste Reinder, wat hebben wij een mooie vriendschap opgebouwd sinds onze ANIOS periode 
in het AVL. Zoveel interesses die wij gemeen hebben, leuke vakanties, eindeloze discussies over 
geneeskunde en de opleiding. Bedankt voor het meedenken, je steun en scherpe invalshoeken. 
Een vriendschap die naar mijn hart gaat en waarin wij veel kunnen delen.
Beste Rutger, bedankt voor je hulp en steun tijdens de sollicitatieperiode bij de afdeling 
Radiologie in het OLVG. Leuk dat we ook collega’s worden.
Beste Matthijs van Gool, wat was het toch tijdens de voorbereidingen van onze co-schappen. 
Daarna altijd gevlamd met zijn 2en op de Chirurgencup. Bedankt voor je steun en hulp.
Lieve Roos en Daan, wat fijn om jullie al zo lang als vrienden te hebben, jullie regelmatig 
te zien en steun te krijgen in moeilijkere periodes. Een onvoorwaardelijke vriendschap die ik 
koester.
Beste Oskar en Tessa, hartelijk dank voor alle steun en vertrouwen de afgelopen jaren.
Chers amis, Jérémy, Pierre, Adrien, Grégoire, Hugo, Raphaelle, Jad, Clément et Alexandre, 
je suis très heureux de vous avoir comme potes. Tous les bons moments que l’on a passé ensemble 
depuis le lycée.
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Beste Wijttenpromi: Oskar, Christoph, Lucas, Sandro en Hoppie, wat een fantastische tijd 
heb ik met jullie gehad in onze loft. Natuurlijk gaat mijn  gedachte ook uit naar Olivier die wij 
allen erg missen.
Jeroen, hartelijk dank voor het nakijken van de Nederlandse samenvatting, ik ken niemand die 
taalkundig zo sterk is als jij.
Hebe ’05, lieve jaargenoten Oskar, Joris, Ruben, Olvert, Pepijn, Hidde, Michiel, Bart, 
Philip, Bernhard en Ebele. Het is eindelijk zo ver, mijn proefschrift is af. Wat is het altijd 
mooi om elkaar weer te zien en wat hebben wij mooie dingen samen gedaan.
Lieve vrouwe H.E.B.E., wat ben ik blij dat u mij onder uw hoede heeft genomen. Ik heb een 
heerlijke studententijd gehad, en leuke tijd op het huis, mooie dispuutgenoten leren kennen, 
vrienden voor het leven. THB
Lieve Wim, wat ben ik blij met jou als oom. Altijd erg enthousiast en vol nieuwe ideeën. Ik kan 
wel stellen dat jij de grondlegger bent van mijn wetenschappelijke carrière, en een voorbeeld 
voor hoe ik wil zijn als specialist in het ziekenhuis. Dank je voor al je steun al die jaren.
Très très chère Sylvie, tes dessins en peintures sont tellement magnifiques, ma thèse est 
vraiment unique grâce à toi. J’apprécie énormément le temps que tu as passé à les faire. D’une 
certaine manière cela est spécial pour toi aussi. Je suis très heureux que tu viennes à ma défense 
de thèse.
Cher Jean-Paul, merci pour ton aide et tes corrections du résumé de ma thèse. J’ai beaucoup 
apprécié mon stage à la Châtaigneraie et le temps que nous avons passé ensemble avec
Marie-Christine, Mathieu et Aurélie.
Chères familles Malo et Thébault, même si on ne se voit pas si souvent, cela me fait toujours 
très plaisir de vous voir.
Beste Jurriën, bedankt voor alle steun en advies die je mij altijd geeft.
Lieve Lien, familie Schutte, families Petter, van Vianen en Theuvenet, wat ben ik blij met 
zo’n gezellige en eigenzinnige familie als jullie. Wat lachen en kibbelen we toch graag samen.
Beste Cor, Renie, Yoni, Nick, Fay en Lola, ik heb het getroffen om in jullie gezellige familie 
te zijn beland.
Lieve papa en mama. Hartelijk dank voor de opvoeding die jullie mij hebben gegeven en 
mogelijkheid mij te ontwikkelen. Bedankt voor de onvoorwaardelijke steun en liefde. 
Uiteindelijk ben ik toch nog goed terecht gekomen. En mama, wat vind ik het leuk dat jij met 
je naamgenoot ook nog hebt deelgenomen als beoordelaar in deze studie.
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Lieve Mariette, Guillaume en Simon, wat ben ik blij met jullie kleine familie en de schattige 
laatste aanwinst. Bedankt voor de steun al die jaren.
Chères Catherine et Camille, merci pour votre aide toutes ces années où il fallait que j’apprenne 
le Français, mais au final j’ai réussi. Merci pour votre soutien et les bons moments que l’on passe 
ensemble.
Allerliefste Jessie, ondanks dat we een hectisch jaar achter de rug hebben, doet dat mij wel 
beseffen hoeveel steun we aan elkaar kunnen hebben. Het vertrouwen dat je mij geeft en je 
positieve insteek zorgen er voor dat alles altijd wel goed komt. Daarnaast heb jij er voor gezorgd 
dat dit proefschrift er ontzettend strak uitziet. Je creativiteit en het feit dat je een ontzettend 
harde werker bent maakt dat je de allermooiste dingen ontwerpt. Dank je voor de steun en 
liefde die je mij geeft, dat is iets van onschatbare waarde.
